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ABSTRACT 
 
Protein phosphorylation regulates a variety of complex cellular signalling networks. Its monitoring is 
fundamental for understanding the origins of various diseases and drive the development of novel 
therapeutics.  
This work focused on the development of peptidomimetic ligands for the selective binding of 
phosphorylated peptides. Structural studies of the natural human phosphoprotein-binding domains 
(PBDs) revealed the existence of key amino acid residues involved in phosphate recognition: Arg, Lys, 
Tyr, Ser, His, Gly, and Asn. Based on this information, three solid-phase combinatorial libraries (232 
small synthetic affinity ligands in total) were synthesized and screened against target phosphorylated 
peptides. The synthesis of the libraries was based on different chemical reactions: nucleophilic 
substitutions on a triazine ring, Ugi multicomponent reaction, and tandem Petasis-Ugi 
multicomponent reaction. Two lead ligands which selectively bound and eluted phosphorylated 
peptides were identified. The lead ligands were A8A3 and A8C2 – based on the triazine and Ugi 
reactions, respectively - and both possess substituents mimicking the His residue. Ligand A8A3 was 
immobilized onto magnetic nanoparticles coated with silica and dextran and efficiently enriched a 
mixture of trypsin-digested α-casein, β-casein, and bovine serum albumin in mono- and multi-
phosphorylated peptides, comparable to the results obtained when employing a conventional 
protocol with Ti4+-IMAC. 
In parallel, cyclic β-hairpin scaffolds mimicking the Brca1 C-terminal domain were rationally designed 
and synthesized by standard Fmoc solid-phase chemistry. The lead candidate, Cyclic-M2 with the 
sequence cyclo(Glu-Gly-Phe-Gly-Dap-Gly-Dap-DPro-Pro-Gly-Val-Arg-Thr-Gly) was successfully 
immobilized onto a chromatographic support (32 µmol/g). The resultant adsorbent was selective in 
binding to the phosphorylated target peptide allowing a 65% recovery of the phosphopeptide during 
elution. 
 
Keywords: phosphopeptide enrichment, affinity ligands, peptidomimetics, multicomponent reactions, 
β-hairpin. 
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RESUMO 
 
A fosforilação de proteínas regula inúmeros mecanismos de sinalização celular e, como tal, a sua 
monitorização  é fundamental para compreender as origens de uma panóplia de doenças e promover 
o desenvolvimento de novos agentes terapêuticos. 
Este trabalho focou-se no desenvolvimento de novas estruturas biomiméticas para a ligação selectiva 
de péptidos fosforilados.  
Estudos estruturais dos domínios humanos de ligação a fosfoproteínas revelaram a existência de 
aminoácidos-chave envolvidos no reconhecimento do grupo fosfato: Arg, Lys, Tyr, Ser, His, Gly, and 
Asn. Com base nesta informação, três bibliotecas combinatoriais compostas por 232 ligandos 
sintéticos de afinidade foram sintetizadas e avaliadas quanto à capacidade de ligação a péptidos 
fosforilados. Estas bibliotecas basearam-se em diferentes reacções químicas: substituição nucleofílica 
num anel de triazina, reacção multicomponente de Ugi, e reacção multicomponente de Petasis-Ugi. 
Foram identificados dois ligandos principais, um baseado na reacção de triazina – A8A3, e outro 
baseado na reacção de Ugi – A8C2. Ambos apresentam componentes que mimetizam o resíduo de 
His na sua estrutura, ligam selectivamente a péptidos fosforilados a pH 3 e permitem a eluição 
eficiente das espécies fosforiladas. 
O ligando A8A3 foi imobilizado em nanopartículas magnéticas revestidas com sílica e dextrano e 
enriqueceu eficazmente em fosfopéptidos mono- e multi-fosforilados uma mistura de α-caseína, β-
caseína, e albumina de soro bovino (BSA) digeridas com tripsina. 
Em paralelo, estruturas cíclicas de β-hairpins foram modeladas de forma a mimetizar o domínio 
Brca1 C-terminal e sintetizadas por química em fase sólida. A melhor estrutura, M2-cíclico, com a 
sequência ciclo(Glu-Gly-Phe-Gly-Dap-Gly-Dap-DPro-Pro-Gly-Val-Arg-Thr-Gly), foi imobilizada num 
suporte cromatográfico (32 µmol/g). O adsorvente contendo o M2-cíclico ligou-se ao péptido 
fosforilado com elevada selectividade, recuperando-se 65% do péptido aquando da eluição. 
 
Palavras-chave: enriquecimento de fosfopéptidos, ligandos de afinidade, peptidomiméticos, reacções 
multicomponentes, β-hairpin. 
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BACKGROUND 
 
The size of the human proteome is at least 10-fold higher than the number of protein-coding genes 
(≈ 24,000), due to the occurrence of alternative splicing, post-translational modifications, and 
polymorphisms. Additionally, many proteins exist in different conformational and functional states 
[1, 2]. Therefore, there is great interest in the development of high-throughput protein-binding 
detection reagents, which would assist in the specific identification and quantification of numerous 
disease-related proteins. Affinity proteomics is a rapidly expanding field, and several international 
initiatives have already been established towards the creation of large collections of well-validated 
binding reagents. These initiatives include ProteomeBinders (www.proteomebinders.org), Human 
Protein Atlas (www.proteinatlas.com), HUPO Antibody Initiative (www.hupo.org/research/hai), 
Antibody Factory (www.antibody-factory.de), among others [2, 3]. The number of affinity binders is 
continually increasing, and they can be divided in different categories: antibodies; protein scaffolds 
(e.g. affibodies); peptide ligands (natural or synthetic); nucleic acid aptamers; and small chemical 
entities (natural or synthetic) [2, 4]. 
In particular, phosphorylated proteins are involved in complex signalling networks and the 
establishment of specific protein-protein interactions. Many of these phosphoproteins have 
unknown functions, and some have been implicated in human diseases. It is fundamental to unveil 
the interaction landscape of these phosphorylated proteins and their biological binders. In the last 
decades, a plethora of affinity reagents were developed for the specific binding of phosphorylated 
proteins and peptides. Their identification by mass spectrometry (MS) analysis poses a particular 
challenge, due to their low relative abundance in biological samples and to the dynamic character of 
protein phosphorylation [5]. For the correct identification of phosphorylated species there is the 
need to enrich their content in biological samples prior to MS analysis. 
Enrichment and detection of phosphorylated species can be performed using antibodies which are 
still the most commonly used affinity molecules in general. However, the phosphate group presents 
low immunogenicity and is susceptible to cleavage during the immunization process, which hampers 
the generation of high-quality phosphorylation-state specific antibodies [6]. Most strategies currently 
used for phosphopeptide enrichment rely on metal coordination of the phosphate moiety, such as 
immobilized-metal affinity chromatography (IMAC), metal oxide affinity chromatography (MOAC), 
and even small chemical ligands (e.g. Phos-tag). However, these broad-range methodologies do not 
provide sufficient diversity.  
In view of the interest in studying phosphorylated proteins, and the need to develop tools for the 
specific enrichment and detection of phosphorylated species, this work focused on the design and 
production of new specific ligands for the molecular recognition of phosphorylated target peptides. 
xxx 
 
Two research strategies were followed: the combinatorial synthesis of small chemical ligands and the 
rational-design of peptide scaffolds (Figure B.1). This constitutes a novel approach in 
phosphoproteomics with the small and robust affinity ligands presenting potential for higher 
selectivity when compared with conventional chelating resins. 
 
 
Figure B.1 – Schematic representation of the research strategy followed in the present work.  
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CHAPTER 11 
Platforms for the enrichment of phosphorylated proteins and peptides 
 
 
Summary 
 
Protein phosphorylation is a complex and highly dynamic process involved in numerous biological 
events. Abnormal phosphorylation is one of the underlying mechanisms for the development of 
cancer and metabolic disorders. The identification and absolute quantification of specific phospho-
signatures can help elucidate protein functions in signaling pathways and facilitate the development 
of new and personalized diagnostic and therapeutic tools. This chapter presents a variety of 
strategies currently utilized for the enrichment of phosphorylated proteins and peptides prior to 
mass spectrometry (MS) analysis during proteomic studies. The investigation of specific affinity 
reagents, allied to the integration of different enrichment processes, is triggering the development of 
more selective, rapid and cost-effective high-throughput automated platforms.  
                                                        
1
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1.1. Protein Phosphorylation 
 
The selective and reversible phosphorylation of proteins is a key regulatory mechanism for biological 
processes, illustrated by the fact that 30-50% of proteins may be phosphorylated at any time [1]. 
Phosphorylation is recognized as one of the most common post-translational modifications, affecting 
both the folding and function of proteins. Moreover, phosphorylation events in signaling networks 
regulate much of the cellular response to external stimuli, and dysregulation in these networks has 
been linked to multiple disease states (Figure 1.1). There are nine known phosphorylation targets in 
proteins: Tyr, Ser, Thr, His, Asp, Glu, Lys, Arg, and Cys residues. However, in eukaryotic systems, 
phosphorylation predominantly takes place at Ser, Thr, or Tyr residues [1, 2].  
 
 
Figure 1.1 – Phosphoproteomics towards the design of personalized medicine and the development of new 
biomedical tools. Protein phosphorylation networks are implicated in a variety of diseases, including cancer 
[3], neurodegenerative diseases such as Parkinson’s [4] and Alzheimer’s [5], and psychiatric disorders such as 
schizophrenia [6]. Phosphorylated proteins are important biomarkers and drug targets for therapeutic 
intervention. In fact, the study of real-time signaling activity within cellular specimens (e.g. tumors) helps to 
profile phosphorylation events to develop personalized therapies and identify patients who might benefit the 
most from these new therapies. For example, the replacement or combination of nonspecific 
chemotherapeutics by designed drugs that target specific pathways has proven to be a promising field [7]. 
 
1.2. Human phosphoprotein-binding domains (PBDs) 
   
PBDs are involved in the regulation of complex signalling networks by promoting specific protein-
protein interactions, assisting the assembly of multi-protein complexes and connecting upstream 
kinases with their downstream effectors. It is important to bear in mind that, notwithstanding the 
significance of phosphate recognition in the establishment of protein-protein contacts, some 
domains also bind their in vivo targets in a phospho-independent manner (e.g. 14-3-3, Forkhead-
5
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associated (FHA), etc) [8]. However, this work will be focused exclusively on the interactions of PBDs 
with their phosphorylated targets. Although most PBDs display extensive structural differences, it has 
been considered that they may have evolved from common ancesters. As an illustrative example, 
Mad-homology 2 (MH2) domains have structural similarities with FHA domains and mechanistically 
resemble Src-homology-2 (SH2) domains [8, 9].  
 
1.2.1. Human phosphoserine (pSer)/threonine(pThr)-binding domains 
 
1.2.1.1. 14-3-3 
 
This was the first pSer/ pThr-binding domain identified and is expressed in all eukaryotic cells. 14-3-3 
proteins are associated with a variety of cellular processes, such as cell cycle progression, DNA 
damage responses, metabolism, receptor recycling and trafficking, protein degradation and 
apoptosis, among others, although their mechanistic action is not yet fully understood [10, 11]. They 
appear to regulate the catalytic activity of some ligands (e.g. Raf), the interaction between their 
bound ligands and other molecules within the cell (e.g. pro-apoptotic Bcl-2 family protein BAD), and 
controlling the subcellular localization of bound proteins (e.g. Cdc25) [11]. They present three 
fundamental modes of action: (i) conformational change of the ligand; (ii) physical obstruction of a 
specific region on the target ligand, blocking protein-protein and protein-DNA interaction sites, and 
protecting their target ligands against dephosphorylation and/or degradation; (iii) anchoring of two 
target proteins in the vicinity of one another, promoting protein-protein interactions [10, 12]. 
In terms of structure, 14-3-3 proteins are C2-symmetric dimers (either homo- or heterodimers) [10, 
13]. Each monomeric subunit is composed of nine antiparallel α-helices, connected by short loops. 
The four N-terminal helices (A-D) interact by salt bridges, hydrogen bonds, and van der Waals 
interactions with the opposite subunit, forming a central 35 Å wide and 20 Å deep channel, where 
the target ligand binds (Figure 1.2A) [13, 14]. Binding occurs in an amphipathic groove along each 
edge of the channel. A basic pocket, consisting of Lys49, Arg56, and Arg127, along with Tyr128 (from 
helices C and E), are responsible for phosphate binding, through the formation of five ionic bonds 
and a hydrogen bond to three of the phosphate oxygen atoms [10, 12, 13, 15]. The phosphopeptide 
main chain is positioned in an extended conformation by hydrophobic interactions with Leu172, 
Val176, Leu216, Ile217, Leu220, Leu227, and Trp228 from the C-terminal helices, as well as hydrogen 
bonding between the peptide NH and CO backbone groups and side chains of residues in helices E, G 
and I, with Asn173 and Asn224 playing a crucial role (Figure 1.2B) [10, 13-15]. The presence of a 
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proline at the C-terminal two residues to the phosphorylated residue redirects the peptide chain 
away from the binding groove [10, 13]. 
Two consensus binding motifs were found by oriented peptide library screening: Arg-(Ser/Ar)-(+)-
pSer-X-Pro and Arg-X-(Ar/Ser)-(+)-pSer-X-Pro, where Ar is an aromatic residue, + is a basic residue, 
and X is any residue (commonly Leu, Glu, Ala and Met) [10, 14, 16].  
 
 
Figure 1.2 – Schematic representation of 14-3-3 domains binding to a consensus peptide motif. A) 14-3-3 
proteins form cup-shaped dimeric structures. Each monomer (in red and blue) contains nine α-helices (A-I) 
linked by short loops. In this representation, two phosphorylated peptides are simultaneously binding to each 
monomer, but a unique target protein with multiple phosphorylation sites could also bind in an identical 
manner. B) The phosphate group establishes five ionic bonds and one hydrogen bond with Lys49, Arg56 and 
Arg127 and Tyr128. Peptide backbone interacts with Asn173 and Ans224 through hydrogen bonding. Nitrogen 
atoms are colored in blue, oxygen atoms in red, and phosphate group in orange.  (Images A and B are 
reproduced from references [13]  and [10], respectively.) 
 
1.2.1.2. Brca1 C-terminal (BRCT) 
 
BRCT domains consist of 85 to 100 amino acids and have been observed as single, tandem or 
multiple repeats in a variety of proteins, namely BRCA1 (where it was originally identified), 53BP1, 
XRCC1, DNA ligases III and IV, among others [17, 18]. A single protein can contain up to eight of these 
domains, which are of pivotal importance in cellular DNA damage response, being involved in cell 
cycle control and checkpoint-mediated repair. Mutations in BRCA1 sequences encoding the BRCT 
domains have been highly associated with breast and ovarian cancers, by inhibiting phosphopeptide 
recognition [19-21].  
Structurally speaking, each BRCT domain comprises a four-stranded parallel β-sheet flanked by three 
α-helices (α1 and α3 on one side and α2 on the other), presenting highly conserved structures and 
selectivity for the sequence pSer-X-X-Phe, where X is any amino acid (Figure 1.3A). Although these 
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domains recognize both pSer and pThr, the first one binds with much higher affinity [21]. Most 
conserved residues are located in the central β-sheet, in helix α3 and at the C-terminus of helix α1, 
while helix α2 is poorly conserved [19]. Phosphopeptide recognition usually requires the existence of 
two repeats, with the peptide being positioned in a groove at the center of the dimer. The inter-BRCT 
linker is a variable region, both in sequence and length, and it is not clear if its function is solely to 
properly position each domain or if it is also implicated in the establishment of protein-protein 
interactions [17, 19]. pSer interacts with the N-terminal BRCT repeat, whereas Phe is recognized by a 
hydrophobic pocket at the N- and C-terminal repeats interface. Both the main chain NH of Gly1656 
and the OH of Ser1655 of the BRCA1-BRCT domain interact by hydrogen bonding with the phosphate 
group, with the OH group of Ser1655 being further stabilized by hydrogen-bonding with Thr1700. 
The phosphate group also establishes salt bridges with Lys1702, which in turn interacts by hydrogen 
bonding with the main chain CO of Val1654 and Asn1678 (Figure 1.3B) [19, 22]. This type of 
coordination of phosphate oxygen atoms by main chain NH groups, Ser OH groups and positively 
charged side chains resembles the binding mode of 14-3-3 and FHA domains [19]. The Phe-binding 
pocked consists of Leu1701, Phe1704, Met1775 and Leu1839 at the bottom, while Arg1699, Asn1774 
and Arg1835 are positioned at the sides. Particularly, Arg1699 is of extreme importance for the 
positioning of Phe, forming hydrogen bonds through its main chain CO with the main chain NH of 
Phe, while its guanidinium side chain interacts though salt bridges with the main chain CO of Phe [19, 
23]. Moreover, mutations in Met1775 destroy the ability of BRCT-containing proteins to interact with 
their targets, and are often observed in patients with cancer [19, 20].  
 
Figure 1.3 – BRCT domain binding to pSer-X-X-Phe peptide motif. A) Each BRCT domain is composed of four β-
sheets and three α-helices. Phosphopeptide recognition typically requires the presence of two domains, with 
the phosphorylated residue being positioned in the N-terminal BRCT, while the Phe recognition pocket is 
located in the interface between the domains. B) Detailed view of phosphopeptide binding to BRCT domains. 
pSer-binding pocked consists of three critical amino acids: Ser1655, Gly1656 and Lys1702. Phe in position (+3) 
is mainly stabilized by non-polar interactions with Met1775 and backbone interactions with Arg 1699. 
(Reproduced from reference [19].) 
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1.2.1.3. FHA  
 
FHA domains are pThr-binding proteins composed of approximately 140 amino acids [11, 24]. They 
are found in many proteins, including kinases, phosphatases, transcription factors, metabolic 
enzymes and kinesin-like motors [8, 25]. In humans, they have been associated with cancer and 
particularly with a variant form of cancer-prone Li-Fraumeni syndrome [26].  
FHA domains are organized in a 10- or 11- stranded β-sandwich, in a way that closely resembles MH2 
domains (Figure 1.4A) [8, 24]. The loops connecting the strands are essential for pThr binding, which 
occurs at only one end of the domain [24, 27]. Phosphate recognition is made by two conserved 
residues, an Arg of β3-β4 loop and a Ser of β4-β5 loop, and an Arg, Lys or Asn of the β4-β5 loop, 
through hydrogen-bonding and salt-bridging (Figure 1.4B). The γ-methyl group of pThr establishes 
structurally conserved van der Waals interactions, which explains the discrimination of pThr over 
pSer [8, 25]. However, the phosphorylated residue is not the only one conferring specificity. FHA 
domains bind in a sequence-specific manner from pThr-4 to pThr+3 positions, with the highest 
selection in the pThr+3, which is preferably an Asp, a Leu or Ile, depending on the protein. Residues 
from loops β4-β5, β6-β7 and β10-β11 are mostly involved in this interaction [8, 24].  
 
 
Figure 1.4 – Structural details of a pThr-containing peptide binding to FHA domains. A) FHA Domains consist 
of 10- or 11-stranded β-sandwich (colored in pink). pThr-containing motifs interact with FHA domains via β-
strand-connecting loops (colored in white). B) pThr interacts by hydrogen-bonding and salt-bridging with a 
conserved Arg of β3-β4 loop, a conserved Ser of β4-β5 loop, and an Arg, Lys or Asn of the β4-β5 loop. A 
conserved Asn of β6-β7 loop contributes for the specific recognition of residues at pThr+1 and pThr+3 positions 
(Images A and B were reproduced from references [8] and [25], respectively). 
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1.2.1.4. MH2 
 
The transforming growth factor-β (TGF-β) signalling pathway regulates numerous cellular processes, 
both during embryogenesis and in adult life, and the emergence of some diseases such as cancer, 
atherosclerosis, renal and cardiac fibrosis, Marfan syndrome, among others, has been associated 
with the disruption of this pathway [28, 29]. TGF-β signalling pathway is mediated mainly by 
transmembrane receptors with Ser/Thr and weaker Tyr kinase activities, and also cytoplasmic 
effector proteins named Smad [29, 30]. Receptor-specific Smads (R-Smads) and the common 
mediator Smad - Smad4 - are composed of two highly conserved domains, the Mad-homology 1 
(MH1) domain at their N-terminus and the MH2 domain at their C-terminus, which are connected by 
a proline-rich variable linker. The MH1 domain is mainly a DNA-binding domain, although it also 
binds to regulatory proteins and is thought to be a negative regulator of the MH2 domain. On the 
other hand, MH2 domains mediate interactions with a wide range of proteins, including receptors, 
other Smad proteins, nuclear transcriptional co-activators and co-repressors [28, 29]. MH2 domains 
possess a large hydrophobic surface, which facilitates their interaction with proteins that are 
unrelated both in terms of sequence and structure [28]. 
In simplified terms, the receptor kinases suffer oligomerization upon ligand (e.g. TGF-β) binding and 
phosphorylate a R-Smad protein (e.g. Smad1, -2, -3, -5) at its C-terminal MH2 domain in a highly 
conserved region, Ser-Ser-X-Ser, where X is any amino acid. Phosphorylation induces first homo-
trimerization of R-smads and then hetero-oligomerization between R-Smad and Smad4, which 
facilitates R-Smad-Smad4 complex to enter the nucleus where it binds to certain promoters and 
regulates the transcription of a variety of genes (Figure 1.5A) [9, 31].  
MH2 domains consist of approximately 200 amino acids and a central β-sandwich surrounded by a 
three-helical bundle at one side and a loop/helix region at the other (Figure 1.5B) [29, 30]. 
Phosphorylation of R-Smads occurs in two of the three Ser residues of the consensus sequence (e.g. 
Ser465 and Ser467 in Smad2). The negatively charged C-terminus of R-Smad interacts by hydrogen-
bonding and van der Waals forces with a positively charged loop-strand pocket of either R-Smads (in 
homo-oligomerization) or Smad4 (in hetero-oligomerization), which is formed by the L3 loop and the 
β-strand B8. Four conserved amino acids, both in R-Smads and Smad4, play a prominent role in 
phosphate coordination: Lys375 of β-strand B8 and Lys420, Tyr426 and Arg428 of L3 loop (Figure 
1.5C).  Tyr426 and Lys375 make three hydrogen bonds to the phosphate group of Ser465, whereas 
Lys420 and Arg428 hydrogen-bond Ser467. Ser467 is further stabilized by hydrogen-bonding 
between its carboxylate group and Lys420, Arg427 and Arg428 side chains. Intramolecular contacts 
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occur between Ser465 phosphate group and the backbone amide group of Met466, and Ser467 
backbone amide and phosphate group with Ser464 side chain. The interaction between Smads is 
further strengthened by van der Waals contacts [31].  Arg378, which is present in Smad4 but not in 
R-Smads, contributes for the preferential hetero-oligomerization of Smads and also for the 
coordination of phosphorylated Ser467 by hydrogen-bonding [32]. 
 
 
Figure 1.5 – Mechanistic and structural insights of Smad2 MH2 domain. A) Diagram of TGF-β signalling 
pathway. TGF-β binds to a transmembrane receptor complex inducing phosphorylation of Smad2 MH2 domain, 
which in turn binds to Smad4 MH2 domain. Smad2-Smad4 complex then translocates to the nucleus where it 
regulates gene expression. B) MH2 domains consist of a central β-sandwich bordered by three helices on one 
side and three loops and one helix on the other side. C) Phosphate groups of Ser465 and Ser467 are 
coordinated by four conserved residues, Lys375 on β-strand B8 and Lys420, Tyr426 and Arg428 on L3 loop. 
(Reproduced from reference [31].) 
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1.2.1.5. Polo-box (PB) 
 
Polo-like kinases (Plks) are a family of Ser/Thr protein kinases involved in all stages of mitosis, 
cytokinesis, and cell cycle checkpoint response to genotoxic stress [33, 34]. Humans hold five Plk 
family members: Plk1, Plk2, Plk3, Plk4 and Plk5. Plk1 to Plk4 are all involved in cell cycle progression, 
while Plk5 is exclusively implicated in non-proliferative processes, such as neuronal differentiation 
[35].  
Plks have an N-terminal kinase domain (absent in human Plk5) and a C-terminal non-catalytic region 
– the PB domain, which is fundamental for Plk localization and function. This domain comprises two 
Polo-boxes in Plk1, Plk2, Plk3 and Plk5, and a single Polo-box in Plk4. PB domains of Plk1 and Plk2 
recognize a specific phosphorylated sequence, Ser-(pSer/pThr)-(Pro/X), where X is any amino acid. In 
contrast, the PB domain of Plk3 does not act exclusively in a phospho-dependent manner and in fact 
presents low affinity for phosphopeptides. PB domains of Plk4 and Plk5 work completely as phospho-
independent modules [11, 33, 36]. 
The PB domain is a 12-stranded β-sandwich flanked by three α-helices. It is composed of two Polo-
boxes (PB1 and PB2) and a linker between the kinase domain and PB1 (Polo-cap or Pc). Each Polo-box 
consists of 70-80 amino acids forming a 6-stranded anti-parallel β-sheet flanked by one α-helix. PB1 
and PB2 are linked together through a conserved linker sequence (L2). The Pc region comprises one 
α-helix (αA), a loop and a short 310 helical structure that is attached to β1 strand of PB1 by a short 
linker (L1). The Pc folds around PB2 tethering it to PB1.  
Phosphopeptide binding occurs at one edge of the interface between PB1 and PB2 in a conserved 
positively charged cleft (Figure 1.6A) [33, 34]. Binding of phosphate moiety involves not only protein-
peptide interactions, but also extensive hydrogen-bonding to an ordered lattice of water molecules. 
The only residues that directly interact with the phosphate moiety are one conserved His and one 
conserved Lys from PB2 (Figure 1.6B) [11, 33, 34]. Plk1 structure indicates that there is a highly 
conserved Ser residue at pThr-1 position, which hydrogen-bonds to the main chain of conserved 
Trp414 and to the main chain carbonyl of conserved Leu491 via a water molecule. Moreover, it 
establishes significant van der Waals interactions with Trp414 indole group (Figure 1.6C). The 
preference of a Pro residue at pThr+1 position has been attributed to the fact that it redirects the 
peptide backbone, facilitating the positioning of the pThr+2 residue near the binding surface. There is 
some debate in literature as to whether there is a preference for a pThr over a pSer residue in the 
consensus motif [33, 34].  
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Figure 1.6 – PB domain/ phosphopeptide interactions. A) PB domains are composed of two Polo-boxes (PB1 
and PB2), each of them consisting of six β-strands and one α-helix, and an N-terminal region (Pc) which 
surrounds PB2. The Pc region is connected to PB1 by one loop (L1) and the polo-boxes are connected to each 
other through another loop (L2). Phosphopeptide binding occurs at the interface between PB1 and PB2. PB1 is 
coloured red, PB2 is coloured purple and Pc is coloured grey. B) Phosphate moiety is coordinated by a well-
defined network of water molecules. The unique residues that make direct contacts to phosphate are His538 
and Lys540. C) Interactions between the phosphopeptide (coloured blue) and the Polo-box domain Ser at 
position pThr-1 establishes highly conserved interactions with Trp414 and Leu491. Hydrogen bonds are 
represented by dotted lines; van der Waals contacts by purple crescents, and water molecules by green circles. 
(Reproduced from reference [33].)  
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1.2.1.6. WD-40  
 
WD-40-containing proteins are found in all eukaryotes and some prokaryotes, and are known to be 
involved in a wide variety of cellular processes, such as signal transduction, cell cycle control, RNA 
synthesis and processing, chromatin assembly, cytoskeletal assembly, regulation of vesicular 
formation and vesicular trafficking, programmed cell death, etc. [37, 38]. Despite this diversity, there 
is one shared function among WD-40 proteins: all of them support the assembly of multi-protein 
complexes by acting as protein scaffolds, allowing the simultaneous interaction with several proteins 
[37].  The WD repeat consists of 44 to 60 amino acids, generally containing a Gly-His (GH) dipeptide 
11 to 24 amino acids from its N-terminus and a Try-Asp (WD) dipeptide at its C-terminus, although 
none of the dipeptides are completely conserved. There is a conserved 40 amino acid core sequence 
between GH and WD, which is why it is designated as WD-40 repeat. WD-40 proteins possess a 
minimum of 4 WD-40 repeats and up to 16, folding into a β-propeller structure. Each WD-40 repeat 
consists of a 4-stranded antiparallel β-sheet. The propeller blades are composed of 3 β-strands of 
one repeat and one β-strand of the neighbouring repeat, which provides structural stability (Figure 
1.7A)  [37, 38].  
WD-40 domains are able to recognize specific phosphorylated substrates: the WD-40 domain of Cdc4 
binds to the (Leu/Ile)-(Leu/Ile/Pro)-pThr-Pro-X motif, where X is any amino acid except Arg and Lys 
[11, 39]; and the WD-40 domain of β-TrCP binds to the consensus sequence Asp-pSer-Gly-X-X-pSer in 
IκBα, β-catenin and Vpu, and to Asp-pSer-Gly-X-X-X-pSer in ATF4, where X is any amino acid [40, 41].  
In the WD-40 domain of Cdc4, the phosphate moiety of the substrate is coordinated by hydrogen-
bonding to the side chain of Tyr548, and by electrostatic interactions with the guanidinium group of 
three Arg residues (Arg485, Arg467 and Arg534). The conserved Pro residue at pThr+1 position is 
positioned in a hydrophobic pocket composed of Trp426, Thr441, and Thr465 (Figure 1.7B)  [39].  
The WD-40 domain of β-TrCP binds to the first phosphorylated residue of β-catenin (pSer33) and Vpu 
(pSer52) in a similar way: the phosphate moiety hydrogen-bonds to the side chain OH groups of 
Tyr271, Ser309, and Ser325, and interact electrostatically with the guanidinium group of Arg285. The 
second phosphorylated residue - pSer37 in β-catenin and pSer56 in Vpu – establishes fewer 
interactions, and with different amino acids. pSer37 phosphate group establishes electrostatic 
interactions with the side chain of Arg431, and hydrogen-bonds to the side chain of Ser448 and the 
backbone amide of Gly432. pSer56 is located within a positively charged pocket composed of Arg367, 
Arg390, Arg431 and Lys365. The conserved Asp residue at pSer-1 position of β-catenin makes a 
hydrogen-bond with Arg474 and Tyr488, while the Asp of Vpu hydrogen-bonds to Arg474, Arg521, 
Platforms for enrichment of phosphorylated 
proteins and peptides in proteomics 
Chapter 1 
 
13 
 
and Tyr271. Gly at pSer+1 position packs with two Leu residues of β-TrCP both in β-catenin and Vpu 
(Figure 1.7C) [40, 41]. 
 
 
 
Figure 1.7 – WD-40 domains: Structure and recognition of phosphorylated substrates. A) β-propeller 
structure of WD-40 domain of Cdc4 binding to Cdc4-phosphodegron (CPD). Cdc4 is composed of eight propeller 
blades (PB1 to PB8), where each blade consists of three β-strands of one WD-40-repeating unit and another β-
strand of the adjacent repeat. B) Interaction sites between Cdc4 WD-40 domain and CPD. The phosphate 
binding pocket is mainly composed by three Arg residues, which establish electrostatic interactions with the 
phosphate, and a Tyr which hydrogen-bonds to the phosphate through its side chain. Pro at pThr+1 position 
and the hydrophobic residues at positions pThr-1 and pThr-2 are all mainly sited within a hydrophobic cluster. 
Pro establishes an additional contact with Arg485, through van der Waals interactions with its side chain and 
hydrogen-bonding to its main chain carbonyl. C) Binding of β-TrCP to β-catenin (in green) and Vpu (in pink). The 
first pSer coordinates in a similar way in both substrates, establishing conserved interactions with Arg285, 
Tyr271, Ser309, and Ser325. The second phosphorylated residue sits near one Arg in β-catenin and one Lys in 
Vpu. (Images A and B were reproduced from reference [39], and image C was reproduced from [41].) 
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1.2.1.7. WW 
 
WW domains are 38 to 40 amino acid modules widely spread in a variety of signalling proteins and 
that are known to bind proline-rich sequences. They play a multiplicity of roles in cell cycle control, 
transcription, RNA processing, ubiquitin ligation, protein trafficking, control of the cytoskeleton, 
receptor signalling, etc., and have been associated with diseases such as cancer, Liddle’s syndrome, 
Rett syndrome, Duchenne and Becker muscular dystrophies, Huntington’s disease, and Alzheimer’s 
disease [42, 43]. 
 They can be divided into five classes: Group I, Group II, Group III, Group IV and Group V, which bind 
to Pro-Pro-X-Tyr (where X is any amino acid), Pro-Pro-Leu-Pro, Pro-Gly-Met, (pSer/pThr)-Pro, and 
Pro-Arg, respectively [44]. However, this classification has been rather controversial [42]. Here we 
are going to focus on Group IV, since it is the one recognizing phosphorylated substrates. The crystal 
structure of the WW-containing protein Pin1 in complex with the doubly phosphorylated Tyr-pSer-
Pro-Thr-pSer-Pro-Ser peptide of the carboxy-terminal domain of RNA polymerase II has been solved 
and will be used here as an example [44]. WW domain adopts a three-stranded antiparallel β-sheet 
structure and is located at the N-terminus of Pin1, which has a peptidyl-prolyl cis-trans isomerase 
(PPIase) domain at its C-terminus (Figure 1.8A). The PPIase domain catalyse the (pSer/pThr)-Pro bond 
isomerization, while WW domains are only able to bind the trans isomer of their phosphorylated 
substrates. The crystal structure of the Pin1-phosphopeptide complex reveals that the WW domain 
establishes interactions with the second phosphorylated Ser residue through a Ser and an Arg in the 
β1/β2 loop and a Tyr in the β2 strand. Two aromatic residues, a Tyr and a Trp, establish additional 
van der Waals interactions with Thr4, pSer5 and Pro6 of the peptide (Figure 1.8B) [13, 44]. 
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Figure 1.8 – Pin1 WW domain complexed with Tyr-pSer-Pro-Thr-pSer-Pro-Ser peptide of the carboxy-terminal 
domain of RNA polymerase II (CTD peptide). A) Pin1 is composed by a three-stranded antiparallel β-sheet 
structured N-terminal WW domain and a C-terminal PPIase, connected by a linker. B) The CTD peptide binds to 
WW domain through its second phosphorylated Ser residue (pSer5’). The phosphate group binds to the side 
chains of Ser16 and Arg17 though hydrogen-bonding. Arg17 makes an additional bond to the phosphate 
through its backbone NH group. The phosphate group interacts with the side chain of Tyr23 by mediation of a 
water molecule. Both Tyr23 and Trp34 establish van der Waals contacts with the backbone of Thr4’ and pSer5’ 
and the ring atoms of Pro6’ of the CTD peptide. Hydrogen bonds are represented by green dashed lines and 
van der Waals surfaces by gold dotted curves. Amino acids of the CTD peptide are labelled black and with an 
apostrophe for clarity. (Images A and B were reproduced from references [24] and [44], respectively.) 
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1.2.2. Human phosphotyrosine (pTyr)-binding domains 
 
1.2.2.1. SH2  
 
SH2 domains consist of around 100 amino acids, being the first domains recognized to behave as 
phosphorylation-dependent binding modules. Among SH2-containing proteins are kinases, 
phosphatases, transcription factors, adaptor proteins, cytoplasmic signalling molecules, among 
others [45]. Tyr phosphorylation is a general recognition element for SH2 domains (although a few 
have been reported to bind in a phospho-independent mode), but they discriminate among their 
substrates depending on which amino acid residues are positioned carboxy-terminal to pTyr. This 
allows particular SH2 proteins to be recruited and trigger specific signalling pathways [45, 46]. In fact, 
SH2 domains can be divided in three main groups, depending on substrate specificity: Src-like, 
phospholipase C-γ1 (PLC-γ1)-like, and Grb2-like, which select for pTyr-Glu-Glu-Ile, pTyr-hydrophobic-
X-hydrophobic (where X is any amino acid), and pTyr-X-Asn-X (where X is commonly a Val residue) 
motifs, respectively [47-49].  
SH2 domains fold into a β-meander containing one four-stranded and one three-stranded β-sheet, 
which are connected to each other by one β-strand. The four-stranded β-sheet is capped by two 
additional α-helices. The phosphopeptide binds in an extended conformation perpendicular to the 
four-stranded β-sheet. The pTyr residue binds at one side of the β-sheet, with two Arg residues (one 
from αA and one from βB) playing a central role in phosphate coordination. The Arg from αA 
together with side chain and backbone atoms from βD strand residues further stabilize the aromatic 
ring of pTyr. Residues from pTyr+1 to pTyr+5 are positioned in the opposite side of the β-sheet, 
binding to atoms from the loops between αB and βG (loop BG) and between βE and βF (loop EF) 
(Figure 1.9). These last interactions depend on the class of SH2 domains [45, 50]. 
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Figure 1.9 – Structure and binding specificity of SH2 domains. SH2 domains fold into a β-meander structure, 
composed of four stranded and three-stranded β-sheets, which are connected by one β-strand, the N-terminus 
of which is denominated βD and the C-terminus of which is denominated βD’. Two α-helices (αA and αB) flank 
the four-stranded β-sheet. The phosphopeptide sits perpendicular to this β-sheet, with the pTyr interacting by 
hydrogen-bonds with two Arg residues (Arg αA2 and Arg βB5) at one side of the β-sheet. The aromatic group of 
pTyr is stabilized by an amino-aromatic bond to Arg αA2 and other interactions with residues from βD strand. 
The residues from pTyr+1 to pTyr+5 are located on the opposite side on the β-sheet, and make contacts to 
loops BG and EF. (Reproduced from reference [45].) 
 
1.2.2.2. Phosphotyrosine-binding (PTB)  
 
PTB domains may be found in a wide range of adaptor and scaffold proteins, being implicated in cell 
growth, immune response, neural development, tissue homeostasis, etc. Mutations on PTB domains 
have been linked to Alzheimer’s, diabetes, and cardiovascular diseases [51]. All PTB domains share 
the same structural conformation, folding into a 7-stranded β-sandwich which is flanked on its C-
terminus by one α-helix, although they have non-conserved primary sequences (Figure 1.10A) [45, 
51, 52]. PTB domains have been classified in three main classes based on their structural and 
functional features: Shc-like, IRS-like and Dab-like. The canonical recognition motif is Asn-Pro-X-
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(Tyr/pTyr). Both Shc-like and IRS-like domains recognition is dependent on the presence of a 
phosphorylated Tyr residue on the consensus sequence, while Dab-like domains recognize the non-
phosphorylated sequence (or even a Phe instead of a Tyr). In the three cases, the peptide binding 
pocket is composed of residues from β5 strand and the C-terminal α-helix, but the recognition is 
made by different amino acids. In IRS-like domains the peptide binding pocked consists of two Arg 
residues (Figure 1.10B). For Shc-like domains, the phosphate group is coordinated by hydrogen-
bonding to two Arg residues and one Lys (Figure 1.10C).  Dab-like domains bind to their target 
sequences driven by the establishment of hydrogen-bonds and hydrophobic interactions with amino 
acids on β5 strand, rather than recognition of the Tyr residue itself (Figure 1.10D) [51]. Other PTB 
domains recognizing peptide sequences different from the canonical Asn-Pro-X-(Tyr/pTyr) motif have 
been reported, and most PTB domains are known to bind phospholipids as well, enlightening the fact 
that there are no universal patterns of recognition [51, 53]. 
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Figure 1.10 – Structure and binding-specificity of PTB domains. A) PTB domains are seven-stranded β-
sandwiches flanked by one C-terminal α-helix (α1). A1 – The peptide folds into a β-strand conformation that 
establishes antiparallel interactions with the β5 strand of PTB. A2 – The peptide forms a type-I β-turn at its 
consensus motif. A3 – Tyr/pTyr-binding pocket. A4 – N-terminal residues interact by hydrophobic contacts with 
β5-strand and C-terminal α-helix. B) Phosphate coordination is achieved through contacts with two Arg 
residues in IRS-like domains. C) Two Arg residues and one Lys form a triangular network of hydrogen bonds 
with the phosphate group in Shc-like domains. D) Non-phosphorylated Tyr is recognized by hydrogen-bonding 
to one Gly and van der Waals interactions with a His in Dab-1 protein, but this is not a general recognition 
mode for Dab-like domains. Instead, these domains mainly interact with their targets through hydrogen-
bonding and hydrophobic contacts to amino acids on their β5 strand. (Image A was adapted from reference 
[52]. Images B, C and D were reproduced from reference [51].) 
 
1.2.2.3. Conserved domain 2 (C2) 
 
Originally recognized as calcium-dependent phospholipid binders involved in signal transduction and 
vesicular trafficking, C2 domains have shown their ability to bind pTyr-containing protein motifs as 
well [54, 55]. These domains consist of approximately 130 amino acids structured into an eight-
stranded β-sandwich. The crystal structures of two Protein kinases C (PKCδ and PKCθ) C2 domains in 
complex with an optimal sequence selected from peptide library screens were solved, revealing the 
key elements for pTyr recognition (Figure 1.11A)  [54, 55]. C2 domains selectively bind to the 
(Tyr/Phe)-(Ser/Ala)-(Val/Ile)-pTyr-(Gln/Arg)-X-(Tyr/Phe)-X motif, where X is any amino acid. The 
peptide adopts an elongated conformation across one end of one β-sheet towards the other β-sheet 
A
B C D
1
4
2
3
Chapter 1 Platforms for enrichment of phosphorylated 
proteins and peptides in proteomics 
 
20 
 
[54]. pTyr lies in a basic pocket and coordinates via hydrogen-bonding to the side chain and main 
chain NH group of one His residue, ring-stacking interactions between the phenyl group of pTyr and 
the same His residue, and electrostatic interactions with the side chains of one Arg and one Lys 
(Figure 1.11B). Other highly conserved residues further contribute for peptide recognition and 
binding affinity, through the establishment of side and main chain direct or water-mediated contacts 
[54, 55]. 
 
Figure 1.11 – C2 domains as pTyr-binding modules. A) Sequence homology between PKCδ and PKCθ C2 
domains. Identical, highly similar, similar and non-conserved residues are coloured red, blue, green and black, 
respectively. Blue arrows indicate residues that are fundamental for peptide recognition. B) C2 domains of 
PKCδ and PKCθ form a β-sandwich composed of two four-stranded β-sheets (in light blue). The peptide (in stick 
representation) binds transversally to these β-sheets. The side chains of the amino acids involved in pTyr 
recognition are in space-filling representation and marked. (Reproduced from reference [55].) 
 
1.3. Phosphoprotein and phosphopeptide enrichment 
 
Phosphoproteomics is the systematic identification and characterization of phosphoproteins, usually 
by combining mass spectrometry (MS) strategies with phospho-specific enrichment methods. MS is 
the workhorse for the detection of phosphosites within a single protein or a complex protein 
mixture. Unfortunately, because of a low phosphorylation stoichiometry, a diversity of 
A
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phosphorylated protein forms and the transient nature of phosphorylation states, the amount of 
phosphorylated species in biological samples and protein digests is low. Thus, the enrichment of 
phosphoproteins and phosphopeptides prior to MS analysis is a mandatory step [2, 56]. This chapter 
highlights current and emerging platforms for phosphopeptide enrichment prior to MS analysis 
(Figure 1.12), because several recent reviews have successfully focused on MS analysis alone [57, 58]. 
For simplicity, the enrichment processes are described for phosphopeptides, as most phosphoprotein 
containing samples are enzymatically digested before further MS analysis. 
 
 
Figure 1.12 – Platforms for phosphopeptide enrichment. Established methods include immunoprecipitation, 
ion exchange chromatography (either Strong Cation Exchange (SCX) or Strong Anion Exchange (SAX)), 
Immobilized Metal Affinity Chromatography (IMAC), Metal Oxide Affinity Chromatography (MOAC) and, more 
recently, Phosphoprotein-binding Domains (PBDs). Novel tag-receptor systems and phosphate-affinity ligands 
have been developed as alternative methodologies. These methods can be further combined with enrichment 
platforms, as magnetic adsorbents and/or functionalized MALDI plates, before MS analysis. 
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1.3.1. Established strategies for phosphopeptide capture 
 
Established approaches for the enrichment of phosphopeptides from complex biological samples 
involve chromatographic steps based on affinity, metal ion and ion exchange interactions (Figure 
1.12). The platforms described in this section are those whose applications have been extended 
beyond the proof of concept with simple protein digests, and in which large-scale proteomic efforts 
using tissue samples have been implemented. 
Affinity purification requires the coupling of an affinity ligand to a beaded matrix. In immunoaffinity 
chromatography, antibodies are utilized as affinity reagents, and therefore, this approach is limited 
by the commercial availability of antibodies against phosphorylated Ser, Tyr and Thr residues. The 
low specificity of antiphosphoserine and antiphosphothreonine antibodies has limited their 
widespread application as opposed to antiphosphotyrosine antibodies. Antiphosphotyrosine 
antibodies are more specific, reliable, and far more frequently used, being able to detect multiple Tyr 
phosphorylations on a variety of protein substrates [56, 59].   
PDBs have also been used as ligands in affinity chromatography to target phosphorylated species 
[60]. Currently, there are 17 commercially available kits, based on different naturally occurring SH2 
domains, for the selective capture of phosphotyrosine (pTyr) (Table 1.1).  
Biological affinity reagents are expensive and usually labile; therefore, other strategies for the 
selective recognition of phosphorylated species have been explored using more durable and low-cost 
purification matrices. 
Immobilized metal affinity chromatography (IMAC) and metal oxide affinity chromatography (MOAC) 
are widely used for phosphopeptide enrichment. In IMAC, metal ions (Fe3+, Al3+, Ga3+, Zr4+) are 
chelated to a stationary phase, such as silica, agarose beads or monoliths, via nitriloacetic acid (NTA), 
imidodiacetic acid (IDA) or tris-(carboxymethyl)-ethylenediamine  ligands [61]. 
In MOAC, metal oxides, commonly titanium dioxide - TiO2, are the anchoring point to entrap the 
phosphopeptide through the formation of multi-dentate bonds. Metal oxides can also be regarded as 
Lewis acids, where an ion exchange mechanism may be involved in the phosphate-metal oxide 
interaction. Several factors can influence the recognition of the phosphorylated species, such as 
synthesis conditions and the nature of the metal oxides, as recently reviewed [62]. Both IMAC and 
MOAC bind singly and multi-phosphorylated peptides. However, IMAC columns present stronger 
avidity towards multi-phosphorylated peptides. The multi-phosphorylated peptides present high 
binding affinity to MOAC supports, which makes elution difficult, and hence mono-phosphorylated 
species are more easily identifiable with MOAC [2, 63]. Additionally, a limitation in both IMAC and 
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MOAC, is the frequent nonspecific binding of peptides containing acidic amino acids (e.g. Glu and 
Asp) [2, 56]. Very recently a new technique, coined SIMAC (sequential elution from IMAC), has been 
reported as an improved version and combination of IMAC and TiO2 [2].   
Ion exchange chromatography represents another useful tool for the prefractionation of 
phosphopeptides prior to enrichment. In strong cation exchange (SCX) chromatography, acidic 
conditions promote the interaction between positively charged tryptic peptides and the negatively 
charged functional groups on the SCX particles. In appropriate acidic conditions, carboxyl groups will 
be protonated, and phosphopeptides will retain negative charges on phosphate groups. 
Phosphopeptides will be less positively charged, and therefore elute in earlier fractions than non-
phosphorylated species [64]. Although the amount of contaminants co-adsorbing to the ion-
exchange resin is still considerable, this type of adsorbent is usually combined with other enrichment 
methods, such as IMAC or MOAC [2, 56].   
In anion exchange chromatography, phosphorylated species are typically more retained than their 
non-phosphorylated counterparts. However, acidic peptides bind strongly to the resin and the 
subsequent recovery of phosphopeptides is still a difficult task. Recently, a strong-anion exchange 
(SAX) capillary monolith was coupled with matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF MS) using buffers with pH values compatible with protein digestion 
and preparation of the MALDI matrix solution; phosphopeptides were detected at concentrations 
down to the attomole level [65]. 
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Table 1.1 – Commercially available phosphoprotein and phosphopeptide enrichment kits. 
Company Kits 
Calbiochem 
(http://www.merckmillipore.com/) 
ProteoExtract® Phosphopeptide Enrichment TiO2 Kit 
ProteoExtract® Phosphopeptide Capture Kit 
Clontech 
(http://www.clontech.com/) 
BDTM Phosphoprotein Enrichment Kit 
TALON® PMAC Magnetic Phospho Enrichment Kit 
EMD4Biosciences 
(http://www.emdchemicals.com/) 
Calbiochem® Phosphoprotein Enrichment Kit 
ProteoExtract® Phosphopeptide Enrichment TiO2 Kit 
GE Healthcare 
(http://www.gelifesciences.com/) 
TiO2 Mag Sepharose
TM 
GL Sciences 
(http://www.glsciences.com/) 
Titansphere Phos-TiO Kit 
Glygen 
(http://www.glysci.com/) 
Phosphopeptide Enrichment NuTip 
Phosphopeptide Enrichment TopTip 
Phosphopeptide Enrichment Lab-in-a-Plate 
Phosphopeptide Enrichment Lab-in-a-Plate Flow-Thru Plate 
Invitrogen 
(http://www.invitrogen.com/) 
Captivate™ Microscale Phosphopeptide Isolation Kit 
Pro-Q® Diamond Phosphoprotein Enrichment Kit 
Komabiotech 
(http://www.komabiotech.com/) 
EzWayTM Phos-Pep Enrichment Kit 
EzWayTM Phos-Pro Enrichment Kit 
Millipore 
(http://www.millipore.com/) 
ZipTip with 0.6 µL metal chelate resin 
Perkin Elmer 
(www.perkinelmer.com) 
Phos-trap™ Enrichment Kit 
Phos-TagTM 
(http://www.phos-tag.com) 
Phos-tagTM Agarose 
Qiagen 
(http://www.qiagen.com/) 
Phosphoprotein Purification Cartridge 
Phosphoprotein Purification Kit 
IMAC Mass Spec Focus Chips 
Sigma-Aldrich 
(http://www.sigmaaldrich.com/) 
Phos-SelectTM Gallium Silica Spin Column Kit 
Phos-SelectTM High Capacity Iron Coated Plate 
Phos-SelectTM Iron Affinity Gel 
Supel-Tips Zr Pipette Tips 
Supel-Tips Ti Pipette Tips 
Thermo Scientific 
(http://www.piercenet.com/) 
Phosphoprotein Enrichment Kit 
SH2 Domain Phosphotyrosine Capture Kits (17 kits) 
Ga-IDA Phosphopeptide Enrichment Kit 
Fe-NTA Phosphopeptide Enrichment Kit 
Magnetic Titanium Dioxide Phosphopeptide Enrichment Kit 
TiO2 Phosphopeptide Enrichment and Clean-up Kit 
ZirChrom 
(www.zirchrom.com) 
Titanium Dioxide SPE Tips 
Zirconium Dioxide SPE Tips 
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1.3.2. Combining traditional strategies with novel solid supports 
 
1.3.2.1. On-Plate enrichment with MALDI-TOF MS 
 
The detection of phosphorylated peptide fragments by MS is hampered by their low abundance, low 
ionization efficiencies, and by the ion suppression effect of the non-phosphopeptides. When positive 
ion mode is used, the negative charges on phosphate groups decrease the net charge of the ionized 
peptide. Moreover, phosphopeptides are usually less hydrophobic, and present low isoelectric point 
(pI) values and low-gas phase basicities, which makes them difficult to analyze by electrospray 
ionization mass spectrometry (ESI MS) or MALDI-TOF MS [66]. Negative ion mode is commonly used 
to circumvent the problem, because phosphopeptides present increased signal intensities. However, 
the determination of phosphorylation sites is challenging because negative polarity MS/MS spectra 
are difficult to interpret. One alternative would be to perform the detection of phosphopeptides by 
MS using negative ion mode, and then switch the polarity to positive ion mode when determining 
the phosphorylation site by MS/MS. This process  represents  an  unpopular  option  because  it  is 
time-consuming  and  leads  to  decreased  scanning  rates [56]. Reducing sample complexity by 
applying phospho-enrichment methods will reduce the ion suppression effect. Therefore, the use of 
simplified protocols for capture, concentration and analysis of protein digests in a single step is 
extremely valuable. A single step process increases signal-to-noise (S/N) ratios, minimizes sample 
loss, and improves the detection of target molecules. ESI mass spectrometers are popular in protein 
phosphorylation analysis, because they can be easily coupled to separation techniques such as the 
commonly used liquid chromatography (LC). Until recently, the utilization of MALDI-TOF MS required 
a preceding enrichment step, utilizing methods presented in the previous section. It is now possible 
to integrate the process of enrichment and analysis through modification of MALDI plates with a 
variety of materials, where IMAC and MOAC functionalities remain the preferred option. The process 
consists of adding the sample to a functionalized MALDI probe, rinsing the sample on the probe, and 
finally adding the matrix [67].  
Enhanced MALDI signals can be obtained by using patterned polycationic gold-coated silicon, such as 
poly(acrylic acid) (PAA) derivatized with polyethylenimine or complexed with Fe3+ [68]. Coupling an 
NTA derivative to the PAA surface, before complexation with Fe3+, significantly improves the 
selectivity of the probe. Moreover, detection can be further enhanced by using 2′,4′,6′-
trihydroxyacetophenone (THAP) mixed with diammonium hydrogen citrate (DAHC) as the MALDI 
matrix [69]. THAP/DAHC can be used either in positive or negative ion mode analysis, and increases 
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the S/N ratio for phosphopeptides by an order of magnitude, compared to the more commonly 
employed α-cyano-4-hydroxycinnamic acid (α-CHCA) matrix. The use of THAP/DAHC presents three 
main advantages: (i) reduction of sodium contaminants in the sample solution, because di-sodium 
citrate precipitates are formed during the co-crystallization procedure; (ii) enhancement of 
phosphopeptide ionization during positive ion mode MS, as a result of the formation of complexes 
between ammonium cations and phosphate groups; and (iii) detection of both phosphorylated and 
non-phosphorylated peptides as protonated molecules, because of the loss of ammonia during MS 
analysis [70].  
Another option to target phosphopeptides makes use of NTA functional groups immobilized on a 
gold surface via a 1,8-octanedithiol linkage and followed by loading Fe3+ or Ga3+ ions on the surface. 
The procedure briefly consists of the immersion of gold substrates first in an ethanolic solution of 
1,8-octanedithiol, which forms a self-assembled monolayer (SAM) on gold, followed by a solution of 
N-[5-(3-maleimidopropylamido)-1-carboxypentyl]-iminodiacetic acid, and finally a FeCl3 or Ga(NO3)3 
solution. Weak acidic conditions (pH 4-5) are required for the optimal enrichment of phosphorylated 
species. Moreover, Ga3+-NTA surfaces seem to present better results in terms of reproducibility than 
Fe3+-NTA surfaces. Although these SAMs offer a good performance in the on-probe enrichment of 
phosphopeptides, further optimization is needed with crude samples [71].  
An IDA derivative, IDA-1,2-epoxy-9-decene, immobilized  on the surface of a porous silicon wafer 
through a photochemical reaction, and then grafted with Fe3+, is able to trap mono- and tetra-
phosphopeptides specifically from tryptic digests of β-casein. 2,5-Dihydroxybenzoic acid (2,5-DHB) 
containing 1% phosphoric acid (H3PO4) was selected as the MALDI matrix, because it performed 
better than α-CHCA, probably because 2,5-DHB is also a metal chelating agent [72, 73]. The addition 
of H3PO4 to the matrix is known to enhance phosphopeptide ion signals during MALDI-TOF MS 
analysis [73]. 
Universal metal-chelating plastic MALDI chips for signal enhancement of phosphopeptides have also 
been developed. The chips are fabricated by the copolymerization of acrylic acid N-
hydroxysuccinimide ester and methyl methacrylate monomers in a 1:13.3 molar ratio under UV 
exposure in a sandwich mold (glass plate, spacer and silicon master). The surface is activated with 
N,N-bis(carboxymethyl)-L-lysine hydrate, before metal chelation. Chelated hard metal ions (e.g. Fe3+, 
Ga3+, Al3+) enrich phosphopeptides at low pH values, with Ga3+ being the most selective. Ga3+-MALDI 
chips have been evaluated in terms of signal intensities, and are fully comparable to the 
commercially available PHOS-Select Iron Affinity Gel from Sigma for phosphopeptide analysis (Table 
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1.1). Intermediate metal ions, such as Ni2+ and Cu2+, have demonstrated their efficiency to bind 
whole phosphorylated proteins at higher pH values [72].  
MALDI plates modified with high-capacity polymer brushes are a promising alternative to 
conventional methodologies. Gold substrates functionalized with poly(2-hydroxyethyl methacrylate) 
(PHEMA) brushes and derivatized with Fe3+-NTA, present a phosphopeptide binding capacity of 0.6 
µg/cm2, and a detection limit for tryptic peptides derived from β-casein of < 15 fmol. Fe3+-NTA-
PHEMA-modified plates exhibited phosphopeptide recoveries of around 70%, similar to the 
commercially available TiO2 NuTips, and even higher than ZipTipMC pipet tips, ZrO2 NuTips, and 
Qiagen IMAC Mass Spec Focus Chips (Table 1.1) [74]. These PHEMA-NTA-Fe3+ brushes might be 
enclosed by a hydrophobic poly(dimethylsiloxane) layer, reducing the spot diameter around 8 times, 
and subsequently lowering the sample volume and the detection limit by fivefold [67].  
The approaches described above are based on IMAC-functionalized MALDI plates, therefore 
presenting the drawbacks related to conventional IMAC methods, such as the nonspecific binding of 
acidic peptides. A more sensitive alternative uses a zirconium phosphonate-modified porous silicon 
surface (ZrP-pSi), enabling the detection of phosphopeptides from the tryptic digestion of 2 fmol β-
casein. The low detection limit allows for the identification of phosphorylated species even when a 
mixture of β-casein and bovine serum albumin in a molar ratio of 1:100 is used, whereas IMAC-based 
approaches lose specificity when high concentrations of non-phosphopeptides are present. However, 
multi-phosphorylated peptides are preferentially enriched relative to singly phosphorylated peptides 
using this approach, most probably because of a stronger interaction with the ZrP-pSi surface [75].  
 
1.3.2.2. Magnetic phospho-fishing 
 
During the past decade, superparamagnetic particles have been the focus of intense research, 
especially in the fields of bioseparation and biomedicine. They are non-porous adsorbents, easily 
manipulated by an external magnetic field, and present a high surface/volume ratio, leading to high 
binding capacities and fast binding kinetics [76]. The scope of application of magnetic particles for 
biotechnological separations is wide, but it is only relatively recently that magnetic materials have 
begun to be used for enrichment and identification of phosphopeptides. A variety of methods, which 
merge the fundamentals of metal ion affinity chromatography with magnetic separation have 
appeared in the past decade, and magnetic beads for phosphoproteomics analysis are already 
commercially available (Table 1.1).   
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In view of the success of using metal oxide coated adsorbents for the selective enrichment of 
phosphorylated species, alumina-coated iron oxide magnetic particles (Fe3O4@Al2O3) are able to 
concentrate phosphopeptides selectively from tryptic digests, with a capacity of 60 µg of 
phosphopeptides/g of particles. Specifically, Fe3O4@Al2O3 is mixed with an acidified tryptic digest 
solution containing phosphorylated species. The acidic conditions prevent the binding of non-
phosphopeptides containing acidic amino acid residues. After washing with a solution of 0.15% 
trifluoroacetic acid (TFA) in acetonitrile (ACN)/water, the peptide-loaded Fe3O4@Al2O3 particles are 
mixed with a MALDI matrix (2,5-DHB/ 1% H3PO4), and deposited on the MALDI plate using the dried 
droplet method. The entire process, including enrichment step and MALDI-TOF MS analysis, is 
extremely fast taking only ≈5 min [77]. These particles provide higher selectivity towards 
phosphopeptides than Fe3+-immobilized magnetic silica microspheres, commercial Fe3+–IMAC resins, 
and TiO2 beads [78]. Moreover, the interference of the particles in the laser desorption/ionization 
process is negligible, in view of the small size of the particles, which do not hinder signal intensities, 
resolution or mass accuracy of the mass spectra [79]. 
Zirconia-coated magnetic nanoparticles (Fe3O4@ZrO2) are also applied in integrated phosphopeptide 
capturing and digestion. The protein-Fe3O4@ZrO2 conjugates are heated in a microwave oven in the 
presence of trypsin, and digestion time was reduced to approximately 1 min. As magnetic 
nanoparticles absorb microwave radiation, the heating rate of the digestion solution is accelerated, 
and proteins attached to Fe3O4@ZrO2 denature, becoming more vulnerable to enzymatic digestion 
[80].  
Recently, other metal oxides, such as titanium dioxide (TiO2) [81], gallium trioxide (Ga2O3) [82], tin 
dioxide (SnO2) [83], tantalum pentoxide (Ta2O5) [84], niobium pentoxide (Nb2O5) [85], and zinc oxide 
(ZnO) [86] have also been used as coating materials for magnetic particles. Coating Fe3O4 
nanoparticles with two metal oxides, TiO2 and ZrO2, allowed the capture of a larger amount of 
phosphopeptides when compared to Fe3O4@ZrO2 or Fe3O4@TiO2 alone, and efficiently enriched both 
mono- and multi-phosphorylated peptides [87]. 
Table 1.2 presents the detection limits for phosphopeptides, mostly obtained from tryptic digests of 
caseins and enriched using magnetic nanoparticles with different coatings. Although the MS analysis 
referred to in Table 1.2 were all conducted in MALDI-TOF MS instruments in positive ion mode, 
several factors might have influenced the sensitivity of the analysis. These include the digest and 
enrichment conditions, the type of mass spectrometer, laser or matrix utilized, and the maintenance 
conditions of the instrument.  
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As an alternative to regular ZrO2, a novel strategy using zirconium phosphonate (Zr
4+-PO3
2-) as a 
coating shell has been proposed. The strong multi-coordination effect between Zr4+-PO3
2- and 
phosphoric species provides a more selective and sensitive support. The process can be easily 
combined with SCX separation, resulting in a high performance methodology to enrich 
phosphopeptides from complex real samples [88, 89].  
Iron oxide magnetic particles have also been coated with silica and grafted with a silane coupling 
agent (3-glycidoxypropyltrimethoxysilane with iminodiacetic acid – GLYMO–IDA). Fe3+ or Ce4+ ions 
can be immobilized on this surface, resulting in high phosphate selectivity; Ce4+ is particularly 
selective [90, 91]. Using the same principle, magnetic particles are coated with NTA and Zr4+ and Ga3+ 
ions to enrich phosphopeptides from complex real samples. Fe3O4/NTA-Zr
4+ offered a better trapping 
performance than Fe3O4/NTA-Ga
3+, which is probably related to the coordination number of both 
metals [92].  
Mesoporous materials consist of ordered porous networks with controllable pore sizes, high surface 
areas, and large pore volumes. Titanium grafted magnetic mesoporous silica (Fe3O4@Ti-mSiO2) has 
been successfully applied for phosphopeptide enrichment, by combining the affinity and size 
exclusion properties of the support [93]. 
Bacterial magnetic nanoparticles (BMP) present an interesting alternative to the regularly used 
synthetic magnetic particles, because they do not require any surface functionalization before the 
immobilization of the metal ion. BMPs of Magnetospirillum consist of Fe3O4 crystals coated with 
bacterial lipid membrane, which contains phospho- and sulfolipids for excellent metal binding 
affinity. Both Zr4+ and Fe3+ ions were immobilized on the surface of BMP of Magnetospirillum. Zr4+-
immobilized BMP favored the enrichment of multi-phosphopeptides, whereas Fe3+-immobilized BMP 
preferred singly phosphorylated peptides.  Fe3+-immobilized BMP presents a lower detection limit 
(Table 1.2), probably because of the larger amount of Fe3+ attached to the BMP. Moreover, BMP 
themselves were able to enrich a specific phosphopeptide from an α-casein digest through weak 
interactions [94].  
Rare earth metals present strong affinity towards phosphate moieties. γ-Fe2O3 magnetic 
nanoparticles coated with a shell of ammonium fluoride and lutetium fluoride (γ-
Fe2O3@xNH4F.yLuF3) have been reported to efficiently enrich samples of β-casein tryptic digest, 
nonfat milk tryptic digest and human serum in phosphorylated peptides [95]. 
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 Particles coated with an yttrium phosphate (YPO4) hollow porous affinity shell (Fe3O4@hYPO4) have 
also been successfully used in phosphopeptide enrichment [96]. Faster adsorption/ desorption 
dynamics and low non-specific binding can be obtained by capping Fe3O4 first with polyacrylate and 
then with a ultrathin YPO4 shell (PA-Fe3O4@YPO4) [97]. 
 
Table 1.2 – Magnetic particles with different coatings for the enrichment of phosphopeptides2. 
Core Shell 
Coupling 
Agent 
Metal 
Ions 
MALDI matrix 
Tryptic 
digest 
Sensitivity Refs. 
Fe3O4
a
 
P(HEMA-
GMA)
b
 
IDA 
Fe3+/ 
Ga
3+
 
2,5-DHB + 1% H3PO4 in 
0.1% TFA/ 30% ACN 
- - [98] 
Fe3O4 SiO2 
GLYMO–
IDAc 
Fe3+ 
2,5-DHB + 1% H3PO4 in 
10% MeOH 
FLTEpYVATR
d
 5 fmol 
[91] 
α-casein 20 fmol 
Fe3O4 SiO2 
GLYMO–
IDAc 
Ce4+ 
2,5-DHB + 1% H3PO4 in 
50% ACN 
- - [90] 
Fe3O4 SiO2 
NTAe 
derivative 
Ga3+/ 
Zr4+ 
2,5-DHB + 1% H3PO4 in 
ACN/ H2O (2/1) 
Mixture of  
α- and β-
caseins 
50 fmol [92] 
Fe3O4 Al2O3 - - 
2,5-DHB + 1% H3PO4 in 
ACN/ H2O (2/1) 
α-casein 25 fmol [77] 
Fe3O4 TiO2 - - 2,5-DHB + 1% H3PO4 β-casein 50 fmol [81] 
Fe3O4@C
a,f SnO2 - - 
2,5-DHB + 1% H3PO4 in 
50% ACN 
β-casein 80 fmol [83] 
Fe3O4@C
f
 Ga2O3 - - 
2,5-DHB + 1% H3PO4 in 
50% ACN 
β-casein 40 fmol [82] 
Fe3O4 ZrO2 - - 
2,5-DHB + 0.5% H3PO4 
in  ACN/ H2O (2/1) 
β-casein 45 fmol [80] 
Fe3O4 SiO2 PO3
2- Zr4+ 
2,5-DHB + 1% H3PO4 in 
70% ACN 
β-casein 0.5 fmol [89] 
 
 
                                                        
2  a The  analytes  on  MALDI  target  were  the  phosphopeptides  coupled  to  particles,  except  for  these  
where  peptides  were  previously  eluted  from  the  magnetic  beads; 
b 
P(HEMA-GMA):  poly(2-hydroxyethyl  
methacrylate-co-glycidyl  methacrylate); c GLYMO-IDA:  3-glycidoxypropyltrimethoxysilane  (GLYMO)  with  
iminodiacetic  acid  (IDA); d FLTEpYVATR:  pure  standard  phosphopeptide; e NTA:  Nitriloacetic  acid; f 
Fe3O4@C:  Carbon-coated  Fe3O4; 2,5-DHB:  2,5-Dihydroxybenzoic  acid;  H3PO4:  Phosphoric  acid;  ACN:  
Acetonitrile; MeOH: Methanol; TFA:  Trifluoroacetic  acid;  CHCA:  a-Cyano-4-hydroxycinnamic  acid. 
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Table 1.2 (cont.) – Magnetic particles with different coatings for the enrichment of phosphopeptides 
3
. 
Core Shell 
Coupling 
Agent 
Metal 
Ions 
MALDI matrix 
Tryptic 
digest 
Sensitivity Refs. 
Fe3O4 ZnO - - 
2,5-DHB + CHCA + 0.5% 
H3PO4 in ACN/ H2O (2/1) 
β-casein 2.5 fmol [86] 
Fe3O4 C18
g - - 
2,5-DHB + 1% H3PO4 in 
75% ACN 
α-casein 10 fmol 
[99] 
β-casein 1 fmol 
BMPh - - 
Fe3+ 
2,5-DHB + 1% H3PO4 β-casein 
0.5 pmol 
[94] 
Zr
4+
 2 pmol 
γ-Fe2O3
 a
 xNH4F
.
yLuF3
i
 - - 
2,5-DHB + 1% H3PO4 
in 50% ACN 
β-casein 50 pmol [95] 
Fe3O4
 a Ti-mSiO2
j - - 
2,5-DHB + 1% H3PO4 
in 50% ACN 
β-casein 10 fmol [93] 
Fe3O4
a YPO4 - - 
2,5-DHB + 1% H3PO4 
in 50% ACN 
β-casein 10 fmol [96] 
PA-Fe3O4
a,k YPO4 - - 
2,5-DHB + 1% H3PO4 
in 50% ACN 
β-casein 8 fmol [97] 
 
1.3.3. Proof-of-concept strategies for phosphopeptide enrichment  
 
1.3.3.1. Chemical tags 
 
The conversion of the phosphate moieties into different functional groups permits the introduction 
of tag-receptor systems that provide an efficient alternative for phosphopeptide enrichment (Figure 
1.13). A variety of chemical derivatization procedures are available for tagging phosphate groups in 
proteins and peptides. These include, for example, the combination of β-elimination, Michael 
addition and proteolysis [100]. 
Based on the concept of isotope-coded affinity tags [101], a phosphoprotein isotope-coded affinity 
tag (PhIAT) has been introduced. Phosphate moieties are chemically replaced by isotope and biotin-
labeled affinity tags to enrich and measure quantitatively O-phosphorylation states in proteins. The 
                                                        
3
 
a 
The  analytes  on  MALDI  target  were  the  phosphopeptides  coupled  to  particles,  except  for  these  
where  peptides  were  previously  eluted  from  the  magnetic  beads;  g C18:  octadecyltrimethoxysilane; h 
BMP: Bacterial Magnetic Particles; i xNH4F.yLuF3: ammonium fluoride and lutetium fluoride; 
j Ti-mSiO2: titanium 
grafted mesoporous silica; k PA-Fe3O4: polyacrylate capped Fe3O4; 2,5-DHB:  2,5-Dihydroxybenzoic  acid;  H3PO4:  
Phosphoric  acid;  ACN:  Acetonitrile. 
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process consists of the hydroxide ion-mediated β-elimination of the O-phosphate moiety and 
Michael addition of either the light or heavy isotopic version of 1,2-ethanedithiol (EDT). The isotope-
labeled peptide is then biotinylated using (+)-biotinyl-iodoacetamidyl-3,6-dioxaoctanediamine, and 
isolated from non-phosphorylated species using avidin chromatography. This method not only 
reveals the phosphorylation sites within a protein, but also selectively enriches the phosphopeptide 
content from complex protein samples. However, there are some disadvantages: (i) simultaneous 
identification of hydrophobic peptides; (ii) nonspecific binding of samples containing endogenous 
biotin and biotin-binding proteins; (iii) formation of diastereomers (i.e., epimers) upon Michael 
addition of EDT; and (iv) the need to use harsh denaturating conditions during elution [102].  
A simplified, more sensitive and efficient approach based on site-specific  labeling and isolation of 
cysteinyl- peptides has been proposed [103]. Here, the biotin affinity tag of PhIAT is replaced by a 
phosphoprotein isotope-coded solid-phase tag (PhIST). The tag is comprised of a photosensitive 
linker covalently bound to aminopropyl glass beads, a leucine isotope-coded linker containing six 12C 
and one 14N (light) or six 13C and one 15N (heavy), and a thiolate-reactive group. The captured 
peptides are released easily by UV photocleavage of the photosensitive linker and analyzed by 
capillary liquid chromatography tandem mass spectrometry (LC-MS/MS) [104].  
Chemical labeling of phosphorylation sites can also be achieved through an arginine-mimic chemical 
tag, guanidinoethanethiol (GET). pSer residues are converted into guanidinoethylcysteine (Gec) by β-
elimination/Michael addition in the presence of a barium catalyst, which accelerates the efficiency of 
the reaction. Proteolytic digestion occurs at Gec because it is recognized as a trypsin cleavage site. 
The method is applied to gel electrophoresis and also for on-bead chemical labeling coupled to TiO2 
enrichment. This method has been shown to be highly reproducible and sensitive, because basic 
guanidine moiety increases the peak intensities for the GET-labeled tryptic peptides by MS [105, 
106].  
Alternatively, a fluorescent affinity tag (FAT) consisting of rhodamine conjugated to a cysteamine 
moiety, selectively modifies phosphorylated Ser and Thr residues in a one-pot reaction. Subsequent 
use of commercially available anti-rhodamine affinity columns allows for the successful enrichment 
of FAT-labeled proteins and peptides [107].  
These chemical labeling methods rely on a β-elimination reaction and, therefore, present drawbacks 
associated with non-specific labeling of cysteines and O-glycosylated residues. However, blocking the 
sulfhydryl group of cysteines by alkylation or oxidation, and performing enzymatic deglycosylation 
can reduce non-specific labeling. In addition, these methods are not applicable to pTyr residues, 
because they cannot undergo β-elimination [100].   
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Phosphoramidate chemistry can be used in the derivatization of phosphopeptides with sulfhydryl 
groups that are subsequently linked to iodoacetyl groups immobilized on a solid support. However, 
this approach involves six chemical reactions, leading to considerable sample loss mainly during the 
O-methylesterification steps. Despite a low final yield of ≈20%, this method is highly selective, 
resulting in contaminant-free phosphopeptides, and is equally applicable in the identification of pSer, 
pThr and pTyr moieties [108]. 
Phosphorylated residues can also be converted to their corresponding methyl esters and then 
subjected to a one-pot reaction in the presence of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide 
(EDC), imidazole and a soluble dendrimer  [109]. Although this method allows for high recoveries of 
phosphopeptides, the EDC-mediated catalysis reaction is extremely slow and requires blocking all 
carboxylate groups of the peptides, which is not very feasible or scalable. 
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Figure 1.13 – Strategies for phosphopeptide enrichment and analysis using chemical tags. The most common 
chemical modifications rely on β-Elimination/Michael Addition and Carbodiimide Condensation.  
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Figure 1.13 (cont.) - (a) Phosphoprotein isotope-coded affinity tag (PhIAT):  pSer and pThr containing proteins 
are isotopically labeled using light (L=H) or heavy (L=D) versions of 1,2-ethanedithiol (EDT) and biotinylated; (b) 
Phosphoprotein isotope-coded solid-phase tag (PhIST): the biotin moiety is replaced by aminopropyl beads 
covalently linked with a photosensitive linker, a stable isotope-coded leucine moiety, and a thiolate-reactive 
group; (c) Guanidinoethanethiol tag (GET): pSer containing proteins are derivatized through β-elimination and 
Michael addition of an arginine-mimic, guanidinoethanethiol. The guanidine moiety has excellent proton 
affinity, increasing the detection by MS; (d) Fluorescent affinity tag (FAT): pSer and pThr containing proteins 
undergo β-elimination/ Michael addition through cysteamine moiety of FAT, which also contains guanidine and 
rhodamine moieties, facilitating the enrichment via anti-rhodamine antibodies; Chemical tags based on (e) 
glass beads derivatized with iodoacetyl groups and (f) an aminated dendrimer, react by carbodiimide 
condensation with phosphorylated peptides. EDC: N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide. 
 
1.3.3.2. Phosphate-affinity ligands 
 
Phosphate affinity tags rely on the chemical modification of phosphate groups with a molecule 
amenable to capture by affinity adsorption, whereas phosphate-affinity ligands specifically recognize 
phosphate moieties on peptides and proteins. The traditional affinity ligands for phosphopeptide 
enrichment referred to above (i.e. antibodies, SH2 domains and metal-chelating) are being replaced 
by alternative structures (Figure 1.14). 
A new phosphate-binding molecule based on an alkoxide-bridged dinuclear metal complex – “Phos-
tag” - has been reported and is commercially available (Table 1.1). This affinity ligand has passed the 
proof-of-concept stage and is one of the most promising for future implementation in large 
proteomic studies [110]. The complex was first reported as a dinuclear Zn(II) complex, 1,3-bis[bis(2-
pyridinylmethyl)amino]-2-propanolato dizinc (II), but can also be complexed with manganese (Figure 
1.14a). Phos-tag molecules have a vacancy on two metal ions, capturing phosphomonoester dianions 
bound to Ser, Thr, and Tyr residues [111-113]. This tag has been coupled to biotin [111], acrylamide 
[111] and agarose [114] and used in a range of phosphopeptide separation and identification 
procedures, such as affinity chromatography [114], electroblotting [115] and SDS-PAGE [116]. The 
phosphate-Phos-Tag complex, ROPO3
2- - (Zn2+-Phos-Tag)3+,  has a characteristic mass shift of 581.1 Da 
and total charge that changes from -2 to +1, thereby facilitating the analysis of the phosphorylated 
compounds by MS [113].  As an alternative to the complex and laborious synthesis of Phos-Tag, 
dinuclear bispyridylmethylamine–tyrosine–acrylamide ligands have been prepared by a twofold 
Mannich reaction and used to enhance the separation of phosphoproteins in gel electrophoresis 
(Figure 1.14b) [117].  
Other synthetic ligands include anthracene derivatives consisting of dinuclear Zinc(II)-dipicolylamine 
(Zn(II)-Dpa) receptors that exhibit high affinity to mono-phosphopeptides, and are based on the 
cooperative binding of both Zn(II)-Dpa sites  (Figure 1.14c) [118]. These structures also show great 
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promise as identifiers of disease markers [119]. By coupling two Zn(II)-Dpa modules with 2,2’-
bipyridine as a spacer in 4,4’-, 5,5’-, or 6,6’-substitution, high selectivity for multi-phosphopeptides 
has been achieved, as a result of multi-point interactions and intrapeptide crosslinking [120].  
Rationally developed amphiphilic Zn2+-cyclens have also proven to be efficient in the molecular 
recognition of phosphate moieties (Figure 1.14d) [121]. Enhanced phosphopeptide binding affinities 
have been observed under physiological conditions by coupling a cooperative second binding site 
that recognizes a carboxylate or imidazole amino acid side chain functionality [122, 123]. 
Molecularly imprinted polymers can also target phosphorylated species. A phosphate-selective 
molecularly imprinted polymer has been prepared using 1-allyl-2-urea as a functional monomer and 
a diphenylphosphate template. The imprinted polymer exhibited high binding ability and selectivity 
for phosphate in aqueous media, with a 70% phosphate recovery [124]. A phosphotyrosine-
imprinted polymer receptor, using two urea-based monomers and an N,O-protected pTyr template, 
has been recently developed. These receptors have proved to be resistant, inexpensive, reusable, 
pTyr selective, and present binding constants for the amino acid template of around 107 M-1 in 
aqueous-rich solvents, comparable to the affinity constants of pTyr specific antibodies [125, 126].  
 
 
Figure 1.14 – Structure of phosphate-affinity ligands. (a) Phos-tag ligands consist of 1,3-bis[bis(2-
pyridinylmethyl)amino]-2-propanolato dimetal(II) complex. (b) Dinuclear bispyridylmethylamine–tyrosine–
acrylamide ligands. (c) Anthracene derivatives consisting of dinuclear zinc(II)-dipicolylamine receptors. (d) 
bis(Zn(II)-cyclen) ligands. M2+ is either Zn2+ or Mn2+. 
(a) (b)
(c) (d)
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1.4. Perspectives 
 
The success of phosphoproteomic studies results from a combination of efficient and selective 
phosphopeptide enrichment tools, as well as sensitive analytical techniques. While the analytical 
techniques are massively undertaken by a plethora of MS protocols, this chapter has focused on the 
current and future alternative methods for the enrichment of phosphorylated species.  
Immunoaffinity, metal ion and ion exchange interactions, coupled to chromatographic matrices, 
remain the obvious choice for large proteomic efforts. Nonetheless, there is an enormous interest in 
the search for more selective, low cost and integrated platforms for phosphopeptide enrichment 
[127]. In recent years, a substantial armory of enrichment methods for phosphoproteomic studies 
has been reported. Most described methods rely on the chelation between metal ions and the 
phosphate groups of proteins, or on the selective chemical modification of the phosphate moieties 
with functional groups amenable for detection and purification purposes. However, the high 
functional and structural diversity of phosphorylated proteins and peptides renders these techniques 
less specific. The identification of molecular recognition elements is fundamental for the design of 
context-independent, novel, affinity-molecules towards phosphorylated proteins and peptides [128]. 
Several international consortia are being established to identify systematically large collections of 
quality and validated affinity reagents against the human proteome [129, 130]. Antibodies and their 
engineered forms are the typical affinity reagents, but engineered proteins, nucleic acid aptamers 
and unnatural skeletons represent viable alternatives for this highly challenging biological target.  
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CHAPTER 2 
Combinatorial libraries of synthetic ligands for phosphorylated peptides 
 
 
Summary 
 
The structural study of phosphoprotein-binding domains (PBDs), and the identification of recognition 
elements, such as key amino acid residues and three-dimensional constraints, between these PBDs 
and their phosphorylated targets, inspires the development of tailor-made molecules able to 
selectively bind phosphorylated proteins and peptides. In this work, combinatorial libraries of solid-
phase biomimetic ligands have been developed using three different molecular skeletons based on 
the triazine reaction, the Ugi reaction, and a tandem Petasis-Ugi reaction. The ligands were further 
screened against a small peptide comprising a consensus sequence (pSer-X-X-Phe, where pSer is 
phosphoserine and X is any amino acid) that specifically binds the Brca1 C-terminal (BRCT) domain. 
Lead ligands were selected based on their binding capacities and phosphopeptide enrichment 
efficiencies.  
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2.1. Introduction 
 
Affinity ligands are classified in two major classes: biospecific and pseudobiospecific. Biospecific 
ligands are the natural binding partners of a particular target. Pseudobiospecific ligands are 
chemically defined molecules, either biological (e.g. peptides, aptamers) or synthetic (e.g. 
hydrophobic, thiophilic, mixed-mode, meta-chelating ligands), which are able to specifically bind the 
same target. Biomimetic ligands are engineered molecules with improved features which belong to 
one of the subclasses of pseudobiospecific ligands (e.g. engineered protein domains, de novo 
designed ligands, etc) [1, 2]. This class of ligands has been developed to overcome drawbacks of their 
naturally-occurring templates, presenting high chemical resistance to cleaning-in-place and 
sterilization-in-place procedures, high scalability, high binding capacities and low production costs [1, 
3]. They have been used for the purification of a myriad of target molecules, such as antibodies [4, 5], 
glycoenzymes [6], insulin precursors [7], and clotting factors [8], among others. 
Ligand design has been led by four strategies: (i) use of natural binder as template; (ii) use of a 
molecule that is known to bind the target site as template; (iii) use the target molecule itself to study 
the interactions around the binding site; and (iv) examine and mimic the biological interactions 
between the natural ligand and the target [9]. The fourth strategy was the one followed in this work.  
Besides the ligand per se, other considerations must be taken into account in order to obtain high 
affinity and target selectivity, such as the nature of the matrix and the chemistry used for ligand 
coupling. The matrix should establish as few non-specific interactions with the target molecule as 
possible, and care must be taken upon ligand immobilization in order to keep its functional moiety 
accessible for target binding. Moreover, the chemical bonds between the ligand and the matrix 
should remain stable during adsorption and elution steps [10].   
The discovery and production of novel ligands for different targets is urged by massive breakthroughs 
in computational modelling, high-throughput screening methodologies and combinatorial synthesis 
approaches. Both biological and synthetic biomimetics have been successfully synthesized by 
combinatorial strategies, which include synthetic peptide and small chemical library synthesis, phage 
display for the discovery of biological ligands, among others. Different combinatorial methodologies 
and their respective advantages and drawbacks are beyond the scope and will not be extensively 
discussed here, but can be reviewed elsewhere [11-13].   
The synthesis of large libraries of compounds directly attached to a solid support eliminates laborious 
intermediate purification steps, allowing the ease removal of excess reagents, by-products and 
solvents by a separation process, such as filtration [13]. Ligands synthesized in solution-phase, on the 
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other hand, are more easily characterized by mainstream techniques, such as nuclear magnetic 
resonance (NMR) and mass spectrometry (MS), but their post-synthesis matrix coupling remains a 
challenge.  
One critical factor upon the design of these combinatorial libraries is to ensure molecular diversity. 
This can be achieved by introducing distinct appendages into a same molecular skeleton (appendage 
diversity); using chiral reagents (stereochemical diversity); and using different molecular skeletons 
(scaffold diversity) [14].  
In the present work, three combinatorial libraries of fully synthetic ligands were built based on three 
chemical reactions: triazine, Ugi and a tandem Petasis-Ugi reaction.  
The triazine reaction consists in a modified ‘mix-and-split’ procedure, where a cyanuric-chloride-
modified matrix reacts by two subsequent nucleophilic substitutions (Figure 2.1) [15]. 
 
Figure 2.1 – Solid-phase synthesis of triazine-based scaffolds. A solid matrix functionalized with a nucleophile 
(denoted by Nü) readily reacts with cyanuric chloride at 0°C. The cyanuric chloride-modified scaffold undergoes 
two subsequent nucleophilic substitutions by R1- and R2-substituted nucleophiles, where R1 and R2 can be any 
selected functional groups. The first substitution occurs at 30°C for 24h and the second substitution at 80°C for 
48h. Nucleophiles include amines, hydroxyls, thiols, etc, and careful selection of the R1 and R2 moieties is 
imperative to avoid cross-reactivity.  
1h @ 0°C
+
24h @ 30°C
48h @ 80°C
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Multicomponent reactions are one-pot reactions which consist in the combination of three or more 
compounds to yield a single product. The resulting product retains all of the atoms of the starting 
materials, excepting the condensation products [14]. Both Petasis and Ugi reactions fall into this 
category.  
Ugi reaction was reported in 1959 by Ivar Ugi and co-workers, and consists in the condensation 
between a primary or secondary amine, an aldehyde or ketone, a carboxylic acid and an isonitrile 
[16]. Ugi reaction on solid-phase is depicted in Figure 2.2. 
 
 
Figure 2.2 – Mechanism of Ugi reaction on solid-phase. The first step of the Ugi reaction consists in the 
condensation between the amine component and the aldehyde/ ketone (herein attached to the solid support) 
to form an imine, which in turn reacts with the carboxylic acid via an acid-base reaction to give an iminium ion. 
A nitrilium ion is then generated by the reaction between the iminium and the isocyanide component. The 
nitrilium ion further reacts with the carboxylate ion generated in the imine activation step, yielding an unstable 
imino-anhydride, which then undergoes a Mumm rearrangement (irreversible step) to generate the final Ugi 
product [17].  
 
The Petasis borono-Mannich reaction consists of adding an aldehyde, an amine, and a boronic acid, 
being named after its discovery by Nicos A. Petasis in 1993 [18]. The reaction has been used for the 
synthesis of α-amino acids, amino alcohols, 2-hydroxymorpholines, 2H-chromenes, etc. Secondary 
amines are the most reactive, followed by bulky primary amines, but the employment of tertiary 
amines has been reported as well [19-21]. The presence of a hydroxyl group in the amine or aldehyde 
component has been recognized to be fundamental for the activation of the boronic acid. Therefore, 
aldehydes comprising hydroxyl or carboxyl groups, such as glycolaldehyde, glyoxylic acid and 
+
Mumm
Rearrangement
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salicylaldehyde are commonly reported [20, 22, 23]. Petasis and Zavialov have also successfully used 
α-keto acids, such as pyruvic acid, instead of the aldehyde component [21].  
The reaction mechanism which is currently considered more energetically favourable is represented 
in Figure 2.3, but some mechanistic differences may be observed depending on the nature of each of 
the components [20, 22-24].  
 
Figure 2.3 – Proposed mechanism of Petasis borono-Mannich reaction on solid-phase. In this example, the 
amine component is attached to the solid matrix and glyoxylic acid is used as the aldehyde component. The 
first step of the reaction consists of a condensation between the amine and the aldehyde components yielding 
a zwitterion species. The carboxylate of the zwitterion then reacts by nucleophilic addition with the boron from 
the boronic acid, forming a negatively charged tetra-coordinated boronate intermediate – the “ate complex”. 
The boronic acid substituent (R1) then migrates to the iminium’s electrophilic carbon, which is the irreversible 
step of this reaction. Both the product and boric acid are then generated by a hydrolysis reaction.  
 
As illustrated in Figure 2.3, in this case the Petasis product generates a free carboxylic acid (deriving 
from the glyoxylic acid component), which can be further employed as a component in other 
reactions, such as the Ugi reaction. The tandem Petasis-Ugi reaction tremendously increases 
molecular diversity, by allowing the incorporation of a higher number of functional groups. 
  
+
+
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2.2. Materials and Methods 
 
2.2.1. Chemicals 
 
All reagents were of the highest purity available and the solvents were pro-analysis. 
 
1-Pyrenemethylamine hydrochloride (AP), 2-(ethylthio)ethylamine (A10), 2-ethylhexanal (B4), 3-(4-
hydroxyphenyl)propionic acid (C3), 3-(ethylthio)propanoic acid (C5), 3-(methylthio)propionaldehyde 
(B5), 3-indoleacetic acid (C7), 3-thienylboronic acid, 4-imidazolecarboxaldehyde (B1), 4-
imidazolecarboxylic acid (C1), agmatine sulfate salt (A7), amino-2-propanol (A2), ammonium 
bicarbonate, ammonium hydroxide solution (NH4OH), bicinchoninic acid kit for protein determination 
(BCA), cadaverine dihydrochloride (A5), coumarin-3-carboxylic acid (C6), cyanuric chloride, 
epichlorohydrin, glyoxylic acid monohydrate, histamine (A8), indole-3-carboxaldehyde (B7), 
isopentylamine (A9), isopropyl isocyanide, m-xylylenediamine (A11), N,N-dimethyl-4,4′-azodianiline 
(A1), ninhydrin, phenethylamine (A3), phenol, phenylacetaldehyde (B3), phenylboronic acid, 
potassium cyanide, propionaldehyde (B2), pyrene-1-boronic acid, pyridine, sodium bicarbonate 
(NaHCO3), sodium periodate, sodium thiosulfate, succinamic acid (C2), tetrahydrofuran-3-
carboxaldehyde solution (B6), tris(hydroxymethyl)aminomethane (A12), tryptamine (A6), tyramine 
(A4), and γ-aminobutyric acid (C4) were acquired from Sigma-Aldrich. 2-Propanol and methanol 
(MeOH) were obtained from Roth, 4-aminomethylphenylboronic acid hydrochloride from Synthonix, 
and acetic acid glacial from Pronalab. Acetone and dimethylformamide (DMF) were purchased from 
VWR. Acetic anhydride, ethanol absolute PA, hydrochloric acid 37% (HCl), nitric acid, sodium acetate 
and sodium hydroxide (NaOH) were acquired from Panreac. The peptides Ser-Gln-Val-Phe-Pro-Trp 
(SW6) and pSer-Gln-Val-Phe-Pro-Trp (SW6-P) were > 98% pure and were purchased from Genecust 
and Caslo.  
 
2.2.2. Chromatographic materials 
 
SepharoseTM CL-6B was acquired from GE Healthcare. Captiva 96-well 20u filter plate with the 
respective duo seal 96-well Pl seal and Captiva 96-well plate cover were purchased from Agilent 
Technologies. Half-area UV-Star® 96-well microplates, black immunograde 96-well microplates, and 
96-well transparent microplates were obtained from Greiner Bio-One, Brand, and Sarstedt, 
respectively. 
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2.2.3. Instrumentation 
 
Ligand synthesis was carried out in an IKA KS 4000 ic control shaker. Inductively Coupled Plasma -  
Atomic Emission Spectroscopy (ICP-AES) analysis for the detection of boron and sulphur in ligand-
functionalized agarose was conducted in a Horiba Jobin-Yvon Ultima Spectrophotometer at an 
impressed potential of 1200 kW. Fluorescence microscopy assays used an Olympus BX51 microscope 
(400X magnification), a U-MWB filter (λexc = 460-490nm; λem = 515-700nm), an UPlanFL objective, 
an U-RFL-T lamp, and Cell View software for monitoring.  Fluorescence and absorbance readings in 
96-well microplates were conducted in a Tecan F200 Microplate Reader using a λexc = 280 (20) nm – 
λem = 340 (35) nm filter, and 560 (10) nm filter, and a 280 (5) nm filter (Tecan).  
 
2.2.4. Methods 
 
2.2.4.1. Epoxy-activation of agarose  
 
SepharoseTM CL-6B was washed with distilled deionised water (dd water) (10x resin volume) in a 
sinter funnel using vacuum suction, and then resuspended in dd water (1 mL/ g moist agarose) and 
NaOH 10 M (0.04 mL/ g moist agarose). The suspension was incubated for 30 min at 34°C with orbital 
shaking (230 rpm). Epichlorohydrin was then added in the proportion of 0.072 mL/ g moist agarose 
and the mixture was left for another 3 h at 34°C in the orbital shaker (230 rpm). In the end, the resin 
was washed with dd water (10x resin volume). In order to determine the amount of epoxy groups, 1 
g of epoxy-activated agarose was incubated with 3 mL of an aqueous solution of sodium thiosulfate 
1.3 M for 20 min at room temperature (RT) with agitation. Epoxy groups were then quantified by 
titration with 0.1 M HCl. Typical values were 21 ± 1 µmol epoxy/ g moist agarose. 
 
2.2.4.2. Functionalization of agarose with 4-aminomethylphenylboronic acid   
 
4-Aminomethylphenylboronic acid hydrochloride (3 equivalents (eq.) molar excess relative to epoxy) 
was dissolved in dd water with an eq. of NaOH, in order to make the amine reactive towards the 
epoxy groups on agarose. Then, the boronic acid solution was added to the epoxy-activated agarose 
(1 mL solution/ g moist agarose) and the reaction was left for 24h at 60°C with orbital agitation (200 
rpm). The resin was thoroughly washed with dd water by vacuum filtration.  
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2.2.4.3. Petasis reaction on boronic acid modified agarose 
   
Agarose functionalized with 4-aminomethylphenylboronic acid was washed with 25% (v/v) ethanol/ 
dd water (5x resin volume) and 50% (v/v) ethanol/ dd water (5x resin volume). A mixture of 1-
pyrenemethylamine hydrochloride and glyoxylic acid monohydrate (5 molar eq. of each compound in 
excess relative to the epoxy) in 50% (v/v) ethanol/ dd water was added and the reaction occurred for 
48h at 60°C with orbital shaking (1 mL/ g moist resin). NaOH was added to the amine component in 
the proportion of 1 molar eq. NaOH/ molar eq. of 1-pyrenemethylamine hydrochloride. 1-
Pyrenemethylamine hydrochloride had been previously dissolved in a small amount of DMF. 
Ultimately, the functionalized resin was washed first with 50% (v/v) ethanol/ dd water (5x resin 
volume) and finally with dd water (10x resin volume).  
 
2.2.4.4. Functionalization of agarose with amine groups 
 
Epoxy-activated agarose was resuspended in 5 M NH4OH (1.5 mL/ g moist resin) and incubated 
overnight in the orbital shaker at 40°C with agitation at 200 rpm. Aminated agarose was then washed 
with dd water (10x resin volume). The presence of amines was confirmed by the Kaiser test [25], 
which consists of adding 50 µl of 5% ninhydrin in ethanol (w/v), 50 µl of 80% phenol in ethanol (w/v) 
and 50 µl of 2% 0.001 M potassium cyanide in pyridine (v/v) to 0.1 g of moist aminated agarose and 
0.9 mL dd water and heating the samples in a water-bath at 100°C for 5 min. The test is based on the 
reaction between ninhydrin and primary amines, yielding a purple/blue colour.  
 
2.2.4.5. Petasis reaction on aminated agarose 
   
Aminated agarose was washed with 25% (v/v) ethanol/ dd water (5x resin volume) and 50% (v/v) 
ethanol/ dd water (5x resin volume). Glyoxylic acid monohydrate and phenylboronic acid (5 molar 
eq. of each compound in excess relative to the epoxy) in 50% (v/v) ethanol/ dd water (0.5 mL of 
each/ g moist agarose) were subsequently added and the reaction occurred for 48h at 60°C with 
orbital shaking (200 rpm). In the end, the Petasis-scaffolded agarose was washed with 50% 
ethanol/dd water (v/v) (5x resin volume) and dd water (10x resin volume) by vacuum suction.  
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2.2.4.6. Blocking of unreacted amines on Petasis-functionalized agarose 
 
Petasis agarose was washed in a sinter funnel with 20% to 100% DMF (in 20% increments). The resin 
was resuspended in a solution of 10% (v/v) acetic anhydride in DMF and incubated for 24h at room 
temperature with orbital agitation (200 rpm). In the end, the resin was washed with 100% to 20% 
DMF in 20% decrements and dd water (10x resin volume).  
 
2.2.4.7. Petasis-Ugi library synthesis 
 
After blocking the amines, Petasis-functionalized agarose was washed with MeOH (20% to 100% 
MeOH in 20% increments), resuspended in MeOH (1 mL/ g moist resin), and distributed for 84 wells 
(0.25 g resin/ well) of a 96-well filter plate. A 1 mL pipette tip was end cut in 4 mm and 0.5 mL of 
resin slurry was pipetted to each well, which corresponds to approximately 0.25 g resin. This step is 
critical to guarantee a uniform distribution of resin in the filter plate. The slurry was left to drain by 
gravity in order to remove the solvent. In the end, the 96-well filter plate was end capped with a 
proper seal.  In the meantime, aldehyde and amine components (5 molar eq. of each relative to 
epoxy) were dissolved in MeOH (0.25 mL/ component/ well) and were reacted for 2h at 60°C in the 
orbital shaker (200 rpm), in order to facilitate the imine formation required for the Ugi reaction. After 
this period, each mixture of amine and aldehyde (0.5 mL/ well) was added to the Petasis resin, along 
with isopropyl isocyanide (5 molar eq. relative to epoxy). The filter plate was covered with a plate 
cover and the reaction was left for 48h at 60°C in the orbital shaker (100 rpm). The Petasis-Ugi 
ligands were then washed with 0.75 mL of 100% to 20% MeOH (in 20% decrements) and then with 
dd water (10x 0.75 mL). The amines used were A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, and A12. 
The aldehydes were B1, B2, B3, B4, B5, B6, and B7. A1, A7, and A12 were dissolved in 50% (v/v) DMF/ 
MeOH. NaOH 1M was added to A5 (1 molar eq.) and A7 (2 molar eq.)  
 
2.2.4.8. Functionalization of agarose with aldehyde groups 
 
Epoxy-activated agarose was resuspended in NaOH 5 M (1 mL/ g moist resin) and incubated 
overnight at 40°C with agitation at 200 rpm. The resin was then thoroughly washed with dd water 
using vacuum filtration and resuspended in sodium periodate 0.1 M (1 mL/ g moist resin), followed 
by incubation at 45°C and 200 rpm for 6h. After that, the resin was washed with dd water (10x resin 
volume).  
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2.2.4.9. Ugi library synthesis 
 
The procedure for Ugi library synthesis is similar to the one described for Petasis-Ugi library 
(§2.2.4.7), but in this case aldehyde-functionalized agarose was distributed by the 96-well filter plate 
(0.25 g/ well). Amines A1 to A12 (5 molar eq. relative to epoxy, 0.25 mL/ well) were added to each 
column of the filter plate; the plate was sealed and incubated for 2h at 60°C in the orbital shaker 
(100 rpm). After that period, the carboxylic acid components (5 molar eq. relative to epoxy, 0.25 mL/ 
well) were added to each row of the filter plate, and isopropyl isocyanide (5 molar eq. relative to 
epoxy) was added to the 84 wells. The up and end-capped filter plate was then incubated for 48h at 
60°C in the orbital shaker (100 rpm). The rest of the procedure is identical to §2.2.4.7. The carboxylic 
acids used were C1, C2, C3, C4, C5, C6, and C7. C1, C4 and C6 were dissolved in 50% (v/v) DMF/ 
MeOH, while the rest of the carboxylic acids were dissolved in MeOH.  
 
2.2.4.10. Triazine library synthesis 
 
Aminated agarose was washed with and resuspended in a cold solution of 50% (v/v) acetone/ dd 
water with 1 molar eq. of NaHCO3 relative to epoxy (1 mL/ g moist agarose). Cyanuric chloride (5 eq. 
molar excess relative to epoxy content) was dissolved in acetone (8.6 mL/ g cyanuric chloride) and 
added to the aminated resin, followed by incubation for 1h in ice at 200 rpm. After incubation, the 
triazine-functionalized resin was washed with acetone (2x resin volume), 50% (v/v) acetone/dd water 
(3x resin volume) and dd water (5x resin volume). The cyanuric chloride-functionalized agarose was 
then distributed by 64 wells of a 96-well filter plate (0.25 g/ well), and the solvent was left to drain by 
gravity. After end-capping the filter plate, amines A1 to A8 were added to each column of the filter 
plate (2 molar eq. of each relative to epoxy; 0.5 mL/ well), an upper cover was placed and the filter 
plate was incubated for 24h at 30°C with agitation (100 rpm). Afterwards, the ligands were washed 
with the solvent in which each amine was dissolved (5x 0.75 mL) and dd water (5x 0.75 mL), and in 
the end the solvent was left to drain by gravity. The filter plate was end-capped, and amines A1 to A8 
were then added to each row of the filter plate (5 molar eq. of each relative to epoxy; 0.5 mL/ well). 
The filter plate was sealed and incubated for 48h at 80°C in the orbital shaker (100 rpm). In the end, 
the ligands were washed with the solvent in which each amine was solubilized (5x 0.75 mL), 0.1 M 
hydrochloric acid (HCl) (1x 0.75 mL), dd water (1x 0.75 mL), 0.1 M NaOH in 30% isopropanol (v/v) 
(regeneration buffer; 0.75 mL), and finally dd water (5x 0.75 mL). All the amines were dissolved in dd 
water, with the exception of A1, A6 and A7, which were dissolved in 50% (v/v) DMF/ dd water. 
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NaHCO3 1M (1 molar eq. relative to epoxy) was added to each amine. NaOH 1M was added to A5 (1 
molar eq. relative to A5) and A7 (2 molar eq. relative to A7). 
 
2.2.4.11. Sample preparation for ICP-AES 
 
Petasis-Ugi, Ugi and triazine ligands were prepared accordingly to the methodologies described 
above, but all reactions were carried out in flasks instead of 96-well filter blocks. The components 
used for the synthesis of Petasis ligands were: (i) aminated agarose, 3-thienylboronic acid, and 
glyoxylic acid monohydrate for ligand D3; and (ii) 4-aminomethylphenylboronic acid-functionalized 
agarose, 1-pyrenemethylamine hydrochloride and glyoxylic acid monohydrate for ligand D7. The 
components used for the synthesis of Petasis-Ugi ligands were: D3-functionalized agarose, 2-
(ethylthio)ethylamine, propionaldehyde, and isopropyl isocyanide for ligands D3A10B2 (without the 
intermediate step of blocking unreacted amines) and D3bA10B2 (after acetylating free amines on D3-
functionalized agarose). The components used for the synthesis of Ugi ligand A10C2 were aldehyde-
functionalized agarose, 2-(ethylthio)ethylamine, succinamic acid and isopropyl isocyanide. A 
symmetric triazine ligand was synthesized using 2-(ethylthio)ethylamine (ligand A10A10). Ligand-
functionalized agarose was dried at 100°C for 5 days. Agarose was weighted before and after the 
drying process, in order to determine the weight difference between moist and dried agarose. A 
known amount of dried agarose was weighted and put in a glass flask to which 1 mL of 1:3 (v/v) nitric 
acid/ HCl was added. The flask was heated in a water-bath at 60°C until the agarose was solubilized, 
and then 2 mL of dd water was added to the sample. Samples were taken for ICP-AES analysis.  
 
2.2.4.12. Sample preparation for fluorescence microscopy 
 
Petasis-Ugi, Ugi and triazine ligands were synthetized in flasks. The components used for the 
synthesis of Petasis ligand D4 were aminated agarose, pyrene-1-boronic acid, and glyoxylic acid 
monohydrate. The components used for the synthesis of Petasis-Ugi ligands D4APB2 and D4bAPB2 
were D4-functionalized agarose, 1-pyrenemethylamine hydrochloride, propionaldehyde, and 
isopropyl isocyanide. The components used for the synthesis of Ugi ligand APC2 were aldehyde-
functionalized agarose, 1-pyrenemethylamine hydrochloride, succinamic acid and isopropyl 
isocyanide. Triazine ligand APAP was synthesized using 1-pyrenemethylamine hydrochloride as the 
amine nucleophile. Samples were pipetted to a microscope slide analysed by fluorescence 
microscopy in an Olympus BX51 microscope. 
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2.2.4.13. Screening of solid-phase combinatorial libraries 
 
Petasis-Ugi, Ugi and triazine libraries were washed with regeneration buffer followed by dd water (3 
cycles of washes, 0.75 mL/ well). Library equilibration was performed by washing the libraries 
extensively with the binding buffer (8x 0.75 mL/ well on average), until the UV absorbance of the 
washes at 280 nm was below 0.005 (last washes were collected in a half-area UV-Star® 96-Well 
microplate). Two binding buffers were tested: 50 mM acetate pH 4 and 50 mM ammonium 
bicarbonate pH 8. SW6 and SW6-P peptides were solubilized in binding buffer (1 mg/ mL) and 0.25 
mL of each peptide was loaded per well. The ligand-functionalized resins were incubated with the 
peptides for 1h at room temperature with manual shaking. The libraries were then washed with 
binding buffer (8x 0.25 mL). Both the flow-through and washes were collected in 96-well black 
microplates by centrifugation at 600 rpm for 20 s, and the fluorescence intensity was read on a 
microplate reader using a λexc = 280 (20) nm – λem = 340 (35) nm filter. After that, 25 µl of each 
sample was transferred from the black microplate to a 96-well transparent microplate to perform the 
BCA assay. The assay consists of adding 200 µl of BCA working reagent to 25 µl of sample and 
incubating the mixture 30 min at 37°C in the dark. The absorbance of the samples was then 
determined in the microplate reader at 560 nm.  
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2.3. Results and Discussion 
 
Three combinatorial libraries of synthetic biomimetic ligands were synthesized in solid-phase using 
three different chemical scaffolds and agarose as the solid support. These libraries were designed 
based on the study of key structural elements of different phosphoprotein-binding domains (PBDs) 
and resulted in 232 small molecules. The ligands were further screened against a pSer-Gln-Val-Phe-
Pro-Trp peptide (named SW6-P), which contains the consensus amino acid sequence - pSer-X-X-Phe 
(X is any amino acid) - known to specifically bind the Brca1 C-terminal (BRCT) domain. 
 
2.3.1. Synthesis of Triazine, Ugi and Petasis-Ugi based scaffolds 
 
The synthesis of triazine and Ugi-based ligands on agarose beads has been previously reported, and 
their experimental conditions optimized [15, 26]. Although the tandem Petasis-Ugi reaction is known 
since 2003, up till now it was never attempted to use this scaffold for proteomic experiments, neither 
was its synthesis on chromatographic supports. Portlock and co-workers used this reaction for the 
solid-phase synthesis of small molecular weight compounds for drug discovery using RINK amine and 
RINK isonitrile resins [27]. Besides having a different application, they have used a different 
methodology. In their approach, the solid support is introduced as one of the Ugi components, while 
here it is used as one of the Petasis components.  
The feasibility of Petasis-Ugi reaction on agarose was assessed by using both boronic acid- and 
amine-functionalized agarose. If Petasis reaction goes to completion, then the boron element would 
not be present in the final product, since only its R-substituent (R-B(OH)2) is incorporated upon the 
reaction. Agarose functionalized with 4-(aminomethyl)phenylboronic acid was reacted with glyoxylic 
acid and 1-pyrenemethylamine, and the amount of boron in Petasis-scaffolded agarose (mol B/ g 
agarose) was quantified by ICP-AES. These three components were selected due to the absence of 
problematic functional groups that could potentially interfere with the accurate course of the 
reaction: glyoxylic acid is the simplest α-keto acid and the other two components only possess 
aromatic substituents. ICP results show that only 30% of the 4-(aminomethyl)phenylboronic acid 
actually reacts with the agarose, and 70% of this reacted to yield the Petasis product (Figure 2.4). The 
30% of the boronic acid that did not react is sufficient to hamper the scaffold applicability in 
chromatographic processes, since the solid support should be as inert as possible. Boronic acids are 
strong Lewis acids and easily react in acid-base reactions. They are able to form covalent, ionic and 
hydrogen bonds, and are known to coordinate sugars and amino acids comprising 1,2- or 1,3- Lewis 
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base donors, such as hydroxyl, carboxyl or imidazole groups [28]. Unreacted boronic acids could 
establish non-specific bonds with the target proteins, hampering the applicability of the affinity 
support. In light of this, a different approach using aminated agarose was then pursued.  
 
 
Figure 2.4 – Petasis reaction on boronic acid functionalized agarose. Epoxy-activated agarose was 
functionalized with 4-(aminomethyl)phenylboronic acid. The boronic acid-modified agarose was then used as 
one of the components in Petasis reaction. The amine and aldehyde components were 1-pyrenemethylamine 
and glyoxylic acid, respectively. Yields of reaction were calculated by ICP-AES based on the amount of boron 
present in the solid support (mol B/ g support).  
 
Aminated agarose was reacted with 3-thienylboronic acid and glyoxylic acid, and both boron and 
sulphur were quantified in the Petasis-scaffolded agarose by ICP-AES (Figure 2.5). The yield of the 
reaction is determined by the incorporation of sulphur in the solid support (mol S/ g moist agarose), 
and corresponds to 18% relative to the epoxy groups on agarose4. No boron was detected in the 
Petasis-scaffolded agarose, which indicates that the boronic acid is not binding in a non-specific 
manner to the solid support, and that Petasis reaction is plausibly proceeding as expected.  
                                                        
4 The determination of amine groups on agarose by the Kaiser test (which is a qualitative test) is not as reliable 
as the determination of epoxy groups by titration with HCl. Therefore, as aminated agarose derives from 
epoxy-activated agarose, all calculations were performed relative to epoxy-activated agarose. 
+
+
48h @ 60°C
Ethanol/H2O
30% Yield
70% Yield
24h @ 60°C
H2O
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Figure 2.5 – Petasis reaction using aminated agarose as solid support. Approximately 4 µmol of sulphur were 
incorporated per g of moist agarose, which corresponds to a reaction yield of 18%. No boron was detected in 
the final product, which is consistent with the occurrence of the Petasis reaction. These results were obtained 
by ICP-AES.  
 
The extent of multicomponent reactions, as the Petasis reaction, is highly dependent on the 
structure and electronic properties of each of the components and on the reaction conditions, such 
as the temperature and solvent selected. Petasis reaction has been performed in a variety of 
solvents, such as ethanol, dichloromethane, MeOH, toluene, DMF, etc [20]. Régnier and co-workers 
obtained good results by using microwave irradiation in a solvent-free system as well [29]. A low cost 
and environmentally friendly alternative is the use of water, which has been reported to be a suitable 
media for this reaction. The reaction kinetics may be significantly influenced by the use of this 
solvent, since it presents large surface tension, high specific heat capacity, high polarity, high 
cohesive energy, and the ability to form hydrogen-bonds [22, 23].  
In the present work a mixture of 50% (v/v) ethanol/ water was selected for the Petasis reaction, since 
the use of protic solvents is reported to increase the reactivity of primary amines [30]. It is difficult to 
select a universal solvent system and the appropriate temperature to perform these reactions, since 
the overall goal of this work is to build universal scaffolds, which can then be tuned to target specific 
substrates by changing the individual components. 
ICP-AES results demonstrate that there is a high amount of amines in the solid-support that did not 
react to yield the Petasis product, and these amines may compete with the free amines in solution in 
the subsequent Ugi reaction. In a library of synthetic ligands, the yields of reaction may be 
completely different from one ligand to another; therefore, it is fundamental to block the unreacted 
amines before performing the Ugi reaction on Petasis-scaffolded agarose (Figure 2.6).   
PETASIS SCAFFOLD
48h @ 60ºC
50% Ethanol/H2O
+ +
18% Yield
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Figure 2.6 – Blocking primary amines with acetic anhydride. Unreacted amines on Petasis-scaffolded agarose 
were blocked using a 10% (v/v) solution of acetic anhydride in DMF. The success of the reaction was confirmed 
using Kaiser test. Petasis-scaffolded beads presented a purple colour characteristic of primary amines, while a 
whitish colour was observed after the blocking reaction. The Petasis reaction preceding the blocking reaction 
was performed using aminated agarose, phenylboronic acid and glyoxylic acid.  
 
Aldehyde-functionalized beads could also be employed as the solid-phase component of the Petasis 
reaction, while using the amine and boronic acid in solution-phase. However, care must be taken 
upon the selection of the aldehyde to be immobilized, since it can be a determining factor for the 
success or failure of the reaction. Schlienger and co-workers performed the Petasis reaction on solid-
phase using Wang polystyrene resins and observed that the most reactive aldehydes bear a α- or β-
hydroxyl group [31]. This might also be explained by the mechanism of Petasis reaction highlighted in 
Figure 2.3.  
The triazine, Ugi and Petasis-Ugi scaffolded agarose beads used in this work are illustrated in Figure 
2.7.  
 
24h @ 60°C
10% (v/v) in DMF
Primary 
amines
Acetylated
amines
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Figure 2.7 – Structures of triazine, Ugi and Petasis-Ugi based scaffolds. Triazine-scaffolded beads have two 
amine substituents (R1 and R2), which result from two sequential nucleophilic substitutions. Ugi scaffolds have 
three substituents derived from an amine (R1), a carboxylic acid (R2), and an isocyanide (R3). Petasis-Ugi 
scaffolds have four substituents derived from a boronic acid (R1), an amine (R2), an aldehyde (R3) and an 
isocyanide (R4). The components which were varied in this work are highlighted in colours; the others were 
kept constant.  
 
As for Petasis-scaffolded beads, the success of triazine and Ugi reactions was also followed by the 
incorporation sulphur onto their structures, and subsequent detection by ICP-AES. The scaffolded 
beads used for these studies are depicted in Figure 2.8.  
Amine
Carboxylic Acid 
Petasis-Ugi
Triazine Ugi
Amine
Amine
Amine
Aldehyde 
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Figure 2.8 – Structures of scaffolded agarose beads used for ICP-AES studies. A) Petasis-scaffolded bead (D3). 
B) Petasis-Ugi-scaffolded bead with unreacted amines (D3A10B2). C) Petasis-Ugi-scaffolded bead after blocking 
free amines (D3bA10B2). D) Ugi-scaffolded bead (A10C2). E) Triazine-scaffolded bead after the first nucleophilic 
substitution (A10). F)  Triazine-scaffolded bead after the second nucleophilic substitution (A10A10). The 
sulphur atom is highlighted by a dashed circle.  
 
The results show that all the reactions are successfully performed on agarose (Figure 2.9). Petasis 
reaction (D3) presents the lower yield (18% relative to epoxy-activated agarose), but the subsequent 
Ugi reaction on Petasis-scaffolded beads is highly efficient. In fact, the Petasis-Ugi scaffolds present 
reaction yields between 90% (D3A10B2) and 100% (D3bA10B2) relative to the Petasis-scaffolded 
beads. The free amines do not seem to be interfering with the Ugi reaction, although it is possible to 
see a slight increase in the reaction yield for the support containing the acetylated amines 
(D3bA10B2). Ugi reaction on aldehyde-functionalized beads (A10C2) occurs with 94% yield, which 
corresponds to 19.8±0.8 µmol S/ g moist agarose. The first nucleophilic substitution on triazine ring 
(A10) allows the incorporation of 11.2±0.7 µmol S/ g moist agarose, which corresponds to a reaction 
yield of 53% relative to epoxy-activated agarose. Ligand A10A10 possess 21.6±1.6 µmol S/ g moist 
agarose, which means the second nucleophilic substitution occurs with a reaction yield of 100% 
relative to the first substitution. These results are in accordance with the fact that the energy 
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necessary for the second nucleophilic substitution is much larger than for the first, and elucidates 
why it is important to perform the first nucleophilic substitution at lower temperature (30°C) and the 
second nucleophilic substitution at higher temperature (80°C) in order to accurately control the 
reaction. 
 
 
Figure 2.9 – Incorporation of sulphur onto scaffolded agarose beads. The reaction yields are relative to the 
moles of epoxy in epoxy-activated agarose. Petasis-scaffolded beads present the lower yield (18%). Petasis-Ugi 
scaffolds (D310B2 and D3bA10B2) present yields on 33% and 44% relative to epoxy-activated agarose, but the 
extension of the reaction relative to the Petasis-scaffolded beads is of 90% and 100%, respectively. Yields of 
94% and 100% are observed for Ugi (A10C2) and triazine (A10A10) reactions on agarose beads, respectively. 
 
On-bead scaffold functionalization was also evaluated by fluorescence microscopy by using a pyrene 
moiety as a reporter molecule (Figure 2.10). Pyrene displays a very particular feature, as it is able to 
form an excited-state dimer (excimer) when two pyrene molecules are superimposed in a proper 
position, increasing the maximum emission wavelength [32]. 
Fluorescence microscopy images are in accordance with ICP-AES results (Figure 2.11). All scaffolds 
present green light emission due to the presence of pyrene in their structures. Petasis-scaffolded 
beads present the lower fluorescence intensity, which might be explained by a low reaction yield of 
Petasis reaction, as previously observed. It is possible to see an increase in the fluorescence intensity 
from Petasis (D4) to Petasis-Ugi (D4APB2 and D4bAPB2) scaffolds, due to the presence of one and 
two pyrene molecules, respectively. However, it should be noted that fluorescence microscopy gives 
qualitative and not quantitative information. Fluorescence emission may be influenced by quenching, 
a phenomenon which consists in the reduction of fluorescence intensity. This may happen due to the 
interaction between the fluorophore and a quencher molecule, such as oxygen, halogens, amines, 
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etc, which can diffuse in solution or be present in a molecule in close proximity to the fluorophore; 
although, non-molecular mechanisms may also be involved in the quenching process [33]. This might 
explain why the fluorescence emitted by triazine scaffolds after the first nucleophilic substitution 
(AP) is much lower than the fluorescence observed after the second nucleophilic substitution (APAP), 
since there is a chloride atom in the vicinity of the chromophore in ligand AP. Another possible 
explanation can be related with the fact that the energy provided at 30°C is not enough for an 
efficient first nucleophilic substitution using 1-pyrenemethylamine in the triazine reaction. Amines, 
as any other functional compounds, present different reactivities. A high fluorescence emission is 
observed for both Ugi (APC2) and triazine ligand APAP, which is also in agreement with the ICP-AES 
results, where similar reaction yields were determined. 
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Figure 2.10 – Structures of scaffolded agarose beads used for fluorescence microscopy studies. A) Petasis-
scaffolded bead (D4). B) Petasis-Ugi-scaffolded bead with unreacted amines (D4APB2). C) Petasis-Ugi-
scaffolded bead after blocking free amines (D4bAPB2). D) Ugi-scaffolded bead (APC2). E) Triazine-scaffolded 
bead after the first nucleophilic substitution (AP). F)  Triazine-scaffolded bead after the second nucleophilic 
substitution (APAP).  
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Figure 2.11 – Fluorescence microscopy results of scaffolded agarose beads functionalized with a fluorophore 
– pyrene. Agarose was used as negative control. The images were acquired using an Olympus BX51 microscope 
(400X magnification) with a U-MWB filter (λexc 460–490 nm; λexc 515–700 nm) and an Olympus U-RFL-T lamp. 
All images were acquired with an exposition time of 100 ms. The monitoring software was Cell-View System. 
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2.3.2. Library Design: Selection of amine, aldehyde, and carboxylic acid components for ligand 
synthesis 
 
Structural studies of the ten human PBDs (§1.2) revealed the existence of prevalent amino acids 
which are directly involved in phosphate coordination: Arg, Lys, Tyr, Ser, His, Gly, and Asn (Figure 
2.12).  
 
Figure 2.12 – Frequency of amino acids involved in the coordination of phosphate groups in PDBs. The amino 
acid frequencies were calculated based on the total number of amino acids establishing direct bonds to the 
phosphate moiety in PDBs. Arg and Lys clearly play key roles in phosphate binding. 
 
Based on these results, different amine, aldehyde and carboxylic acid components were selected for 
the synthesis of the libraries. Some of these components were chosen to mimic the prevalent 
identified amino acids, while others were selected in order to increase library diversity. The main 
functional groups used in the libraries are amines and hydroxyl groups, but aliphatic and aromatic 
moieties were also introduced to mimic hydrophobic interactions. 
Although the multicomponent reactions used herein allow the incorporation of three or more 
components, in this work we have started to vary only two components on each time per scaffold. 
All components of Petasis reaction were kept constant. The reaction was performed using aminated 
agarose, phenylboronic acid and glyoxylic acid. As referred previously, the carboxylic acid resultant 
from this reaction will be used as one of the components on the subsequent Ugi reaction, where the 
isocyanide component was also kept constant. Isopropyl isocyanide was used due to its small size 
(preventing steric hindrance effects) and the fact that its R-substituent is a simple alkyl group 
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(preventing cross-reactivity). Therefore, in Petasis-Ugi scaffolds the variable components were the 
amine and the aldehyde (Table 2.1).  
The Ugi reaction was performed on aldehyde-functionalized beads and again the isocyanide moiety 
was maintained constant. The components varied in this case were the amine and the carboxylic acid 
(Table 2.2). 
Eight amines were used in the nucleophilic substitutions of triazine reaction, resulting in a 64 ligand 
library ( 
Table 2.3). The triazine library is theoretically symmetric, because it is indifferent to use a certain 
amine in the first or second nucleophilic substitution. However, as amines have different reactivities, 
it is not guaranteed that there is 50% incorporation in the first nucleophilic substitution. Highly 
reactive amines may be incorporated in a higher extent at 30°C, while low reactive amines may 
present a much lower reaction yield.  
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Table 2.1 – Amine and aldehyde components of Petasis-Ugi library. Twelve amines (A1 to A12) and seven 
aldehydes (B1 to B7) were used to build a 84 ligand library. The compounds that were selected to mimic 
particular amino acid residues are next to the respective three letter amino acid code. 
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Table 2.2 - Amine and carboxylic acid components of Ugi library. Twelve amines (A1 to A12) and seven 
carboxylic acids (C1 to C7) were used to build a 84 ligand library. The compounds that were selected to mimic 
particular amino acid residues are next to the respective three letter amino acid code. 
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Table 2.3 - Amine components of triazine library. Eight amines were used to build an 84 ligand library. The 
amines used in the first and second nucleophilic substitutions are represented in the first and second columns, 
respectively. The compounds that were selected to mimic particular amino acid residues are next to the 
respective three letter amino acid code. 
 
 
The five most prevalent amino acids (Arg, Lys, Tyr, Ser, His) are represented in all three libraries. 
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2.3.3. Screening of solid-phase combinatorial libraries 
 
All libraries were screened against the SW6-P peptide and its non-phosphorylated version SW6. As 
the optimal binding condition is unknown, screenings were performed at pH 4 and pH 8, due to the 
fact that pSer (pKa1=2.19 (PO3H2), pKa2=5.78 (PO3H
-), pKa3=9.85 (NH3
+)) is known to have one 
negative charge on the phosphate group at pH 4 and two negative charges in the phosphate group at 
pH 8 [34]. The non-bound peptide was quantified in a 96-well microplate reader by two methods: Trp 
fluorescence emission and the BCA assay. Among the aromatic amino acids, Trp is the one displaying 
the largest extinction coefficient, with absorption and emission wavelengths of approximately 280 
nm and 350 nm, respectively [33]. BCA assay is based on the formation of a Cu2+-protein complex in 
alkaline environments. Peptide bonds, Trp, Tyr and Cys residues are able to reduce the Cu2+ to Cu+, 
forming a purple-blue complex with BCA which absorbs at 562 nm. BCA assay presents a lower 
sensitivity when compared to the quantification by tryptophan fluorescence emission, which can be 
observed in Figure 2.13.  Therefore, for simplicity and relevance, only fluorescence results are 
presented here. 
 
 
Figure 2.13 – Amount (in mg) of SW6-P peptide bound per g of ligand-functionalized agarose (either with 
Petasis-Ugi, Ugi or triazine scaffolds). The fact that the slope of the trendline is lower than 1 means that for 
the same ligand the amount of non-bound peptide detected is higher when using tryptophan fluorescence than 
BCA assay, which means the fluorescence method is more sensitive. This figure was plotted with data from 188 
ligands. 
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The binding capacity is given by the amount of peptide (either SW6 or SW6-P) bound per gram of 
ligand-functionalized agarose (Equation 2.1). The results were also analysed in terms of SW6-P mole 
fraction, in order to determine the selectivity of the ligands towards the phosphorylated peptide 
(Equation 2.2). The ligands are only selective towards phosphopeptides if the phosphopeptide mole 
fraction is above 50%.  
 
Equation 2.1 - Ligand binding capacity in mg of peptide per g of support.  
                     ⁄   
                 
         
 
 
Equation 2.2 - Phosphopeptide mole fraction (%). 
                                
                  
         
                  
          
                      
         
     
 
Petasis-Ugi ligands present low binding capacities both at pH 4 and pH 8, probably due to the low 
amount of ligand existent in the beads, as the Petasis reaction presented low yields as previously 
stated. In both cases, there was a maximum of 30% SW6-P peptide bound. At pH 4 all the ligands that 
bind to SW6-P are selective towards this peptide, presenting SW6-P mole fractions of 100%. The 
other ligands do not bind at all to either SW6-P or SW6, which might be happening due to the lack of 
affinity, although we cannot rule out the possibility of synthesis failure and, therefore, not having the 
desired ligand or having it at low concentrations. A larger number of ligands bind at pH 8, but the 
maximum binding capacity and SW6-P mole fraction values observed are similar to the ones obtained 
at pH 4 (Figure 2.14). Amines A1, A2, A3 and aldehyde B7 seem to be playing key roles on SW6-P 
binding at pH 4, while amine A4 and aldehyde B7 seem to be critical for binding at pH 8. 
Ugi ligands present much higher binding capacities than Petasis-Ugi ligands, both at pH 4 and pH 8. 
However, by the SW6-P mole fractions it is clear that the selectivity for the phosphopeptide is higher 
at pH 4. At this pH, all ligands presenting higher binding capacities comprise amine A8, which mimics 
His residue, suggesting that the imidazole group may be playing a decisive role in phosphate 
coordination. Generally speaking, the carboxylic acid component does not seem to be critical for 
binding, since ligands with the same amine and different carboxylic acids have similar binding profiles 
(Figure 2.15).  
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Figure 2.14 – Screening results of Petasis-Ugi ligands. Screenings were performed by adding 0.25 mL of 
peptide in binding buffer (1 mg/ mL) to each well of a 96-well filter plate containing 0.25 g of ligand-
functionalized resin. The unbound peptide from flow-through and washes was collected in 96-well black 
microplates and the fluorescence intensity of the samples was measured in a microplate reader (λexc = 280 
(20) nm – λem = 340 (35) nm filter). A) Amount of SW6-P peptide bound per g of ligand-functionalized support 
using 50 mM acetate buffer pH 4 as binding buffer. B) Schematic diagram representing the SW6-P mole fraction 
(%) determined when using 50 mM acetate buffer pH 4 as binding buffer. C) Amount of SW6-P peptide bound 
per g of ligand-functionalized support using 50 mM ammonium bicarbonate buffer pH 8 as binding buffer. D) 
Schematic diagram representing the SW6-P mole fraction (%) determined when using 50 mM ammonium 
bicarbonate buffer pH 8 as binding buffer.  
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Figure 2.15 – Screening results of Ugi ligands. Screenings were performed by adding 0.25 mL of peptide in 
binding buffer (1 mg/ mL) to each well of a 96-well filter plate containing 0.25 g of ligand-functionalized resin. 
The unbound peptide from flow-through and washes was collected in 96-well black microplates and the 
fluorescence intensity of the samples was measured in a microplate reader (λexc = 280 (20) nm – λem = 340 
(35) nm filter). A) Amount of SW6-P peptide bound per g of ligand-functionalized support using 50 mM acetate 
buffer pH 4 as binding buffer. B) Schematic diagram representing the SW6-P mole fraction (%) determined 
when using 50 mM acetate buffer pH 4 as binding buffer. C) Amount of SW6-P peptide bound per g of ligand-
functionalized support using 50 mM ammonium bicarbonate buffer pH 8 as binding buffer. D) Schematic 
diagram representing the SW6-P mole fraction (%) determined when using 50 mM ammonium bicarbonate 
buffer pH 8 as binding buffer. 
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Triazine ligands present both higher binding capacities and higher SW6-P mole fractions at pH 4. This 
might be related not only with the amines used for the ligands, but also with the triazine ring itself, 
since one of its nitrogen atoms may be protonated at acidic pH, and might also be involved in 
phosphate coordination (Figure 2.16).  
All libraries presented higher percentages of binding and higher selectivity towards SW6-P at pH 4; 
therefore, this pH was chosen to continue the studies. As the initial libraries were only screened 
once, it is fundamental to re-synthesize and re-screen the best ligands in order to determine the 
reproducibility of the results. The criteria used to select the best ligands were different for each 
library and are presented in Table 2.4. The ligands were not only chosen based on these criteria, but 
also on their structures.  Therefore, the 16 Petasis-Ugi ligands selected were narrowed to 7, since 
some of the ligands did not display relevant structural differences. Conversely, 2 additional Ugi 
ligands (A1C2 e A1C6) were selected to join the 8 presented on Table 2.4. Therefore, a total of 7 
Petasis-Ugi ligands, 10 Ugi ligands, and 10 triazine ligands were re-synthesized and re-screened at pH 
4. The screening results resultant from three synthesis and screenings for Petasis-Ugi, Ugi and 
triazine ligands are presented in Figure 2.17, Figure 2.18, and Figure 2.19, respectively. In general 
terms, ligands with low binding capacities present high error bars, which is observable for all 7 
Petasis-Ugi ligands, and for some Ugi (A1C1, A1C2, A1C7, A2C3, A4C3) and triazine (A1A3, A5A4, 
A7A3, and A7A4) ligands. This might be happening due to two main factors: (i) low ligand density, 
which makes the accessibility of the ligand to the target peptide restricted; (ii) the affinity of the 
ligand to the SW6-P target is low and the binding is mainly governed by non-specific interactions. The 
rest of triazine and Ugi ligands present error bars below 26% and 18% on average, respectively. 
Ligand A3B6 is the lead Petasis-Ugi ligand, presenting the higher binding capacity and the lowest 
error bar (27%).   
Noteworthy, amine A8 is present in 4 triazine ligands and 5 Ugi ligands. Moreover, the 5 amino acids 
(Arg (A7), Lys (A5), Tyr (A4), Ser (A2), His (A8)) which were identified in the structural studies as key 
players in phosphate recognition are all represented in triazine lead ligands (A1A8, A5A4, A6A2, 
A6A4, A7A3, A7A4, A8A3, A8A4, A8A6). 
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Figure 2.16 – Screening results of triazine ligands. Screenings were performed by adding 0.25 mL of peptide in 
binding buffer (1 mg/ mL) to each well of a 96-well filter plate containing 0.25 g of ligand-functionalized resin. 
The unbound peptide from flow-through and washes was collected in 96-well black microplates and the 
fluorescence intensity of the samples was measured in a microplate reader (λexc = 280 (20) nm – λem = 340 
(35) nm filter). A) Amount of SW6-P peptide bound per g of ligand-functionalized support using 50 mM acetate 
buffer pH 4 as binding buffer. B) Schematic diagram representing the SW6-P mole fraction (%) determined 
when using 50 mM acetate buffer pH 4 as binding buffer. C) Amount of SW6-P peptide bound per g of ligand-
functionalized support using 50 mM ammonium bicarbonate buffer pH 8 as binding buffer. D) Schematic 
diagram representing the SW6-P mole fraction (%) determined when using 50 mM ammonium bicarbonate 
buffer pH 8 as binding buffer. 
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Table 2.4 – Criteria used for the selection of best ligands. 
Ligand % Binding SW6-P SW6-P Mole Fraction (%) Number of ligands 
Petasis-Ugi ≥ 15 100 16 
Ugi 
> 30 100 
8 
> 60 90 ≥ x > 100 
Triazine ≥ 50 100 10 
 
 
 
Figure 2.17 – Screening results of Petasis-Ugi ligands (N=3). Screenings were performed by adding 0.25 mL of 
peptide in 50 mM acetate pH 4 (1 mg/ mL) to each well of a 96-well filter plate containing 0.25 g of ligand-
functionalized resin. The unbound peptide from flow-through and washes was collected in 96-well black 
microplates and the fluorescence intensity of the samples was measured in a microplate reader (λexc = 280 
(20) nm – λem = 340 (35) nm filter). 
 
0,0
0,2
0,4
0,6
0,8
1,0
A1B6 A1B7 A2B6 A2B7 A3B5 A3B6 A4B7
m
g 
SW
6
-P
/ 
g 
su
p
p
o
rt
 
Chapter 2 Combinatorial libraries of synthetic ligands for 
phosphorylated peptides 
 
82 
 
 
Figure 2.18 – Screening results of Ugi ligands (N=3). Screenings were performed by adding 0.25 mL of peptide 
in 50 mM acetate pH 4 (1 mg/ mL) to each well of a 96-well filter plate containing 0.25 g of ligand-
functionalized resin. The unbound peptide from flow-through and washes was collected in 96-well black 
microplates and the fluorescence intensity of the samples was measured in a microplate reader (λexc = 280 
(20) nm – λem = 340 (35) nm filter). 
 
 
 
 
Figure 2.19 – Screening results of triazine ligands (N=3). Screenings were performed by adding 0.25 mL of 
peptide in 50 mM acetate pH 4 (1 mg/ mL) to each well of a 96-well filter plate containing 0.25 g of ligand-
functionalized resin. The unbound peptide from flow-through and washes was collected in 96-well black 
microplates and the fluorescence intensity of the samples was measured in a microplate reader (λexc = 280 
(20) nm – λem = 340 (35) nm filter). 
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2.4. Conclusions 
 
In this work, by performing structural studies of the natural occurring human PBDs, three different 
libraries of biomimetic ligands consisting of 232 small molecules were developed. These ligands were 
synthesized in a solid-phase combinatorial high-throughput platform using three different chemical 
scaffolds, based on triazine reaction, the Ugi reaction and the Petasis-Ugi reactions. The feasibility of 
these reactions on agarose was proved by ICP-AES and fluorescence microscopy assays. Ligands were 
screened against the SW6-P peptide, which comprises the consensus sequence of the BRCT domain, 
and its non-phosphorylated counterpart at pH 4 and pH 8. The use of acidic conditions revealed to be 
beneficial, leading to higher binding capacities and phosphopeptide mole fractions. Lead ligands 
comprised components mimicking His, Tyr, Arg, Ser and Lys amino acid residues, which are 
systematically observed in the coordination of phosphate to PBDs.  
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CHAPTER 3 
Chromatographic evaluation and optimization of lead ligands 
 
 
Summary 
 
Synthetic affinity ligands based on the Petasis-Ugi, Ugi, and triazine reactions have been 
successfully applied for the enrichment of a phosphoserine (pSer)-containing peptide known to 
be specifically recognized by the Brca1 C-terminal (BRCT) domain. This chapter explores the 
potential of previously identified lead ligands to enrich samples containing various 
phosphorylated peptides. In particular, the enrichment of peptides phosphorylated in 
threonine (pThr) and tyrosine (pTyr), and also a multi-phosphorylated peptide, was assessed 
by high-throughput screening (HTS). These phosphorylated peptides are known to specifically 
bind other phosphoprotein-binding domains (PBDs), such as Src-homology-2 (SH2) and 
Forkhead-associated (FHA) domains. Binding conditions have been optimized for the best 
ligands by changing pH and salt concentration. Elution efficiency has been evaluated with 
different organic solvents, acids, bases and competitor molecules.  Partition equilibrium 
experiments reveal that the binding of all phosphorylated and non-phosphorylated peptides 
followed the Langmuir adsorption model. Both phosphorylated and non-phosphorylated 
peptides present low association equilibrium constants (KA), but phosphorylated peptides have 
higher maximum binding capacities (Qmax), which might be an indication of higher specificity 
for phosphorylated peptides. 
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3.1. Introduction 
 
High-throughput screening (HTS) methodologies in 96-well format have been widely used to 
screen a variety of compounds, such as drugs, peptides, and affinity ligands [1-3].  Besides its 
usefulness in the discovery of novel molecules, HTS can also be applied in process 
development and optimization of chromatographic separations. It is time and cost-effective, as 
it allows the parallel screening of different experimental parameters, uses small quantities of 
materials, and eliminates day-to-day variability [1, 4, 5]. Coffman and co-workers reported the 
use of a 96-well batch-binding miniaturized robotic system, which allows the easy evaluation 
and tailoring of several factors, such as incubation time, binding and elution conditions, 
amount of protein and resin, hold-up volume, etc.  Batch-binding methodologies yield 
information on thermodynamics, selectivity, and binding kinetics. In addition, HTS systems can 
be coupled to automated analytical systems, such as high-gradient liquid chromatography and 
capillary electrophoresis [1]. The major challenge of HTS methodologies is mainly related to 
translation of data to scale-up operations, but it provides qualitative results which can be used 
to guide the development of laboratory- and manufacturing-scale chromatographic processes 
[1, 4]. Also, this is not particularly problematic when referring to phosphoprotein and 
phosphopeptide enrichment, as it usually takes place in small scale. 
The optimization of binding conditions depends on the mode of chromatography (e.g. 
hydrophobic, ion-exchange, mixed-mode, immobilized metal affinity chromatography (IMAC)), 
involving the proper selection of the buffering species, and the adjustment of experimental 
parameters, such as pH, temperature, ionic strength, etc. The influence of salt is particularly 
complex. Hofmeister discovered that protein solubility is not only influenced by the 
concentration of salt, but also by its nature. He ranked different ions according to their salting-
in and salting-out effectiveness for globular proteins (Figure 3.1) [6, 7]. The effects of anions 
are more pronounced when compared to cations, due to their asymmetric effect on 
polarizable water molecules [8]. These ions have been classified according to their ability to 
change the hydrogen bonding network of water. Ions coined kosmotropes are considered to 
be water-structure makers, having stabilizing and salting-out effects on proteins. Chaotropes 
are water-structure breakers, and have destabilizing and salting-in effects [6, 9]. However, 
there is some debate in the scientific community involving this subject. In fact, the solute itself 
may have influence on the salting-in/ salting-out behaviour, rather than the ion-water 
interaction alone [9, 10].  
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Figure 3.1 – The Hofmeister series. Adapted from [8]. 
 
An efficient elution strategy is not straightforward, as simple protocols usually involve 
incomplete breaking of the protein-ligand interaction. Low pH buffers are commonly used to 
break ionic bonds, but high pH buffers are also recurrent, and sometimes both are used 
subsequently. The addition of high concentrations of salt also disrupts ionic bonds, but might 
foment hydrophobic interactions. Hydrogen bonds are affected by the addition of 
denaturating agents and detergents, such as urea and guanidine-HCl, but their applicability is 
limited by the loss of function of the purified protein. Other strategies involve the use of 
water-miscible organic solvents and competitive elution. The last one has several advantages, 
namely the use of mild conditions and high specificity, but might have limitations associated 
with the cost of the competitor molecule and time-effectiveness [11].    
 
3.2. Materials and Methods 
 
3.2.1. Chemicals 
 
All reagents were of the highest purity available and the solvents were pro-analysis. 
 
4-imidazolecarboxylic acid (C1), amino-2-propanol (A2), ammonium bicarbonate (NH4HCO3), 
ammonium hydroxide solution (NH4OH), boric acid (H3BO3), cyanuric chloride, epichlorohydrin, 
glyoxylic acid monohydrate, histamine (A8), isopropyl isocyanide, N,N-Dimethyl-4,4′-
azodianiline (A1), phenethylamine (A3), phenylboronic acid, phosphoric acid (H3PO4), 
propionaldehyde, sodium bicarbonate (NaHCO3), sodium periodate, sodium thiosulfate, 
Chaotropes
Kosmotropes
HCOO- < F- < SO4
2- < CH3COO
- < PO4
3-
Na+ < Li+ < Ba2+ < Ca2+ < Mg2+
SCN- > I- > ClO4
- > NO3
- > Br-> Cl-
Cs+ > Rb+ > NH4
+ > K+
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succinamic acid (C2), tetrahydrofuran-3-carboxaldehyde solution (B6), 
tris(hydroxymethyl)aminomethane, trifluoroacetic acid (TFA), tryptamine (A6), and tyramine 
(A4) were acquired from Sigma-Aldrich. 2-Propanol and methanol (MeOH) were obtained from 
Roth, glycine from Acros Organics, and acetic acid glacial from Pronalab. Acetone and 
dimethylformamide (DMF) were purchased from VWR. Acetic anhydride, acetonitrile (ACN), 
ethanol absolute PA, hydrochloric acid (HCl) 37%, sodium acetate, sodium chloride (NaCl) and 
sodium hydroxide (NaOH) were acquired from Panreac. Ser-Gln-Val-Phe-Pro-Trp  (SW6), pSer-
Gln-Val-Phe-Pro-Trp (SW6-P), Thr-Gln-Val-Asp-Ala-Trp (TW6), pThr-Gln-Val-Asp-Ala-Trp (TW6-
P), Tyr-Glu-Glu-Ile-Pro-Trp (YW6),  pTyr-Glu-Glu-Ile-Pro-Trp (YW6-P), Tyr-Ala-Gly-Ser-Thr-Asp-
Glu-Asn-Thr-Asp-Ser-Glu-Trp (YW13), and Tyr-Ala-Gly-pSer-pThr-Asp-Glu-Asn-pThr-Asp-Ser-
Glu-Trp (YW13-P) peptides were > 98% pure and were purchased from Genecust and Caslo. 
 
3.2.2.  Chromatographic materials 
 
SepharoseTM CL-6B was acquired from GE Healthcare. Captiva 96-well 20u filter plate with the 
respective duo seal 96-well Pl seal and Captiva 96-well plate cover were purchased from 
Agilent Technologies. Half-area UV-Star® 96-well microplates, black immunograde 96-well 
microplates, and 96-well transparent microplates were obtained from Greiner Bio-One, Brand, 
and Sarstedt, respectively. 
 
3.2.3.  Instrumentation 
 
Ligand synthesis was carried out in an IKA KS 4000 ic control shaker. Fluorescence readings in 
96-well microplates were conducted in a Tecan F200 Microplate Reader using λexc = 280 (20) 
nm – λem = 340 (35) nm; 560 (10) nm; and 280 (5) nm filters (Tecan).  
 
3.2.4. Software 
 
Ligands and peptides were sketched on ChemBioDraw® Ultra 13.0 software, and their 
properties were determined using charge, logD, major microspecies, and pKa plugins from 
MarvinSketch 4.1.13 software (ChemAxon). Data from partition equilibrium experiments was 
fitted by nonlinear regression using OriginPro 8.5.1 SR2. 
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3.2.5. Methods 
 
3.2.5.1. Solid-phase synthesis of Petasis-Ugi ligands 
 
Petasis ligand was synthesized on agarose according to §2.2.4.5 and §2.2.4.6. Petasis-modified 
agarose was washed with MeOH (20% to 100% in 20% increments) in a sinter funnel, and the 
resin was weighted and equally distributed between 2 flasks. In the meantime, each amine and 
aldehyde components (5 molar eq. of each relative to epoxy) were dissolved in MeOH (0.5 mL/ 
g moist resin / component/ flask) and were reacted for 2h at 60°C with agitation (200 rpm). 
Each mixture of amine and aldehyde was then added to the Petasis-modified agarose (1 mL/ g 
moist resin/ flask), followed by isopropyl isocyanide (5 molar eq. relative to epoxy). The 
reaction occurred for 48h at 60°C with constant shaking (200 rpm). At the end, Petasis-Ugi 
ligands were washed with MeOH (100% to 20% in 20% decrements) and finally with distilled 
deionised (dd) water (10x resin volume). The amine components were A2 and A3, while the 
aldehyde component was B6. 
 
3.2.5.2. Solid-phase synthesis of Ugi ligands 
 
Aldehyde-functionalized agarose was prepared according to §2.2.4.8, washed with MeOH in 
20% increments using vacuum filtration, weighted and distributed among three flasks. Amine 
components (5 molar eq. of each relative to epoxy) were dissolved either in MeOH (for A1) or 
50% (v/v) DMF/ MeOH (for A8) (0.5 mL/ g moist resin/ component/ flask), and added to each 
flask containing aldehyde-modified agarose. The mixture was incubated for 2h at 60°C in an 
orbital shaker (200 rpm). Each carboxylic acid component (5 molar eq. of each relative to 
epoxy) was then added to the mixture (0.5 mL/ g moist resin/ component/ flask), followed by 
isopropyl isocyanide (5 molar eq. relative to epoxy), and the reaction was carried on at 60°C 
for 48h with agitation (200 rpm). Lastly, Ugi ligands were washed with MeOH in 20% 
decrements, followed by dd water (10x resin volume). The carboxylic acids used were C1 and 
C2; the first one was dissolved in 50% (v/v) DMF/ MeOH, and the second in MeOH. 
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3.2.5.3. Solid-phase synthesis of triazine ligands 
 
Cyanuric chloride-modified agarose was prepared according to §2.2.4.10, thoroughly washed 
with dd water, weighted and divided between 4 flasks. The first amine component (2 molar eq. 
relative to epoxy; 1 mL/ g moist resin/ flask) was added to each flask and the reaction occurred 
for 24h at 30°C. After this period, the ligands were washed with the solvent in which each 
amine was dissolved (5x resin volume) and dd water (5x resin volume). The second amine 
component (5 molar eq. relative to epoxy; 1 mL/ g moist resin/ flask) was then added to each 
flask, and the mixture was reacted for 48h at 80°C. In the end, the ligands were washed with 
the solvent in which each amine was solubilized (5x resin volume), 0.1 M HCl (1x resin volume), 
dd water (1x resin volume), 0.1 M NaOH in 30% isopropanol (v/v) (regeneration buffer; 1x 
resin volume), and finally dd water (5x resin volume). The amine components were A1, A3, A4, 
A6, and A8. All the amines were dissolved in dd water, with the exception of A1 and A6, which 
were dissolved in 50% (v/v) DMF/ dd water. NaHCO3 1M (1 molar eq. relative to epoxy) was 
added to each amine.  
 
3.2.5.4. Screening of ligands against phosphorylated and non-phosphorylated peptides  
 
Petasis-Ugi, Ugi, and triazine ligands were distributed between the wells of 96-well filter plates 
(0.25 g of ligand-functionalized agarose/ well). The plates were washed with regeneration 
buffer followed by dd water (3 cycles of washes, 0.75 mL/ well), followed by 50 mM acetate pH 
4 (8x 0.75 mL/ well on average), until the UV absorbance of the washes at 280 nm was below 
0.005 (last washes were collected in a half-area UV-Star® 96-Well microplate). TW6, TW6-P, 
YW6, and YW6-P peptides were solubilized in 50 mM acetate pH 4 (1 mg/ mL) and 0.25 mL of 
each peptide was loaded per well. The ligand-functionalized resins were incubated with the 
peptides for 1h at room temperature with manual shaking. The libraries were then washed 
with 50 mM acetate pH 4 (8x 0.25 mL). Both the flow-through and washes were collected in 
96-well black microplates by centrifugation at 600 rpm for 20 s, and the fluorescence intensity 
was read on a microplate reader using a λexc = 280 (20) nm – λem = 340 (35) nm filter. 
 
 
 
 
Chapter 3 Chromatographic evaluation and 
optimization of lead ligands 
 
94 
 
3.2.5.5. Optimization of binding conditions 
 
Binding conditions were optimized for ligands A6A4, A8A3, A8C2, and A3B6. These ligands 
were distributed by the wells of 96-well filter plates (0.25 g/ well), and incubated with one of 
the following: (i) a mixture of SW6-P, TW6-P and YW6-P (0.5 mg/mL total peptide; 0.25 mL/ 
well); (ii) a mixture of SW6, TW6 and YW6 (0.5 mg/mL total peptide; 0.25 mL/ well); (iii) YW13-
P (0.5 mg/mL; 0.25 mL/ well); or (iv) YW13 (0.5 mg/mL; 0.25 mL/ well). The binding buffers 
tested were the following: 50 mM Gly pH 3; 50 mM acetate pH 4; 50 mM acetate pH 5; 50 mM 
acetate pH 6; 50 mM Tris pH 7; 50 mM NH4HCO3 pH 8; 50 mM Tris pH 9; 50 mM Gly pH 10; and 
50 mM Gly pH 11. Different concentrations of NaCl (25, 50, 100, 250, 500, 1000 mM) were 
further tested for 50 mM Gly pH 3 buffer. The screening procedure was similar to §3.2.5.4.  
 
3.2.5.6. Screening of negative controls against phosphorylated peptides 
 
Agarose, aminated agarose (agarose-NH2) and aldehyde-functionalized agarose (agarose-CHO) 
were screened against all phosphorylated peptides using 50 mM glycine pH 3. The screening 
procedure was similar to §3.2.5.4. 
 
3.2.5.7. Optimization of elution conditions 
 
Elution conditions were optimized for ligands A8A3 and A8C2. After screening each peptide or 
peptide mixture using the best binding condition determined in §3.2.5.5, 0.25 mL of each 
eluent was loaded into each well of the 96-well filter plate. The elution fraction was collected 
in 96-well black microplates by centrifugation at 600 rpm for 20 s, and the fluorescence 
intensity was read on a microplate reade using a λexc = 280 (20) nm – λem = 340 (35) nm filter.  
This step was repeated until no peptide was detected in the elution fraction. The different 
eluents tested were: 50% (v/v) ACN/H2O + 1% acetic acid (Sol 1); 50% (v/v) MeOH/H2O + 1% 
acetic acid (Sol 2); MeOH (Sol 3); 50% (v/v) ACN/H2O + 0.1% NH4OH (Sol 4); 50% (v/v) ACN/H2O 
+ 1% H3PO4 (Sol 5); 50% (v/v) ACN/H2O + 0.1% TFA + 1% H3PO4 (Sol 6); 50% (v/v) ACN/H2O + 1% 
H3BO3 (Sol 7); 50% (v/v) ACN/H2O + 0.1% TFA + 1% H3BO3 (Sol 8).  
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3.2.5.8. Partition equilibrium experiments 
 
A8A3- and A8C2-functionalized agarose was distributed by the wells of a 96-well filter plate 
(0.25 g/ well). The ligands were then incubated overnight at 30°C and 100 rpm with different 
concentrations (0.05, 0.1, 0.5, 1, 2.5, 5, 7.5, 10 mg/ mL; 0.25 mL/ well) of one the following:   (i) 
a mixture of SW6-P, TW6-P and YW6-P; (ii) a mixture of SW6, TW6 and YW6; (iii) YW13-P; or 
(iv) YW13. The flow-through was collected in 96-well black microplates by centrifugation at 
600 rpm for 20 s, and the fluorescence intensity was read on a microplate reader using a λexc 
= 280 (20) nm – λem = 340 (35) nm filter. 
 
3.3. Results and Discussion 
 
3.3.1. Screening of lead ligands against pSer-, pThr-, and pTyr-containing peptides 
 
Lead ligands identified in chapter 2 comprised 7 Petasis-Ugi ligands, 10 Ugi ligands, and 10 
triazine ligands. On the basis of their binding capacities, synthesis and screening 
reproducibility, and structural diversity, 2 Petasis-Ugi ligands (A2B6, A3B6), 3 Ugi ligands 
(A1C2, A8C1, A8C2), and 4 triazine ligands (A1A3, A1A8, A6A4, A8A3) were selected and 
screened against pThr- and  pTyr-containing peptides. The peptides selected were pThr-Gln-
Val-Asp-Ala-Trp (TW6-P) and pTyr-Glu-Glu-Ile-Pro-Trp (YW6-P), which comprise consensus 
sequences recognized by FHA and Src-like SH2 domains, respectively  [12, 13]. The binding 
assays were performed at pH 4, and the results were compared with the screenings performed 
against pSer-Gln-Val-Phe-Pro-Trp (SW6-P) (Figure 3.2). The binding capacity values (mg 
phosphopeptide/ g support) indicate that all ligands preferentially bind to SW6-P, followed by 
YW6-P, and finally TW6-P. The ligands were also screened against the non-phosphorylated 
versions of these peptides (SW6, TW6, and YW6) in order to determine the phosphopeptide 
mole fractions, which presented the following order for all ligands: SW6-P mole fraction > 
TW6-P mole fraction > YW6-P mole fraction. As the first libraries were screened against the 
SW6-P peptide, and lead ligands were selected based on the binding profiles of these libraries, 
it is foreseeable that this peptide might present the best performance in terms of binding 
capacities and phosphopeptide mole fractions. The fact that the YW6-P peptide presents mole 
fractions of approximately 50% indicates that the ligands are binding indiscriminately to YW6 
and YW6-P and, therefore, the recognition is not occurring through the phosphate moiety.  
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Figure 3.2 – Screening results of lead ligands against SW6-P, TW6-P and YW6-P. Screenings were 
performed by adding 0.25 mL of peptide in 50 mM acetate buffer pH 4 (1 mg/ mL) to each well of a 96-
well filter plate containing 0.25 g of ligand-functionalized resin. The unbound peptide from flow-through 
and washes was collected in 96-well black microplates and the fluorescence intensity of the samples 
was measured in a microplate reader (λexc = 280 (20) nm – λem = 340 (35) nm filter). A) Left: Amount of 
phosphopeptide bound per g of Petasis-Ugi ligand-functionalized support; Right: Phosphopeptide mole 
fraction (%) for Petasis-Ugi ligands; B) Left: Amount of phosphopeptide bound per g of Ugi ligand-
functionalized support; Right: Phosphopeptide mole fraction (%) for Ugi ligands; C) Left: Amount of 
phosphopeptide bound per g of triazine ligand-functionalized support; Right: Phosphopeptide mole 
fraction (%) for triazine ligands. (N=2) 
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To better understand ligand-peptide interactions, all ligands and peptides were first sketched 
in ChemBioDraw® Ultra 13.0 software, and then their charges and logD at pH 4 were 
determined using MarvinSketch 4.1.13 software from ChemAxon. LogD is defined as the 
octanol-water distribution coefficient and may represent compounds at any pH value [14]. This 
will give an idea of the molecular hydrophobicity of each ligand and peptide at the pH of 
binding. The structures of Petasis-Ugi based ligands, Ugi-based ligands, and triazine-based 
ligands are presented in Table 3.1, Table 3.2, and Table 3.3., respectively.  
 
Table 3.1 – Structures of Petasis-Ugi based ligands immobilized on agarose. The white sphere is a 
schematic representation of an agarose bead. 
Nomenclature Structure 
A2B6 
 
A3B6 
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Table 3.2 – Structures of Ugi-based ligands immobilized on agarose. The white sphere is a schematic 
representation of an agarose bead. 
Nomenclature Structure 
A1C2 
 
A8C1 
 
A8C2 
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Table 3.3 – Structures of triazine-based ligands immobilized on agarose. The white sphere is a 
schematic representation of an agarose bead. 
Nomenclature Structure 
A1A3 
 
A1A8 
 
A6A4 
 
A8A3 
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A variety of different interactions may be involved in the ligand-peptide binding, such as 
hydrogen bonding, hydrophobic interactions, electrostatic interactions, salt-bridging, and van 
der Waals forces. All lead ligands are positively charged at pH 4, while the peptides present net 
negative charges, with the exception of SW6 (Figure 3.3).  
 
 
Figure 3.3 – Net charge of ligands and peptides at pH 4. Values were calculated using the Charge Plugin 
of MarvinSketch software (ChemAxon). 
 
Table 3.4 presents the major protonation form of each peptide at pH 4. Both SW6 and SW6-P 
have a negative charge on the terminal carboxyl group of the peptide. However, the 
interaction is apparently occurring mainly through the phosphate group, since SW6 binds 0% 
to all ligands except A1C2, while SW6-P presents high binding capacities. This is translated into 
high enrichment efficiencies, which are represented by SW6-P phosphopeptide mole fraction 
values of 100% (Figure 3.2). Nonetheless, it is plausible that carboxyl groups might interfere in 
the binding profile of TW6-P and YW6-P peptides, as an increase in the carboxyl group content 
corresponds to a decrease in the enrichment efficiency. Table 3.4 shows that at pH 4 SW6-P 
has one negative charge on the terminal carboxyl group, followed by TW6-P with two negative 
charges on carboxyl groups (one on carboxyl terminal and one on the side chain of Asp 
residue) and YW6-P with three negative charges (one on carboxyl terminal and two on the side 
chains of Glu residues). The phosphopeptide mole fractions decrease in the same order, with 
SW6-P mole fraction > TW6-P mole fraction > YW6-P mole fraction (Figure 3.2). It is reasonable 
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to consider that the ligands might be binding both to the phosphate and carboxyl groups of 
TW6-P and YW6-P peptides. Different strategies have been proposed in order to avoid the 
interference of acidic peptides in phosphopeptide enrichment, with one of the most 
commonly used protocols being the O-methyl esterification of carboxylic acids [15, 16]. The 
main limitations of this method are the occurrence of ester hydrolysis; lack of efficiency of the 
esterification reaction; and the occurrence of side reactions, such as deamidation and 
subsequent methylation of Asn and Gln amino acid residues [17-19]. Ye and co-workers 
reported that the use of ACN in loading and washing solutions affects differently the degree of 
ionization of phosphate and carboxyl groups. The pH values of Asp and Glu amino acids 
increase for higher ACN concentrations, while the pH of the phosphate moiety remains fairly 
constant [20].  
However, electrostatic interactions are most likely not playing a sole role in the binding 
efficiency. In fact, although TW6-P has one extra charge in a carboxyl group and a net charge 
more negative that SW6-P, all ligands present higher binding capacities for SW6-P. The same 
goes for YW6-P, which is the one with the most negative net charge and which present three 
negative charges on carboxyl groups. If the only factor to take into consideration would be the 
net charge of the peptides, then the binding capacities would decrease in the following order: 
YW6-P > TW6-P > SW6-P, which is not observed. Therefore, it is unlikely that the binding is 
occurring (or at least exclusively occurring) through the carboxyl groups.  Other types of 
interactions, such as hydrophobic interactions, may be contributing for binding as well. All 
peptides are hydrophilic at pH 4, which is translated into negative values of logD. However, 
they all possess amino acid residues able to establish hydrophobic interactions with the 
ligands, such as Val, Ile, Phe, Trp, etc.  YW6 and YW6-P peptides present similar values of logD 
at pH 4, which means they have similar hydrophobicity (Figure 3.4). On the other hand, YW6-P 
is more negatively charged than YW6, due to the presence of the phosphate group. In spite of 
this, ligands bind equally to both peptides. One possibility is that the aromatic group of Tyr 
may be interacting with the ligands either or both by hydrophobic interactions and amino-
aromatic bonding. The aromatic ring of Tyr may be acting as a hydrogen bond acceptor, 
interacting with a hydrogen bond donor (such as hydroxyl or amine groups) of the ligands. 
Small partial charges on carbon and hydrogen atoms of the ring are the leading contributors 
for the interaction, rather than delocalized electrons. The amino-aromatic hydrogen bond 
presents half the strength of a common hydrogen bond [21, 22]. This type of interaction has 
been observed in the recognition of pTyr by SH2 domains [23].  
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A comprehensive understanding of these ligand-peptide interactions would implicate 
conducting a more detailed structural analysis by nuclear magnetic resonance (NMR) and/ or 
X-ray crystallography.  However, this would require the solution-phase synthesis of the ligands. 
Until now, the use of solid-state NMR for the structural analysis of organic compounds and 
biomolecules has been somehow restricted by its limited sensitivity and resolution. However, 
recent advances in solid-state NMR made possible to detect proteins in the nanomolar range, 
opening great prospects for ligand characterization and the study of molecular interactions on 
solid-phase [24, 25]. 
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Table 3.4 – Major protonation forms of SW6, SW6-P, TW6, TW6-P, YW6, and YW6-P peptides at pH 4. The protonation forms were determined using the Major 
Microspecies Plugin from MarvinSketch (ChemAxon). 
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Figure 3.4 – Octanol-water distribution coefficient (logD) of ligands and peptides at pH 4. The values were 
obtained using logD Plugin of MarvinSketch software (ChemAxon). Hydrophilic compounds present negative 
logD values, while hydrophobic compounds present positive logD values.  
 
3.3.2. Optimization of binding conditions 
 
Binding conditions were optimized for the best ligands of each library. A8C1 and A8C2 present 
identical binding profiles (Figure 3.2), but cross-reactivity is more prone to occur during the synthesis 
of A8C1, as C1 component has both amine and carboxyl moieties (§Table 2.2). 
 Ligands A6A4 and A8A3 were both selected to proceed with the studies, as they present similar 
binding behaviour and have significant structural differences. However, it is relevant to mention that 
A4, A6, and A8 components may react in different ways in the triazine reaction. Tyramine (A4) is able 
to react with cyanuric chloride both through its amine and hydroxyl functionalities, as they are both 
strong nucleophiles. Nevertheless, if the synthesis is performed at neutral pH, the hydroxyl group will 
be almost unreactive [26]. Tryptamine (A6) is composed of an indole ring and an aliphatic primary 
amine, and histamine (A8) comprises an imidazole group and also an aliphatic primary amine (§Table 
2.3). The amine groups of the indole and the imidazole heterocycles are able to react as nucleophiles, 
as well as the aliphatic primary amines. However, the reaction will favour the incorporation of the 
primary amine in cases of significant steric hindrance for the ring nitrogen. Moreover, it is important 
to guarantee that the reaction is carried out at alkaline conditions, above the pKa values of the amine 
groups of the heterocycles [27, 28].  
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A3B6 was selected as the lead Petasis-Ugi ligand, due to its superior performance in terms of binding 
capacity and selectivity when compared to A2B6 (Figure 3.2). 
Best binding conditions were determined using a mixture of SW6-P, TW6-P, and YW6-P (1:1:1) 
(phosphopeptides mixture). Binding optimization was performed using a mixture of peptides, rather 
than the individual peptides, because it is important to understand the behaviour of the 
phosphopeptide targets when they are screened in more complex mixtures. Ligands were screened 
in parallel against the phosphopeptides mixture and a mixture of SW6, TW6, and YW6 (non-
phosphopeptides mixture), in order to determine the selectivity of the ligands towards the 
phosphorylated peptides. In this case, phosphopeptides mass fractions were calculated instead of 
phosphopeptides mole fractions, because it is not possible to distinguish which of the peptides in 
each mixture are binding to the ligands. It is only possible to determine the total amount (in mg) of 
peptides bound in each screening. The phosphopeptides mass fraction (%) as utilized in this work is 
defined in Equation 3.1.  
 
Equation 3.1 – Phosphopeptides mass fraction (%). 
                                 
                  
         
                  
          
                      
         
     
  
Ligands A6A4, A8A3, A8C2, and A3B6 were screened against the phosphopeptides and the non-
phosphopeptides mixtures at different pH (3 to 11). Higher binding capacities (mg phosphopeptide 
mixture/ g ligand-functionalized support) were obtained at acidic pH, with the highest value at pH 4 
(Figure 3.5A). Ligands presented higher selectivity for phosphopeptides at pH 7 (Figure 3.5B), which 
might be related with the pKa values of pSer (pKa1=1.73; pKa2=6.73), pThr (pKa1=1.70; pKa2=6.71), 
and pTyr (pKa1=1.26; pKa2=6.24) (Figure 3.6). All phosphopeptides present two negative charges at 
pH values equal to or above 7, and one negative charge below it.  
High binding capacities are combined with high enrichment efficiencies at pH 3 (Figure 3.5).  At this 
pH, the carboxyl groups of the peptides are protonated and, therefore, their interference is 
minimized. The non-phosphorylated peptides do not present negative charges, while the 
phosphorylated peptides have one negative charge in the phosphate group (Figure 3.6). On the other 
hand, all ligands are positively charged at pH 3, being able to selectively bind the phosphopeptides 
through their negatively charged phosphate moiety. However, the lower binding capacities of the 
ligands at pH 3 relative to pH 4 might be associated to an incomplete deprotonation of the 
phosphate group of the peptides at more acidic pH. Tsao and co-workers have already reported that 
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carboxyl groups are only completely protonated at pH values below 2, whereas phosphate 
deprotonation is fully achieved at pH values above 3 [29].  
 
A) 
 
B) 
 
Figure 3.5 – Screening results of A6A4, A8A3, A8C2, and A3B6 ligands against a mixture of phosphopeptides 
at different pH. Screenings were performed by adding 0.25 mL of peptide mixture in binding buffer (0.5 mg/ 
mL) to each well of a 96-well filter plate containing 0.25 g of ligand-functionalized resin. The unbound peptides 
from flow-through and washes were collected in 96-well black microplates and the fluorescence intensity of 
the samples was measured in a microplate reader (λexc = 280 (20) nm – λem = 340 (35) nm filter). A) Amount 
of phosphopeptides mixture bound per g of ligand-functionalized support (N=2; stdev ≤ 0.02 mg/g). B) 
Phosphopeptides mass fraction (%) (N=2; stdev ≤ 19%). The binding buffers used were: 50 mM glycine pH 3; 50 
mM acetate pH 4; 50 mM acetate pH 5; 50 mM acetate pH 6; 50 mM tris pH 7; 50 mM NH4HCO3 pH 8; 50 mM 
tris pH 9; 50 mM glycine pH 10; and 50 mM glycine pH 11. 
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A) 
 
B) 
 
C) 
 
 
Figure 3.6 – pKa values of functional groups from A) SW6; B) SW6-P; C) TW6; D) TW6-P; E) YW6; and F) YW6-
P. Values were determined using the pKa Plugin from MarvinSketch (ChemAxon).  
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D) 
 
E) 
 
F) 
 
 
Figure 3.6 (cont.) – pKa values of functional groups from A) SW6; B) SW6-P; C) TW6; D) TW6-P; E) YW6; and F) 
YW6-P. Values were determined using the pKa Plugin from MarvinSketch (ChemAxon). 
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The influence of ionic strength in the binding profile of the peptides has also been investigated, since 
the addition of salt might decrease the non-specific binding of non-phosphorylated peptides. 
Therefore, both phosphopeptides and non-phosphopeptides mixtures were screened at pH 3 with 
increasing concentrations of NaCl (0, 25, 50, 100, 250, 500, 1000 mM). The presence of salt 
dramatically decreases the binding capacity of the ligands and their bias towards phosphopeptides, 
even at low concentrations. This effect has already been observed by Ndassa and co-workers, which 
reported that the addition of NaCl did not provide any improvement in phosphopeptide enrichment 
using immobilized IMAC [30]. 
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A) 
 
  
B) 
 
Figure 3.7 – Screening results of A6A4, A8A3, A8C2, and A3B6 ligands against a mixture of phosphopeptides 
at pH 3 with different salt concentrations. Screenings were performed by adding 0.25 mL of peptide mixture in 
binding buffer (0.5 mg/ mL) to each well of a 96-well filter plate containing 0.25 g of ligand-functionalized resin. 
The unbound peptides from flow-through and washes were collected in 96-well black microplates and the 
fluorescence intensity of the samples was measured in a microplate reader (λexc = 280 (20) nm – λem = 340 
(35) nm filter). A) Amount of phosphopeptides mixture bound per g of ligand-functionalized support (N=2; 
stdev ≤ 0.03 mg/g). B) Phosphopeptides mass fraction (%) (N=2; stdev ≤ 17%).  
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Ligand A3B6 presented low binding capacities and selectivity at all pH values and salt concentrations, 
being not considered for subsequent studies. No significant differences were observed between 
triazine ligands; thus, the lead candidate was selected based on structural aspects. As previously 
stated, ligand A6A4 has two substituents which might originate side reactions and, consequently, this 
ligand was discarded. At this point, the two lead candidates (A8A3 and A8C2) were screened against 
a multi-phosphorylated peptide, in order to access their ability to bind molecules with a higher 
degree of phosphorylation. The multi-phosphorylated peptide has one pSer and two pThr, having the 
following sequence: Tyr-Ala-Gly-pSer-pThr-Asp-Glu-Asn-pThr-Asp-Ser-Glu-Trp (YW13-P). A shortened 
version of this peptide (without the Trp residue) has been reported to bind FHA domains of human 
polynucleotide kinase 3’-phosphatase (PNK) with high specificity and affinity (KD = 190 nm) [31].  
The first parameter changed during the screening of A8A3 and A8C2 against YW13-P and its non-
phosphorylated version YW13 was the pH of the binding buffer. Ligands behaved in a significantly 
different manner in the presence of the multi-phosphorylated peptide, when compared to the 
screenings against the mixture of singly phosphorylated peptides. There is a minor decrease in the 
binding capacity of both ligands between pH 3 and pH 7. Ligand A8C2 binds approximately 90% of 
the multi-phosphorylated peptide at pH 7. Above this pH, the binding capacity of both ligands 
decreases considerably (Figure 3.8). One possible explanation is that the ligands are positively 
charged below pH 7, but are uncharged above it (Figure 3.9), while YW13-P is negatively charged in 
the entire pH range tested ( 
Figure 3.10), as indicated by their pKa values. Therefore, electrostatic interactions between the 
ligands and YW13-P are more prone to occur below pH 7. However, it is important to keep in mind 
that the pKa values give an idea of the major microspecies of each molecule at a given pH, i.e. the 
most frequent protonation form.  If the pH is near the pKa value of any particular functional group, 
the molecule will exist in several protonation forms. Also, the pKa values presented herein were 
calculated by software and may slightly differ from experimental pKa values. The imidazole group 
presents pKa values of 6.84 and 6.55 for ligands A8A3 and A8C2, respectively. Therefore, the ligands 
will also exist as their protonated forms (positively charged) at pH 7. On the other hand, each 
phosphate group presents two negative charges at this pH, and all carboxyl groups are negatively 
charged as well. This might be the reason why ligand A8C2 binds the highest amount of peptide at pH 
7.  
YW13-P and YW13 peptides are acidic peptides, having 5 carboxyl groups in their sequence. The fact 
that the ligands present phosphopeptide mass fractions around 50% below pH 7 indicates that the 
interaction is not occurring though the phosphate moiety in this case.  At pH values of 7 or above, 
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the ligands are much more selective towards YW13-P, but at the expense of lower binding capacities 
(Figure 3.8).  
 
A) 
 
  
B) 
 
Figure 3.8 – Screening results of A8A3 and A8C2 against YW13-P at different pH. Screenings were performed 
by adding 0.25 mL of peptide in binding buffer (0.5 mg/ mL) to each well of a 96-well filter plate containing 0.25 
g of ligand-functionalized resin. The unbound peptides from flow-through and washes were collected in 96-well 
black microplates and the fluorescence intensity of the samples was measured in a microplate reader (λexc = 
280 (20) nm – λem = 340 (35) nm filter). A) Amount of YW13-P bound per g of ligand-functionalized support. B) 
YW13-P mass fraction (%). The binding buffers used were: 50 mM glycine pH 3; 50 mM acetate pH 4; 50 mM 
acetate pH 5; 50 mM acetate pH 6; 50 mM tris pH 7; 50 mM NH4HCO3 pH 8; 50 mM tris pH 9; 50 mM glycine pH 
10; and 50 mM glycine pH 11. (N=2) 
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A) 
 
  
B) 
 
Figure 3.9 – pKa values of A) ligand A8A3, and B) ligand A8C2. Values were determined using the pKa Plugin 
from MarvinSketch (ChemAxon). A methyl group was included in the structure of the ligand in place of the 
agarose bead. 
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                    A) 
 
                    B) 
 
 
Figure 3.10 - pKa values of A) YW13, and B) YW13-P. Values were determined using the pKa Plugin from MarvinSketch (ChemAxon). 
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Ligands were also screened against YW13-P and YW13 at pH 3, but with different concentrations of 
salt, in order to compare their binding profile with the one from the mono-phosphorylated peptides 
mixture (Figure 3.11). The binding capacity of the ligands was not affected for low concentrations of 
salt, but the selectivity of the ligands significantly increased. Ligand A8A3 presented a 
phosphopeptide mass fraction of approximately 98% for a concentration of NaCl of 50 mM, while 
ligand A8C2 was almost 100% selective for a concentration of 100 mM. This is related to the fact that 
multi-phosphorylated peptides bind more strongly to the ligands, due to their enhanced negative 
charge, when compared to non- or mono-phosphorylated peptides. Therefore, the selectivity 
towards multi-phosphorylated peptides increases for low concentrations of salt. For concentrations 
of salt above 100 mM, there is a decrease in both the binding capacity and selectivity. This is in 
accordance to the results obtained by Nühse and co-workers, who used a two-dimensional 
methodology with strong anion exchange (SAX) chromatography prior to IMAC for the separation of 
phosphorylated peptides. They concluded that singly phosphorylated peptides eluted from the SAX 
resin at low concentrations of salt, while multi-phosphorylated peptides were retained, eluting at 
higher salt concentrations [32].  
Loading two separate ligand-functionalized affinity columns, one with a sample with added salt, and 
one with the same sample without salt, would allow the selective enrichment of both mono- and 
multi-phosphorylated peptides from a complex sample.  
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A) 
 
  
B) 
 
Figure 3.11 – Screening results of ligands A8A3 and A8C2 against YW13-P at pH 3 with different salt 
concentrations. Screenings were performed by adding 0.25 mL of peptide in binding buffer (0.5 mg/ mL) to 
each well of a 96-well filter plate containing 0.25 g of ligand-functionalized resin. The unbound peptides from 
flow-through and washes were collected in 96-well black microplates and the fluorescence intensity of the 
samples was measured in a microplate reader (λexc = 280 (20) nm – λem = 340 (35) nm filter). A) Amount of 
YW13-P bound per g of ligand-functionalized support; B) YW13-P mass fraction (%). (N=2) 
 
3.3.3.  Determination of binding capacity of negative controls 
 
The triazine ligand A8A3 is synthesized on aminated agarose and the Ugi ligand A8C2 is synthesized 
on aldehyde-functionalized agarose. Therefore, agarose, agarose-NH2, and agarose-CHO were used 
as negative controls to determine the non-specific binding of phosphorylated peptides to the solid 
support. 
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All individual peptides bind less than 20% to agarose. When agarose is screened against the mixture 
of mono-phosphorylated peptides, the value of non-specific binding corresponds to the sum of the 
values obtained for the individual peptides; thus, the effect is cumulative. Agarose-CHO presents an 
identical performance to agarose itself. The phosphopeptides binding profile to agarose-NH2 is 
similar to the previous ones as well, with the exception of the multi-phosphorylated peptide YW13-P, 
which binds around 95%. At pH 3, amine groups will exist as NH3
+, establishing stronger electrostatic 
interactions with the highly negatively charged multi-phosphorylated peptide. As a result, in the case 
of ligand A8A3, it is uncertain whether YW13-P is binding to unreacted amines or the ligand itself. 
However, as evidenced in chapter 2, triazine reaction presents satisfactory reaction yields, 
minimizing the interference of unreacted amines.   
 
Table 3.5 – Non-specific binding of phosphopeptides (%) to agarose, agarose-CHO, and agarose-NH2. 
Screenings were performed by adding 0.25 mL of peptide in 50 mM glycine pH 3 (0.5 mg/ mL) to each well of a 
96-well filter plate containing 0.25 g solid support. The unbound peptides from flow-through and washes were 
collected in 96-well black microplates and the fluorescence intensity of the samples was measured in a 
microplate reader (λexc = 280 (20) nm – λem = 340 (35) nm filter). (N=2) 
 
Support 
Agarose Agarose-CHO Agarose-NH2 
Peptides 
SW6-P 2 ± 2 4 ± 5 3 ± 4 
TW6-P 2 ± 2 3 ± 4 0 ± 1 
YW6-P 19 ± 3  13 ± 5 20 ± 1 
Mixture of 
SW6-P, TW6-P, and YW6-P 
22 ± 5 18 ± 4 26 ± 2 
YW13-P 1 ± 2 0 ± 0 95 ± 0.2 
 
3.3.4. Optimization of elution conditions 
 
Innumerable strategies have been used for the elution of phosphorylated proteins and peptides, 
depending on the enrichment method used. Peptides bound to ligand-functionalized agarose were 
eluted using different solutions, considering the following parameters: presence of an organic 
solvent, such as ACN or MeOH; use of acidic or alkaline solutions; type of acid added; and presence 
of a competitor molecule (H3PO4).  
Organic solvents disrupt weak hydrophobic interactions between the peptides and the ligand. Lee 
and co-workers reported that including 40 to 50% ACN in the elution buffer increased the elution 
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efficiency of phosphorylated peptides from IMAC beads [33]. MeOH (Sol 2 and Sol 3 - Figure 3.12), 
for example, elutes both non- and mono-phosphorylated peptides, but not the multi-phosphorylated 
peptide YW13-P, which is strongly bound to the ligand through electrostatic interactions. If ACN is 
used instead of MeOH (Sol 1 - Figure 3.12), only mono-phosphorylated peptides are eluted, 
increasing the selectivity of the elution process. However, it should be taken into consideration that 
the elution efficiency is relative to the peptides bound to the ligands. As ligands are highly selective 
towards phosphorylated peptides, the actual percentage of non-phosphorylated peptides bound is 
rather low (< 15% for the mixture of SW6, TW6, and YW6; < 5% for YW13). Nevertheless, the elution 
process should be optimized in order to eliminate or minimize the co-elution of non-phosphorylated 
peptides. 
Both acidic and alkaline conditions have been widely used for the recovery of phosphorylated 
peptides. Thingholm and co-workers introduced a strategy consisting in the sequential separation of 
mono- and multi-phosphorylated peptides from complex mixtures, combining both IMAC and TiO2 
chromatography. They have reported the elution of singly phosphorylated peptides under acidic 
conditions, whereas multiply phosphorylated peptides are subsequently recovered under basic 
conditions [34]. In other study, a basic eluent (NH4OH) has been described to efficiently elute both 
mono- and multi-phosphorylated peptides from IMAC [35]. The elution efficiency of different bases 
has been reported for TiO2 chromatography, and higher phosphopeptide recoveries were obtained 
with NH4OH and NH4H2PO4 eluents, when compared to NH4HCO3 [36].  
In this study, a solution of 50% (v/v) ACN/H2O + 0.1% NH4OH pH 10.2 (Sol 4 - Figure 3.12) allows the 
elution of both mono- and multi-phosphorylated peptides from ligand A8A3, but only mono-
phosphorylated peptides and a few non-phosphorylated peptides are eluted from ligand A8C2. At pH 
10.2, both A8A3 and A8C2 ligands are uncharged and present logD values of 2.19 and -1.58, 
respectively. Therefore, ligand A8A3 is hydrophobic at pH 10.2, while ligand A8C2 is hydrophilic. This 
might be the reason why phosphorylated peptides elute more easily from ligand A8A3, since they 
mainly interact with the ligand through electrostatic interactions. The presence of ACN further 
enhances this effect, as it further disrupts weak hydrophobic interactions that might also exist 
between the ligand and the peptide.  
The influence of weak acids upon elution was evaluated using H3BO3 and H3PO4. H3BO3 did not lead 
to the elution of neither phosphorylated nor non-phosphorylated peptides (Sol 7 - Figure 3.12). 
However, when a strong acid (TFA) was added to the solution both mono- and multi-phosphorylated 
peptides were eluted (Sol 8 - Figure 3.12). A solution comprising 50% (v/v) ACN/H2O+ 0.1% TFA + 1% 
H3BO3 allowed for 94% recovery of YW13-P from ligand A8A3 (Sol  8 - Figure 3.12A). Thingholm and 
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co-workers used increasing concentrations of TFA and were able to elute mono-phosphorylated 
peptides for TFA concentrations between 0.2 and 1% and multi-phosphorylated peptides for TFA 
concentrations above 1% from IMAC adsorbents [34]. 
The use of 1% H3PO4 gave the best results, allowing the recovery of both mono- and multi-
phosphorylated peptides from both affinity ligands (Sol 5 and Sol 6 - Figure 3.12). H3PO4 plays two 
roles, acting as an acid and as a competitor molecule. In this case, adding TFA to the solution did not 
improve the recovery of phosphorylated peptides (Sol 6 - Figure 3.12). A combination of ACN and 
H3PO4 has been reported to be extremely effective in the elution of both mono- and multi-
phosphorylated peptides from IMAC [37].  
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A) 
 
  
B) 
 
Figure 3.12 – Elution of phosphorylated and non-phosphorylated peptides from A) ligand A8A3 and B) ligand 
A8C2. After screening, peptides bound to ligand-functionalized supports were eluted by adding 0.25 mL of 
elution solution to each well of the 96-well filter plate. This step was repeated until no peptide was detected in 
the elution fractions. The eluted peptides were collected in 96-well black microplates and the fluorescence 
intensity of the samples was measured in a microplate reader (λexc = 280 (20) nm – λem = 340 (35) nm filter). 
The elution solutions were: Sol 1 – 50% (v/v) ACN/H2O + 1% acetic acid (pH 3); Sol 2 – 50% (v/v) MeOH/H2O + 
1% acetic acid (pH 3); Sol 3 – MeOH (pH 6.3); Sol 4 – 50% (v/v) ACN/H2O + 0.1% NH4OH (pH 10.2); Sol 5 – 50% 
(v/v) ACN/H2O + 1% H3PO4 (pH 1.6); Sol 6 – 50% (v/v) ACN/H2O + 0.1% TFA + 1% H3PO4 (pH 1.3); Sol 7 - 50% 
(v/v) ACN/H2O + 1% H3BO3 (pH 4.9); Sol 8 - 50% (v/v) ACN/H2O + 0.1% TFA + 1% H3BO3 (pH 1.5). (N=2) 
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3.3.5. Partition equilibrium experiments 
 
A simple bimolecular interaction between a target peptide and a solid-phase ligand is depicted in 
Figure 3.13, where KA is the association equilibrium constant and KD is the dissociation equilibrium 
constant. KA is defined as in Equation 3.2, and KD is 1/KA. 
 
 
Figure 3.13 – Schematic representation of the interaction between an immobilized affinity ligand and a 
target peptide. 
 
 
Equation 3.2 – Association equilibrium constant. [L] is the concentration of the ligand, [P] is the concentration 
of the peptide, and [L-P] is the concentration of the ligand-peptide complex. 
    
[   ]
[ ][ ]
 
 
Herein, the binding constants were determined by partition equilibrium studies, but other 
approaches may be used depending on the suitability of each method for a particular system [38]. 
The experiments consisted of incubating a known amount of partitioning solute (SW6, SW6-P, TW6, 
TW6-P, YW6, YW6-P, YW13, YW13-P) with a fixed amount of affinity matrix (A8A3 and A8C2 
functionalized agarose) at constant temperature, until the mixture reach a chemical equilibrium. The 
adsorption of all phosphorylated and non-phosphorylated peptides followed the Langmuir 
adsorption model for both ligands (Figure 3.14 and Figure 3.15). The model relies on the following 
main assumptions: (i) each molecule occupies one adsorption site, forming a monolayer at the 
surface; (ii) every adsorption site is energetically equivalent; (iii) molecules adsorb independently of 
one another; and (iv) molecules do not interact with each other [39]. The Langmuir adsorption 
isotherm is represented by Equation 3.3. 
 
Equation 3.3 – Langmuir adsorption isotherm. q is the binding capacity (mg peptide bound/g support); Qmax is 
the maximum binding capacity (mg peptide bound/g support); Ceq is the concentration of the peptide in 
solution at the equilibrium (mg/mL); and KA is the association equilibrium constant (mL/mg).  
   
           
         
 
PMatrix + Matrix P
KA
KD
Ligand (L) Peptide  (P) Ligand-Peptide (L-P)
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The KA (M
-1) and Qmax (mg peptide bound/g support) parameters were determined and are recorded 
in Table 3.6 and Table 3.7.  
 
A) B) 
  
  
C) D) 
  
Figure 3.14 – Adsorption isotherms of A) SW6; B) SW6-P; C) TW6; D) TW6-P; E) YW6; F) YW6-P; G) YW13; and 
H) YW13-P for ligand A8A3. Peptides in different concentrations (0-10 mg/mL) were incubated overnight with 
0.25 g of A8A3-functionalized agarose at 30°C. The buffers used were 50 mM Gly pH 3 for SW6, SW6-P, TW6, 
TW6-P, YW6, YW6-P, and 50 mM Gly pH 3 50 mM NaCl for YW13 and YW13-P. The unbound peptide from flow-
through was collected and the fluorescence intensity of the samples was measured in a microplate reader (λexc 
= 280 (20) nm – λem = 340 (35) nm filter). The Langmuir equation was successfully fitted to data by nonlinear 
regression using OriginPro 8.5.1 SR2. (N=2) 
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E) F) 
  
  
G) H) 
  
Figure 3.14 (cont.) – Adsorption isotherms of A) SW6; B) SW6-P; C) TW6; D) TW6-P; E) YW6; F) YW6-P; G) 
YW13; and H) YW13-P for ligand A8A3. Peptides in different concentrations (0-10 mg/mL) were incubated 
overnight with 0.25 g of A8A3-functionalized agarose at 30°C. The buffers used were 50 mM Gly pH 3 for SW6, 
SW6-P, TW6, TW6-P, YW6, YW6-P, and 50 mM Gly pH 3 50 mM NaCl for YW13 and YW13-P. The unbound 
peptide from flow-through was collected and the fluorescence intensity of the samples was measured in a 
microplate reader (λexc = 280 (20) nm – λem = 340 (35) nm filter). The Langmuir equation was successfully 
fitted to data by nonlinear regression using OriginPro 8.5.1 SR2. (N=2) 
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A) B) 
  
  
C) D) 
  
Figure 3.15 – Adsorption isotherms of A) SW6; B) SW6-P; C) TW6; D) TW6-P; E) YW6; F) YW6-P; G) YW13; and 
H) YW13-P for ligand A8C2. Peptides in different concentrations (0-10 mg/mL) were incubated overnight with 
0.25 g of A8C2-functionalized agarose at 30°C. The buffers used were 50 mM Gly pH 3 for SW6, SW6-P, TW6, 
TW6-P, YW6, YW6-P, and 50 mM Gly pH 3 100 mM NaCl for YW13 and YW13-P. The unbound peptide from 
flow-through was collected and the fluorescence intensity of the samples was measured in a microplate reader 
(λexc = 280 (20) nm – λem = 340 (35) nm filter). The Langmuir equation was successfully fitted to data by 
nonlinear regression using OriginPro 8.5.1 SR2. (N=2) 
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E) F) 
  
  
G) H) 
  
Figure 3.15 (cont.) – Adsorption isotherms of A) SW6; B) SW6-P; C) TW6; D) TW6-P; E) YW6; F) YW6-P; G) 
YW13; and H) YW13-P for ligand A8C2. Peptides in different concentrations (0-10 mg/mL) were incubated 
overnight with 0.25 g of A8C2-functionalized agarose at 30°C. The buffers used were 50 mM Gly pH 3 for SW6, 
SW6-P, TW6, TW6-P, YW6, YW6-P, and 50 mM Gly pH 3 100 mM NaCl for YW13 and YW13-P. The unbound 
peptide from flow-through was collected and the fluorescence intensity of the samples was measured in a 
microplate reader (λexc = 280 (20) nm – λem = 340 (35) nm filter). The Langmuir equation was successfully 
fitted to data by nonlinear regression using OriginPro 8.5.1 SR2. (N=2) 
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Table 3.6 – Qmax (mg peptide bound/ g support) and KA (M
-1
) parameters for ligand A8A3. Data was fitted to 
Langmuir equation on OriginPro 8.5.1 SR2. R
2
 is the correlation factor. (N=2) 
 SW6 SW6-P TW6 TW6-P YW6 YW6-P YW13 YW13-P 
Qmax (mg/g) 
3.68 
±0.33 
9.82 
±1.15 
5.69 
±0.26 
7.29 
±0.30 
5.02 
±0.58 
13.07 
±4.26 
4.50 
±0.51 
8.34 
±0.26 
KA (x10
2 M-1) 
1.41 
±0.25 
2.10 
±0.42 
2.24 
±0.16 
2.53 
±0.15 
2.32 
±0.38 
2.55 
±1.14 
9.42 
±2.24 
20.4 
±1.40 
R2 0.990 0.998 0.998 0.999 0.992 0.996 0.993 0.999 
 
Table 3.7 – Qmax (mg peptide bound/ g support) and KA (M
-1
) parameters for ligand A8C2. Data was fitted to 
Langmuir equation on OriginPro 8.5.1 SR2. R2 is the correlation factor. (N=2) 
 SW6 SW6-P TW6 TW6-P YW6 YW6-P YW13 YW13-P 
Qmax (mg/g) 
4.36 
±3.98 
18.27 
±5.44 
3.73 
±0.47 
6.44 
±1.24 
3.14 
±0.18 
6.83 
±1.42 
4.61 
±0.52 
19.32 
±4.93 
KA (x10
2 M-1) 
1.41 
±1.59 
1.47 
±0.53 
3.98 
±0.92 
3.62 
±1.14 
4.45 
±0.54 
13.32 
±7.04 
7.14 
±1.49 
9.73 
±3.76 
R2 0.983 0.999 0.997 0.998 0.996 0.995 0.993 0.999 
 
The low values of the affinity constants (KA < 10
3 M-1) indicate that the adsorption of the peptides to 
the ligands is mainly governed by weak interactions [40]. Both phosphorylated and non-
phosphorylated peptides present binding affinities within the same range, which means the presence 
of the phosphate group does not significantly increases the stability of the peptide-ligand complex.  It 
is important, however, to properly distinguish between the concepts of affinity and specificity, 
although they are both involved in molecular recognition [41]. Affinity may be defined as the 
structural and energetic recognition between two molecules [42]. It is a quantifiable property and is 
characterized by thermodynamical parameters, such as heat capacity and free enthalpy of 
dissociation at equilibrium [43, 44]. It determines the stability of the complex between the two 
molecules, which interact by non-covalent bonding. Specificity is the ability of one molecule to 
discriminate between its target and other competing molecules [44, 45].  It takes into consideration 
that the binding between the two molecules occurs in highly heterogeneous environments. It 
accounts not only for the existence of competing species with different relative concentrations, but 
also for the fact that the target molecule might bind outside its specific site or in different 
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orientations [41]. Specificity is a much more complex concept than affinity, being more accurately 
described by statistical physics [41, 43, 44]. High affinity systems do not necessarily present high 
specificity and vice-versa [41, 43].  
High affinity is usually characterized by KA values between 10
3 and 109 M-1. However, these values 
have been determined for systems comprising the interaction between two macromolecules or a 
small molecule and a macromolecule [40]. In this work, both ligands and target peptides are small 
molecules, which are usually less flexible and have smaller surface areas. Larger molecules such as 
proteins have high structural and functional complexity. Their adsorption is governed by numerous 
factors, including structural re-arrangements; changing surface affinities upon binding; cooperative 
effects; overshooting adsorption kinetics; and aggregation. Although small molecules present higher 
diffusion rates, larger molecules usually bind more strongly to their target due to the larger contact 
area [46].  
Eriksson and co-workers studied the affinity interaction between several phosphorylated peptides 
and a TiO2 surface. They concluded that the KA increases 2-fold per phosphorylation site, i.e. the 
affinity increases with the degree of phosphorylation, although it might be affected by other factors, 
such as the primary sequence of the peptide, the position of the phosphate groups, the existence of 
other charged amino acids, etc. The KA values between the phosphopeptides and TiO2 were in the 
order of 106 M-1 [47].  However, TiO2 interacts with the phosphopeptides by metal coordination, 
through the formation of multi-dentate bonds. The simultaneous coordination to several metal ions 
may increase the binding affinity by up to a factor of 1000 [48].  
Regarding the maximum binding capacities, all phosphorylated peptides presented higher Qmax than 
the non-phosphorylated peptides. As the partition equilibrium experiments were performed 
simultaneously for all peptides and used the same batch of synthesized ligand, it is reasonable to 
assume a constant density of ligand. Therefore, high Qmax values for phosphorylated peptides (even 
though having low binding affinities) might be a consequence of higher specificity of the ligands for 
phosphorylated peptides.  
In a general chromatographic perspective, the capacity factor (k’), which determines the retention of 
a particular target, is related to KA and Qmax by Equation 3.4. This equation is only valid when KACeq < 
1 (Ceq is the concentration of the target in solution at the equilibrium). 
 
Equation 3.4 – Mathematical definition of capacity factor (k’). C is a constant characteristic from the support, 
and usually ranges between 0.5 and 1. Qmax is the maximum binding capacity and KA is the affinity constant. 
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Weak affinity interaction chromatography relies on the dynamic interaction between ligand and 
target (rather than adsorption/ desorption phenomenon), being characterized by low KA values and 
requiring high Qmax. This mode of affinity chromatography is thought to rely on repeated binding 
events or simultaneous weak binding events, presenting high efficiency and improved performance 
in terms of resolving power [49, 50].  
 
3.4. Conclusions 
 
Synthetic affinity ligands based on different chemistries have been successfully used to enrich 
phosphorylated peptides recognized by different PBDs, namely BRCT, FHA, and SH2 domains. Best 
ligands were based on triazine (A8A3) and Ugi (A8C2) reactions, and comprise an imidazole group in 
their structures. These ligands can be considered as multimodal ligands, as they have more than one 
mode of interaction with their targets. Particularly, the presence of heterocyclic groups, such as the 
imidazole group, provides them with the potential to interact both by electrostatic and hydrophobic 
interactions [51].  
Best binding conditions combined with higher specificity were found to be pH 3 for a mixture of 
mono-phosphorylated peptides, and pH 7 for a multi-phosphorylated peptide. However, the multi-
phosphorylated peptide was also successfully enriched at pH 3 when low concentrations of NaCl 
were added (up to 100 mM). A solution of 50% (v/v) ACN/H2O + 1% H3PO4 (pH 1.6) allowed the 
recovery of both mono- and multi-phosphorylated peptides from both ligands, but the use of 50% 
(v/v) ACN/H2O + 0.1% NH4OH (pH 10.2) was effective as well. 
All peptides presented low binding affinities (KA ≈ 10
2-103 M-1) towards both ligands, but 
phosphorylated peptides presented higher Qmax values. This behaviour is typical from weak affinity 
interactions, which provide means for improved kinetics, high-resolution and rapid throughput [52, 
53]. 
A full study by NMR, X-ray crystallography, or even molecular modelling is needed to better 
understand the interactions occurring between the ligands and their phosphorylated targets. 
Nonetheless, these tailored small molecules are promising alternatives to unspecific methods, such 
as IMAC and TiO2 chromatography, contributing for the development of methodologies based on 
molecular recognition, which may have great impact not only in phosphopeptide enrichment at 
laboratory scale, but also as novel diagnostic tools.   
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CHAPTER 4 
Phosphopeptide enrichment using biomimetic magnetic nanostructures 
 
 
Summary 
 
Magnetic nanoparticles coated with silica and dextran (MNP-Si-Si-Dex) were successfully 
functionalized with lead biomimetic ligands based on triazine (ligand A8A3) and Ugi (ligand A8C2) 
reactions with affinity for phosphorylated peptides. The same ligands immobilized on agarose 
presented binding capacities 100 times lower although with higher selectivity. Four synthetic 
phosphopeptides consisting in consensus sequences known to bind three human phosphoprotein-
binding domains were used in these studies. Ligand A8A3 immobilized on MNP-Si-Si-Dex was further 
used to enrich phosphopeptides from tryptic digests of α-casein, β-casein and bovine serum albumin 
(BSA), and the results have been compared with a Ti4+-IMAC approach. 
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4.1. Introduction 
 
The field of nanotechnology has experienced incredible development and expansion in recent years. 
In particular, magnetic nanoparticles (MNPs) present the attractive feature of manipulation by an 
external magnetic field, finding applications in countless fields of science, such as medical imaging, 
drug delivery, biosensing, bioseparation, among others [1-5]. This class of nanoparticles includes 
metallic (e.g. Fe, Co, and Ni nanoparticles), bimetallic (e.g. FePt, FeCo), and iron oxide MNPs [1, 6]. 
The low toxicity, ease of synthesis, and biodegradability of the latter have boosted their widespread 
utilization, and in fact a few formulations have already been approved for clinical usage [1, 6]. In the 
field of magnetic separations, iron oxide MNPs have been used since the 1960´s [4]. By selecting the 
appropriate method of synthesis and coating agents, it is possible to tailor their size, shape, and 
surface chemistry [1, 6]. As a consequence of their small size, MNPs have a high surface-to-volume 
ratio and tend to agglomerate to decrease their surface energy [3, 7]. Due to their highly reactive 
surfaces, MNPs are generally coated with organic and/or inorganic materials to protect them against 
oxidation and acid/base erosion [2, 7]. The choice of the coating agent is extremely important as it 
allows tuning the surface charge, hydrophobic/hydrophilic character, and chemical functionality [6]. 
Polymeric coatings have been widely used to prevent particle aggregation and non-specific binding, 
but the physical-chemical characteristics of the polymer (e.g. molecular weight, hydrophobicity, 
chemical structure, biodegradability) must be considered, as they may affect particles’ performance 
[1, 6, 8]. In the last decade, MNPs have been extensively used for the enrichment of phosphorylated 
peptides. Magnetite (Fe3O4) was successfully used for the selective capture of phosphopeptides from 
tryptic digests of bovine β-casein, cytochrome c, bovine serum albumin (BSA), and horse heart 
myoglobin, but no enrichment was observed when maghemite (γ-Fe2O3) was used [9]. As Fe3O4 is 
easily converted to γ-Fe2O3 in the presence of oxygen [3], one option is to modify the surface of the 
particles, minimizing oxidation and introducing functional groups with high affinity for 
phosphopeptides. Coating agents range from metal oxides (e.g. Al2O3, ZrO2, TiO2, Ga2O3, SnO2, Ta2O5, 
Nb2O5, ZnO) [10], polymers (e.g. polyethyleneimine) [11], hydroxyapatite [12], zirconium arsenate 
[13], yttrium phosphate [14], Ti4+-adenosine tri-phosphate [15],  lanthanum silicate [16], rare earth 
vanadates (REVO4; RE = Sm, Dy, Ho) [17], bentonite [18], ammonium fluoride and lutetium fluoride 
[19], guanidinium [20], alkoxide-bridged  dinuclear  zinc(II)  complex  of  1,3-bis[bis(pyridine-2-
ylmethyl)amino]propan-2-olate (Zn2+-Phos-tag) [21], among many others. The binding mode of the 
majority of these surface-modified MNPs is still by metal chelation. In this work, a different approach 
is developed by using small biomimetic ligands immobilized on MNPs coated with silica and dextran. 
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Silica is used in order to protect MNPs surface and prevent iron leaching pH at acidic pH, while 
dextran is a biocompatible polymer composed of glucose units and is used to minimize non-specific 
binding.  
 
4.2. Materials and Methods 
 
4.2.1. Chemicals 
 
All reagents were of the highest purity available and the solvents were pro-analysis. 
 
1-Pyrenemethylamine hydrochloride (AP), 2,5-dihydroxybenzoic acid (2,5-DHB),  3-
aminopropyltriethoxy silane (APTES), ammonium bicarbonate (NH4HCO3), ammonium hydroxide 
solution (NH4OH), cyanuric chloride, dextran from Leuconostoc mesenteroides (average mol wt 
150,000), DL-dithiothreitol (DTT), epichlorohydrin, formic acid, glutaraldehyde solution (50 wt. % in 
H2O), histamine (A8), iodoacetamide (IAA), iron(II) chloride tetrahydrate,  iron (III) chloride 
hexahydrate, isopropyl isocyanide, ninhydrin, phenethylamine (A3), phenol, phosphoric acid (H3PO4), 
potassium cyanide, pyridine, sodium metasilicate pentahydrate, succinamic acid (C2), tetraethyl 
orthosilicate (TEOS), trifluoroacetic acid (TFA), were acquired from Sigma-Aldrich. 2-Propanol and 
methanol (MeOH) were obtained from Roth, glycine from Acros Organics, and acetic acid glacial from 
Pronalab. Acetone and dimethylformamide (DMF) were purchased from VWR. acetonitrile (ACN), 
ethanol (EtOH) absolute PA, hydrochloric acid (HCl) 37%, sodium chloride (NaCl) and sodium 
hydroxide (NaOH) were acquired from Panreac. Urea was acquired from Merck. Nitrogen gas was 
provided by Air Liquide. Ser-Gln-Val-Phe-Pro-Trp (SW6), pSer-Gln-Val-Phe-Pro-Trp (SW6-P), Thr-Gln-
Val-Asp-Ala-Trp (TW6), pThr-Gln-Val-Asp-Ala-Trp (TW6-P), Tyr-Glu-Glu-Ile-Pro-Trp (YW6),  pTyr-Glu-
Glu-Ile-Pro-Trp (YW6-P), Tyr-Ala-Gly-Ser-Thr-Asp-Glu-Asn-Thr-Asp-Ser-Glu-Trp (YW13), and Tyr-Ala-
Gly-pSer-pThr-Asp-Glu-Asn-pThr-Asp-Ser-Glu-Trp (YW13-P) peptides were > 98% pure and were 
purchased from Genecust and Caslo. 
 
4.2.2. Biochemicals 
 
Trypsin Gold, Mass Spectrometry Grade was purchased from Promega. α-Casein from bovine milk 
(Cat. No. C6780), β-Casein from bovine milk (Cat. No. C6905), and Bovine Serum Albumin (BSA) (Cat. 
No. A2153) were acquired from Sigma-Aldrich. 
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4.2.3. Materials 
 
Half-area UV-Star® 96-well microplates, black immunograde 96-well microplates, and 96-well 
transparent microplates were obtained from Greiner Bio-One, Brand, and Sarstedt, respectively. Sep-
Pak C18 cartridges were purchased from Waters. GELoader tips were purchased from Eppendorf.  
 
4.2.4. Instrumentation 
 
Ligand synthesis was carried out in an IKA KS 4000 ic control shaker. Samples were incubated with 
ligand-functionalized MNP-Si-Si-Dex in a VorTempTM 56 shaking incubator from Labnet. Fluorescence 
readings in 96-well microplates were conducted in a Tecan F200 Microplate Reader using a λexc = 
280 (20) nm – λem = 340 (35) nm filter, and 560 (10) nm filter, and a 280 (5) nm filter (Tecan). 
Dynamic light scattering (DLS) analysis was conducted on a Zetasizer Nano ZS from Malvern. All 
samples were prepared in Milli-Q water to a final concentration of 0.05 mg/mL.  
Prior to Matrix Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry (MALDI-TOF 
MS) analysis, the samples were resuspended in 10 µL 2,5-DHB (25 mg/mL prepared in 70% (v/v) 
MeOH/ 1% (w/v) H3PO4), 0.5 µL applied on a MALDI sample plate and allowed to dry. MS analysis was 
performed on a Waters MALDI micro MX system (Waters, Milford, MA, USA) equipped with a 
nitrogen UV laser (337 nm). Measurements were done in the positive reflection mode with a 
reflectron voltage of 5200 V, delayed extraction time of 700 ns, pulse voltage of 2100 V, flight tube 
voltage of 12000 V, and a detector voltage between 2300-2600 V. An average of 750 laser shots were 
acquired per spectrum. The spectra were processed (baseline correction, smoothing and 
deisotoping) with the Masslynx software (Waters) and the database searches were performed using 
the Mascot search engine. 
 
4.2.5. Methods 
 
4.2.5.1. Synthesis of iron oxide magnetic nanoparticles (MNPs) 
 
A 150 mL aqueous solution of 2 M NH4OH was purged with nitrogen gas for 30 min in a closed 
reactor equipped with a mechanical stirrer (500 rpm).   A 50 mL aqueous solution containing 5.4 g of 
FeCl3.6H2O and 2 g of FeCl2.4H2O was added dropwise to the reactor and the reaction proceeded for 
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2 h with agitation (500 rpm) and under inert atmosphere. Finally, the particles were thoroughly 
washed with distilled deionised water (dd H2O) using magnetic decantation.  
 
4.2.5.2. Coating of MNPs with two silica layers and dextran (MNP-Si-Si-Dex) 
 
An aqueous solution of MNPs (10 mg/mL, 190 mL) was placed in an ultrasonic bath for 15 min at 37 
kHz. Afterwards, 2.28 g of sodium silicate in 80 mL of 50% (v/v) EtOH/dd H2O was added to the MNPs 
and the solution was incubated in a water bath at 40°C with mechanical stirring (500 rpm) for 2 h. In 
the end, particles coated with a silica layer (MNP-Si) were washed by magnetic decantation with 50% 
(v/v) EtOH/dd H2O (2x 270 mL) and dd H2O (3x 270 mL) to remove the excess of sodium silicate. 
MNP-Si were then resuspended in 190 mL of dd H2O and an aliquot of 5 mL was taken for further 
characterization. A solution of 1.85 g MNP-Si in 80 mL of 80% (v/v) EtOH/dd H2O was ultrasonicated 
for 10 min at 37 kHz, followed by addition of 3 mL 5 M NH4OH. TEOS (1.5 mL) was then added slowly 
to the previous solution under ultrasonication for 10 min at 37 kHz. The solution was incubated in a 
water bath for 2h at 40°C with mechanical stirring (500 rpm). The resulting particles with two layers 
of silica (MNP-Si-Si) were washed with 80% (v/v) EtOH/dd H2O (2x 185 mL) and dd H2O (3x 185 mL) 
by centrifugation (13500 g, 20 min), resuspended in 185 mL dd H2O, and an aliquot of 5 mL was taken 
for characterization. An aqueous solution of MNP-Si-Si (14.4 mg/mL, 125 mL) was ultrasonicated for 
5 min at 37 kHz, followed by the addition of 125 mL of an aqueous solution of dextran (14.4 mg/mL). 
The mixture was then incubated in a water bath at 60°C for 2 h with mechanical stirring (500 rpm). 
Finally the particles coated with silica and dextran (MNP-Si-Si-Dex) were washed with dd H2O (5x 250 
mL) by centrifugation (13500 g, 20 min) and resuspended in dd H2O. 
 
4.2.5.3. Amination of MNP-Si-Si-Dex 
 
A solution of MNP-Si-Si-Dex (8mg/mL, 179 mL) in 50% (v/v) EtOH/dd H2O was ultrasonicated for 5 
min at 37 kHz in an ultrasonic bath, followed by the addition of 1 mL acetic acid glacial and 20 mL 
APTES. The mixture was incubated in an orbital shaker (200 rpm) for 1h at 70°C. The particles were 
washed with 50% (v/v) EtOH/dd H2O (3x 200 mL) and dd H2O (3x 200 mL) by magnetic decantation. 
Kaiser test was performed according to §2.2.4.4, but 1 mL of aminated particles (MNP-Si-Si-Dex-NH2) 
was used instead of the moist aminated agarose. Gly solutions (0-0.005 M) were used as standards. 
After the heating step, both samples and standards were diluted 1:20 and their absorbance was 
determined in a microplate reader using a 560 (10) nm filter.  Samples were centrifuged to remove 
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the particles from solution before absorbance measurement. The amount of amine groups was 
estimated to be 529 ± 41 µmol NH2/ g MNP-Si-Si-Dex-NH2. 
 
4.2.5.4. Functionalization of MNP-Si-Si-Dex-NH2 with aldehyde groups 
 
MNP-Si-Si-Dex-NH2 (0.34 g) were suspended in 100 mL of 5% (v/v) glutaraldehyde/dd H2O, 6 mL of 
NaOH 1 M were added, and the solution was ultrasonicated for 5 min at 37 kHz, followed by 
incubation in an orbital shaker (250 rpm) for 1 h at 30°C. In the end, aldehyde functionalized particles 
(MNP-Si-Si-Dex-CHO) were washed with dd H2O (6x 100 mL) by magnetic decantation.  
 
4.2.5.5. Synthesis of triazine ligands (APAP and A8A3), and Ugi ligands (APC2 and A8C2) on          
MNP-Si-Si-Dex 
 
Triazine ligands were synthesized according to §2.2.4.10 and §3.2.5.3, and Ugi ligands were 
synthesized according to §2.2.4.9 and §3.2.5.2. The molar equivalents of each reactant were 
determined relative to the amount of amine groups on MNP-Si-Si-Dex-NH2, instead of epoxy groups 
on epoxy-activated agarose. 
 
4.2.5.6. Screening of biomimetic ligands against phosphorylated peptides 
 
Microcentrifuge tubes containing 10 mg of MNP-Si-Si-Dex, MNP-Si-Si-Dex functionalized with ligand 
A8A3 (MNP-Si-Si-Dex-A8A3) or MNP-Si-Si-Dex functionalized with ligand A8C2 (MNP-Si-Si-Dex-A8C2) 
were placed in a 24-tube magnetic separation rack.  The particles were washed with 0.1 M NaOH in 
30% (v/v) isopropanol followed by dd H2O (3 cycles of washes, 1 mL/ tube), and afterwards with 50 
mM Gly pH 3 (8x 1 mL/ tube). The process consists of adding the solvent/ buffer to the particles in 
the tubes, vortex the solution, place the tubes in the rack, wait until the particles are attracted to the 
magnet and the solution is clear, and remove the supernatant. A mixture of non-phosphorylated 
peptides (SW6, TW6, and YW6; 0.5 mg/mL total peptide) and a mixture of phosphorylated peptides 
(SW6-P, TW6-P, and YW6-P; 0.5 mg/mL total peptide) in 50 mM Gly pH 3 were prepared. YW13 and 
YW13-P were dissolved either in 50 mM Gly pH3 50 mM NaCl (for screening of MNP-Si-Si-Dex-A8A3) 
or 50 mM Gly pH3 100 mM NaCl (for screening of MNP-Si-Si-Dex-A8C2), for a final concentration of 
0.5 mg/mL. Each particle-containing tube was incubated with 1 mL of each peptide solution for 1h at 
room temperature in a shaker incubator (1200 rpm). After that period, the tubes were placed back in 
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the rack and the supernatant removed. The particles were then washed with their correspondent 
binding buffer (6x 1mL/ tube). Both the flow-through and washes were pipetted into the wells of 96-
well black microplates, and the fluorescence intensity was read on a microplate reader using a λexc = 
280 (20) nm – λem = 340 (35) nm filter. 
 
4.2.5.7. Preparation of protein digests 
 
α-Casein and β-casein were solubilized in 50 mM NH4HCO3 pH 8.2 to a final concentration of 1 
mg/mL), and incubated with trypsin (1:100 enzyme-to-protein ratio (w/w)) for 12h at 37°C with 
gentle agitation.  BSA was dissolved in 50 mM NH4HCO3 pH 8.2 with 8 M urea (1 mg/mL). DTT was 
added to a final concentration of 5 mM and the mixture was incubated for 1h at 37°C with mild 
agitation. IAA was added to a final concentration of 10 mM and the BSA solution was incubated in 
the dark for 30 min at room temperature.  DTT was added to a final concentration of 5 mM to 
quench excess IAA and prevent overalkylation and the BSA solution was incubated in the dark for 
another 30 min at room temperature. The solution was diluted 5 times with 50 mM NH4HCO3 pH 8.2 
to reduce the urea concentration, and then incubated with trypsin (1:100 enzyme-to-protein ratio 
(w/w)) for 12h at 37°C with gentle agitation. 1% TFA (v/v) was then added to stop enzymatic activity. 
Each protein digest was desalted using Sep-Pak C18 cartridges. Sep-Pak columns were conditioned 
with ACN (2x 1 mL), and then equilibrated with 0.6% (v/v) acetic acid (2x 1 mL). The acidified tryptic 
digests (1 mL) were loaded onto the columns, the columns were washed with 0.6% (v/v) acetic acid 
(3x 1 mL), and the peptides were eluted with 80% ACN/ 0.6% acetic acid (v/v) (2x 500 µL). The elution 
fractions were pooled together, aliquoted, dried down in the SpeedVac and stored at -80°C. The 
desalting step was performed in an extraction manifold connected to a vacuum pump. 
 
4.2.5.8. Phosphopeptide enrichment using Ti4+-IMAC and semi-complex protein digests 
 
A 534 µm C8 Empore disk was introduced into a GELoader spin tip using a 365 µm (outer diameter) 
fused silica capillary, and the tip was end-cut 0.2 µm below the C8 plug. The column was washed with 
20 µL MeOH. Ti4+-IMAC slurry (10 mg/mL in 30% ACN/ 0.1% TFA (v/v)) was pipetted into the 
GELoader tip, and the tip was inserted into a microcentrifuge tube equipped with an adaptor. The 
tube was centrifuged at 100 g in order to properly pack the Ti4+-IMAC microcolumn. Ti4+-IMAC 
material had been previously prepared according to [22, 23]. Ti4+-IMAC GELoader spin tip was 
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equilibrated with 50 µL of loading buffer (80% ACN/6% TFA (v/v)) by centrifugation at 100 g for 5 
min. A semi-complex protein sample consisting of tryptic digests of α-casein, β-casein and BSA (1:1:1) 
was prepared in loading buffer, loaded onto the Ti4+-IMAC spin tip (0.12 pmol/µL; 50 µL), and 
centrifuged at 50 g for 30 min. The Ti4+-IMAC spin tip was then washed with 50 µL of washing buffer 
1 (50% ACN/0.5% TFA, 200 mM NaCl) by centrifugation at 170 g for 17 min, followed by 50 µL of 
washing buffer 2 (50% ACN/0.1% TFA) by centrifugation at 170 g for another 17 min. 
Phosphopeptides were eluted into a microcentrifuge tube containing 35 µL of 10% (v/v) formic acid, 
by adding 20 µL of 10% (v/v) NH4OH into the Ti
4+-IMAC spin tip, followed by centrifugation at 100 g 
for 20 min. Samples from flow-through and washes were dried down in a SpeedVac and stored at -
80°C for further MS analysis.  
 
4.2.5.9. Phosphopeptide enrichment using biomimetic ligands A8A3 and A8C2 and semi-complex 
protein digests 
 
Microcentrifuge tubes containing 5 mg of ligand-functionalized MNP-Si-Si-Dex (either MNP-Si-Si-Dex-
A8A3 or MNP-Si-Si-Dex-A8C2) were conditioned with loading buffer (2x 500 µL) in a shaker incubator 
(1200 rpm) for 10 min at room temperature. Then, the tubes were placed in a 24-tube magnetic 
separation rack, and supernatant was removed. Semi-complex protein digest samples of α-casein, β-
casein and BSA (1:1:1) (0.024 pmol/µL; 250 µL) were loaded into the tubes and incubated for 1h at 
room temperature with agitation (1200 rpm). The supernatant was removed and the particles were 
washed first with washing buffer 1, and then with washing buffer 2. The washing steps consisted in 
incubating the particles with 250 µL of each buffer in a shaker incubator (1200 rpm) for 10 min at 
room temperature. The elution step consisted in incubating the particles with 10% (v/v) NH4OH for 
10 min at room temperature with agitation. The elution fraction was immediately dried down in a 
SpeedVac and stored at -80ºC for further MS analysis.  
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4.3. Results and Discussion 
 
4.3.1. Synthesis of triazine and Ugi based ligands on MNP-Si-Si-Dex  
 
The feasibility of triazine and Ugi reactions on magnetic nanoparticles coated with two layers of silica 
and dextran was assessed by using pyrene as a reporter molecule. 1-Pyrenemethylamine (AP) was 
used as the amine component in both triazine and Ugi reactions (Figure 4.1).  
 
A) B) 
 
 
Figure 4.1 - Schematic representation of ligands A) APAP (triazine-based) and B) APC2 (Ugi-based) 
immobilized onto MNP-Si-Si-Dex.  
 
MNP-Si-Si-Dex were aminated using APTES (MNP-Si-Si-Dex-NH2) and directly used for the synthesis of 
triazine ligand APAP. Aldehyde groups were further introduced at the surface of the particles by 
reacting the aminated particles with glutaraldehyde, and MNP-Si-Si-Dex-CHO were used as the 
aldehyde component in the Ugi reaction. Fluorescence microscopy results revealed that the 
fluorescence intensity for the same exposition time was lower for MNP-Si-Si-Dex modified with 
triazine ligand APAP, when compared to MNP-Si-Si-Dex functionalized with Ugi ligand APC2 (Figure 
4.2). Fluorescence images were analyzed in ImageJ 1.42q software by measuring maximum gray 
values in selected particle-containing areas. For an 8 bits per pixel image, the intensity of each pixel is 
represented by a number between 0 and 255, where 0 is black, 255 is white, and the values in 
between correspond to different shades of gray. Although ligand APAP has two pyrene molecules in 
its structure, APC2 presents higher fluorescence intensity, which is translated into a gray value two 
MNP
1st layer of silica
2nd layer of silica
Dextran
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times higher (Figure 4.3). This might be due to: (i) a higher density of APC2 ligand at the surface of 
MNP-Si-Si-Dex; or (ii) crosslinking effect of glutaraldehyde during APC2 ligand synthesis causing 
particle aggregation [24]. Glutaraldehyde is a well-known protein crosslinking agent, readily reacting 
with nucleophiles, such as amines, thiols, phenols, etc. It might exist under monomeric, polymeric, 
linear and cyclic forms, and its exact mechanism of action is subject of scientific debate [25]. The 
crosslinking effect may also arise from the presence of unreacted primary amines at the surface of 
the solid support, which can react with aldehyde groups also at the surface, instead of the amine 
component in solution. An alternative methodology consists in coating the particles with oxidized 
dextran, which would directly introduce aldehyde functional groups at the surface, and would avoid 
the crosslinking effect of glutaraldehyde [26, 27].  
 
 Bright Field Fluorescence 
MNP-Si-Si-Dex 
  
Triazine Ligand 
APAP 
  
Ugi Ligand 
APC2 
  
Figure 4.2 – Fluorescence microscopy results of triazine and Ugi scaffolded MNP-Si-Si-Dex functionalized with 
a fluorophore – pyrene. MNP-Si-Si-Dex was used as negative control. The images were acquired using an 
Olympus BX51 microscope (400X magnification) with a U-MWB filter (λexc 460–490 nm; λexc 515–700 nm) and 
an Olympus U-RFL-T lamp. All images were acquired with an exposition time of 5 s. The monitoring software 
was Cell-View System. 
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Figure 4.3 – Maximum gray values for MNP-Si-Si-Dex functionalized with ligands APAP and APC2 measured 
using ImageJ 1.42q software. (N=10) 
 
Fluorescence microscopy results indicate that MNP-Si-Si-Dex is suitable for the solid-phase synthesis 
of both triazine and Ugi ligands. Therefore, triazine (A8A3) and Ugi (A8C2) phosphopeptide-binding 
ligands identified in the previous chapter were synthesized on MNP-Si-Si-Dex (Figure 4.4).  
 
A) B) 
 
 
Figure 4.4 – Schematic representation of ligands A) A8A3 and B) A8C2 immobilized onto MNP-Si-Si-Dex.  
 
The magnetic support was analysed by DLS after each reaction step (Figure 4.5). DLS allows the 
determination of the size of molecules and particles (typically in the sub-micrometre region) by 
measuring their Brownian motion in solution. In simple terms, particles in suspension are in constant 
movement, and they scatter the light at different intensities upon laser illumination. This allows the 
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determination of the velocity of the Brownian motion, and consequently the size of the particles 
using the Stokes-Einstein equation 5 (smaller particles move faster than larger particles) [29, 30].  
The size of each individual non-hydrated particle is accurately determined by transmission electron 
microscopy (TEM), while DLS allows the determination of hydrodynamic diameters (HDs). HDs have 
been measured for aqueous samples with a final concentration of 0.05 mg/ml, and refer to the size 
of solvated particles. Bare MNPs synthesized by the co-precipitation method presented herein have 
core diameters of approximately 10 nm [31], but they rapidly aggregate in solution and even during 
sample analysis by DLS, presenting HDs of approximately 2.3 µm (Figure 4.5A). Coating the particles 
with the first layer of silica using sodium silicate (MNP-Si) is not sufficient to disperse them in 
solution, as the HDs continue to present values in the micrometre region. However, when the 
particles are coated with TEOS (MNP-Si-Si), the second layer of silica makes them highly hydrophilic 
and easily dispersed in aqueous solution, which is translated into HDs of approximately 177 nm. 
Taylor and co-workers have already reported that one layer of silica is insufficient to completely 
shield MNPs surface. In addition, TEOS provided higher silica content when compared to sodium 
silicate [32]. Modification with silica not only boosts particles dispersion in solution, but also 
improves their resistance against iron leaching at acidic environments [33]. Dextran modification 
(MNP-Si-Si-Dex) did not have any significant effect on the HDs of the silica-coated particles; 
therefore, it is uncertain if the amount of dextran used was enough to completely coat the surface. 
Most likely, dextran and silica formed an interconnected porous network and, being dextran a 
neutral polysaccharide, the negative charges of silica prevail in inter-particle interactions.  By coating 
iron oxide particles with dextran strands crosslinked with silica, Grüttner and Teller were able to 
increase their robustness and mechanical properties [34]. Particles amination using APTES (MNP-Si-
Si-Dex-NH2) increases their HD, probably due to non-covalent interactions between amine and 
hydroxyl groups of neighbour particles. This effect has already been observed for dextran coated 
MNPs [35]. Functionalization of MNP-Si-Si-Dex-NH2 with triazine ligand A8A3 is performed by two 
subsequent nucleophilic substitutions on the triazine ring. After the first substitution with histamine 
(Ligand A8), there is a decrease in the HD of the particles, probably due to mixed-mode interactions 
provided by the triazine ring and the imidazole group of histamine, which provide both 
hydrophobicity through their aromatic groups and hydrophilicity through their numerous nitrogen 
atoms. After the second nucleophilic substitution with phenethylamine (Ligand A8A3), the higher 
degree of hydrophobicity leads to larger aggregates in aqueous solution. Particles coated with 
                                                        
5   
    
     
, where HD is the hydrodynamic diameter, kB is Boltzmann's constant, T is the thermodynamic 
temperature, η is the dynamic viscosity, and Dt is the translational diffusion coefficient [28]. 
Chapter 4 Phosphopeptide enrichment using biomimetic  
magnetic nanostructures 
 
146 
 
glutaraldehyde (MNP-Si-Si-Dex-CHO) present the highest HD values. These particles are still 
agglomerated after the Ugi reaction (Ligand A8C2), corroborating the crosslinking effect of 
glutaraldehyde discussed previously.  
Zeta potential values were also determined for all samples and are presented in Figure 4.5B. A 
positively or negatively charged particle dispersed in solution will attract oppositely charged ions to 
its surface. Ions close to the surface will be strongly bound, forming the so called Stern layer, while 
ions more distant to the surface are loosely bound and constitute the diffuse layer. Within this layer 
there is a notional boundary coined the slipping plane and any ions within it move along with the 
particle, while ions outside this boundary will not move with the particle. The potential between the 
particle surface and the dispersing liquid at the slipping plane is called zeta potential (Figure 4.6) [36]. 
Zeta potential values give an indication about the charge of the particles and their tendency to 
flocculate. Particles are stable in solution when they present zeta potential values above 30 mV or 
below -30 mV.   
Bare MNPs presented zeta potential values of approximately 5.6 mV, which means they have 
tendency to flocculate in solution (Figure 4.5B). The modification with the first layer of silica did not 
have any significant effect on the zeta potential, which is consistent with the large HDs observed for 
both MNP and MNP-Si. The second layer of silica (MNP-Si-Si) drastically decreased particles’ zeta 
potential to -30.7 mV, which is in accordance with the small HDs, as particles are stable in solution. 
This effect has been observed by Sun and co-workers, who reported that increasing the amount of 
TEOS, i.e. increasing the thickness of the silica layer, helps sheltering the magnetic dipole attraction 
and dispersing particles in solution. In addition, the silica layer is negatively charged at neutral pH, 
increasing the coulomb repulsion between the particles [37]. The negative value of MNP-Si-Si-Dex 
zeta potential corroborates the existence of silica at the surface, either due to insufficient amount of 
dextran at the surface or to the existence of a polymer-silica network shell. MNP-Si-Si-Dex-NH2 
presents a zeta potential value of -7.2 mV, a much less negative value than MNP-Si-Si-Dex, due to the 
existence of amine groups at the surface. This was further confirmed by the Kaiser test, a 
colorimetric test, which gave a characteristic purple/blue colour owing to the presence of primary 
amines. Although it is essentially a qualitative test, the amount of amine groups was estimated to be 
529±41 µmol NH2/ g support.  Ligand A8 presents a positive zeta potential value (15.6 mV) due to the 
positive charges on the triazine ring and imidazole group of histamine. However, the zeta potential 
after the second nucleophilic substitution decreases to -4.7 mV, a value close to zero, which indicates 
that the particles tend to form bigger aggregates. This is in accordance with the larger HDs observed 
for ligand A8A3 when compared to ligand A8.  MNP-Si-Si-Dex-CHO present zeta potential values 
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more negative than MNP-Si-Si-Dex-NH2, which means the reaction with glutaraldehyde was 
successful, and at least some of the amine groups reacted to give terminal aldehyde functional 
groups. Ligand A8C2 presents positive zeta potential due to the presence of histamine. However, it 
should be kept in mind that the interpretation of zeta potential values is complex, especially when 
referring to polymer- or ligand-coated particles. A multiplicity of factors, such as ionic strength, 
coating thickness, surface curvature, and polymer permeability, must be considered [38].    
 
A) 
 
B) 
 
Figure 4.5 – DLS results of triazine and Ugi-modified particles. A) Hydrodynamic diameters (nm). B) Zeta 
potential values (mV). All samples have a concentration of 0.05 mg/ml in Milli-Q water and the analysis was 
conducted on a Zetasizer Nano ZS from Malvern.  
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Figure 4.6 – Schematic representation of zeta potential. When a negatively charged particle is diffusing in 
solution, a high concentration of counterions will be attracted and strongly attached to the surface (Stern 
layer), while ions located farther from the surface will be more loosely bound (diffuse layer). The diffuse layer 
comprises an inner region, consisting of ions travelling along with the particle upon its movement, and an outer 
region, comprising ions which will not move when the particle moves. The boundary between these regions is 
called the slipping plane, and the potential measured at the slipping plane is called zeta potential. 
 
4.3.2. Comparison between phosphopeptide-binding affinity ligands immobilized in agarose and 
MNP-Si-Si-Dex 
 
The binding capacity and phosphopeptide enrichment efficiency of ligands A8A3 and A8C2 
immobilized on MNP-Si-Si-Dex have been determined by screening the ligands against a mixture of 
mono-phosphorylated peptides (SW6-P, TW6-P, and YW6-P) and the multi-phosphorylated peptide 
YW13-P. The results were compared with the same ligands immobilized on agarose, which have been 
reported on the previous chapters, and are presented in Table 4.1. Generally speaking, the binding 
capacities of the ligands immobilized on MNP-Si-Si-Dex increase 100-fold on average when compared 
to the same ligands immobilized on agarose, but at the cost of lower phosphopeptide enrichment 
efficiencies, which are translated into lower phosphopeptide mass fractions. The higher binding 
capacity of ligand-functionalized MNP-Si-Si-Dex is probably due to the higher amount of functional 
Electrically charged particle 
Stern Layer
Diffuse layer
Slipping Plane
Zeta Potential
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groups available at the surface of the particles, since the support itself (non-functionalized MNP-Si-Si-
Dex) presents a maximum of 20% non-specific adsorption. Nonetheless, the effect of non-specific 
interactions should not be discarded, as they may contribute for the lower selectivity of the ligand-
functionalized support towards the phosphorylated targets.  
The same ligand (either A8A3 or A8C2) present similar binding capacities values for both SW6-
P+TW6-P+YW6-P mixture and YW13-P, but the enrichment efficiency is always superior for the multi-
phosphorylated peptide. This is valid for ligands immobilized on both solid supports (Table 4.1). 
 
Table 4.1 – Screening results of ligands A8A3 and A8C2 immobilized either on agarose or MNP-Si-Si-Dex 
against a mixture of mono-phosphorylated peptides (SW6-P, TW6-P, and YW6-P) and a multi-phosphorylated 
peptide (YW13-P). Screening was performed by loading 0.25 ml of 1 mg/ml phosphorylated peptides in 50 mM 
Gly pH3. The supports were washed with the same buffer until no peptide was detected in the recovered 
fractions. The samples were analysed by measuring the florescence intensity in a microplate reader equipped 
with a λexc = 280 (20) nm – λem = 340 (35) nm filter. The results were normalized per gram of support.  BC is 
the binding capacity in mg target peptide per g support; PMF is the phosphopeptide mass fraction in %.  
  
Solid Support 
Agarose MNP-Si-Si-Dex 
A8A3 A8C2 A8A3 A8C2 
BC 
(mg/g) 
PMF 
(%) 
BC 
(mg/g) 
PMF 
(%) 
BC 
(mg/g) 
PMF 
(%) 
BC 
(mg/g) 
PMF 
(%) 
Ta
rg
e
t 
P
e
p
ti
d
e
s SW6-P+TW6-P+YW6-P 
0.35 
±0.01 
91.83 
±0.02 
0.32 
±0.01 
87.60 
±0.61 
32.61 
±0.44 
64.45 
±13.74 
43.92 
±2.23 
62.23 
±1.30 
YW13-P 
0.31 
±0.01 
98.15 
±2.61 
0.39 
±0.01 
99.64 
±0.51 
37.09  
±1.63 
81.74 
±3.28 
42.80 
±0.10 
72.09 
±1.18 
 
4.3.3. Comparative evaluation of phosphopeptide-binding biomimetic ligands with a novel Ti4+-
IMAC approach for phosphopeptide enrichment 
 
The specificity of ligands A8A3 and A8C2 towards phosphopeptides was further tested by screening 
the ligands against a semi-complex mixture composed of tryptic digests of two standard 
phosphorylated proteins (α-casein and β-casein) and one non-phosphorylated protein (BSA).  The 
eluted peptides have been characterized by MALDI-TOF MS, and the enrichment efficiency of the 
synthetic ligands has been compared with a novel Ti4+-IMAC adsorbent developed by Zhou and co-
workers [22, 39]. The same loading, washing and elution buffers have been used in both 
experiments.  
The Ti4+-IMAC adsorbent consists of monodisperse polystyrene microspheres functionalized with a 
flexible poly(GMA-co-TMPTMA) linker (GMA is glycidyl methacrylate and TMPTMA is trimethylol-
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propane trimethacrylate) coupled to phosphonate groups, which in turn coordinate the Ti4+ (Figure 
4.7). These microspheres are stable under strong acid and alkaline conditions, have large surfaces 
areas, a hydrophilic surface to minimize non-specific adsorption, and have uniform monodisperse 
size distribution, which allows homogeneous column packing, uniform flow profile, and low column 
pressure. The poly(GMA-co-TMPTMA) spacer provides an enhanced hydrophilic character to the 
support, besides diminishing steric hindrance effects. Phosphonate groups are used as chelating 
ligands, instead of the commonly used iminodiacetic acid (IDA) and nitriloacetic acid (NTA), and are 
reported to provide an advantageous structural orientation [22, 39].  
 
 
Figure 4.7 – Illustration of Ti4+-IMAC adsorbent. Polystyrene microspheres are functionalized with a poly(GMA-
co-TMPTMA) linker, which is coupled to phosphonate groups. These groups are able to chelate the Ti4+ ions 
used for phosphopeptide enrichment. (Adapted from [22]) 
 
The tryptic peptide mixture was loaded into a Ti4+-IMAC GELoader spin tip or an Eppendorf 
containing biomimetic ligand-functionalized magnetic beads using 80% (v/v) ACN + 6% (v/v) TFA as 
loading buffer. The presence of ACN in the loading buffer reduces the binding of non-phosphorylated 
peptides by disrupting non-specific hydrophobic interactions, being more effective than MeOH, 
EtOH, and acetone [40]. The optimal amount of ACN depends on the method and is typically 
between 40-80% (v/v) [41-43]. TFA plays two roles in the enrichment process: (i) it efficiently 
Microspheres 
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protonates acidic amino acids, preventing their non-specific binding; and (ii) it disrupts 
intramolecular bonds that often form between the phosphate group and basic residues. These 
intramolecular bonds are the cause of the higher frequency of missed cleavages during 
phosphoprotein digestion, as the enzyme cannot efficiently access the cleavage site [22].  The 
influence of different acids in phosphopeptide binding has been previously studied. Kokubu and co-
workers reported that the selectivity of IMAC/C18 tips towards phosphopeptides increases with the 
acid strength, i.e. TFA ≥ hydrochloric acid > formic acid > acetic acid [40]. The effect of acids was also 
evaluated for TiO2 tips by Aryal and co-workers, who found that the ability of organic acids to exclude 
non-phosphorylated peptides follows a similar order: TFA > formic acid > acetic acid [44]. The 
concentration of the acid plays a significant role as well, but the optimal concentration depends on 
the method used. Extremely low concentrations do not allow complete protonation of the acidic 
residues, while extremely high concentrations lead to incomplete deprotonation of the phosphate 
moiety [40, 44]. The addition of salt to the first washing buffer (Washing Buffer 1: 50% (v/v) ACN + 
0.5% (v/v) TFA + 200 mM NaCl) assists the elimination of non-specific electrostatic adsorption. A 
second washing step using a buffer without salt (Washing Buffer 2: 50% (v/v) ACN + 0.1% (v/v) TFA) 
was performed before the elution step. Finally, the peptides were eluted using an alkaline solution of 
10% (v/v) NH4OH pH 11. The buffers have been previously optimized for Ti
4+-IMAC [22, 39, 41]. Figure 
4.8 presents a schematic representation of the methodology developed in this work. 
 
Chapter 4 Phosphopeptide enrichment using biomimetic  
magnetic nanostructures 
 
152 
 
 
Figure 4.8 – Phosphopeptide enrichment using MNP-Si-Si-Dex functionalized with biomimetic ligands. 
 
The eluates were dried, resuspended in MALDI matrix solution (25mg/mL 2,5-DHB in 70 % (v/v) 
ACN/1% (w/v) H3PO4) and spotted (0.5 µL) in a MALDI target plate. Several matrices (e.g. 2,5-DHB, α-
cyano-4-hydroxycinnamic acid, 2,4,6-trihydroxyacetophenone), co-matrices (e.g. 1,8-bis(dimethyl-
amino)naphthalene)  and additives (e.g. H3PO4, diammonium  hydrogen citrate)  have been tested 
and optimized for phosphopeptide identification using MALDI MS, and their suitability depends on 
the enrichment method used and on whether the analysis is performed in positive or negative ion 
mode [45-47]. 2,5-DHB generates large and heterogeneous crystalline deposits, but it is considered a 
“cool” matrix. In other words, it induces the formation of molecular ions with low internal energy, 
which are stable during the MS analysis. The addition of 1% (w/v) H3PO4 to 2,5-DHB MALDI matrix 
has been reported to enhance phosphopeptide ion signals, probably due to salting out effects which 
will lead to a more efficient incorporation of the phosphopeptides into the growing crystals of the 
matrix [47]. 
MALDI-TOF MS analysis was performed for the semi-complex mixture: (i) non-enriched; (ii) enriched 
using Ti4+-IMAC; (iii) enriched using MNP-Si-Si-Dex-A8A3; and (iv) enriched using MNP-Si-Si-Dex-A8C2 
(Figure 4.9). As can be seen in Figure 4.9D, the mass spectra corresponding to the enriched sample 
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with MNP-Si-Si-Dex-A8C2 presents a very low signal to noise (S/N) ratio and no mass peaks 
corresponding to the loaded phosphopeptides were detected and identified. This might be due to 
low peptide concentration in the elution fraction, or to the poor co-crystallization of the sample with 
the MALDI matrix due to the presence of contaminants in the eluate solution. Regarding the sample 
processed with MNP-Si-Si-Dex-A8A3, the spectrum in Figure 4.9C is dominated by phosphorylated 
peptides, which shows the success of this enrichment process. Furthermore, the S/N ratio of the 
detected peptides is comparable to the mass spectrum of the sample enriched with Ti4+-IMAC (Figure 
4.9B). The list of phosphopeptides identified with the different approaches, Ti4+-IMAC and MNP-Si-Si-
Dex-A8A3, is presented in Table 4.2 and Table 4.3, respectively. The number of phosphopeptides 
identified with both methodologies is the same (9 phosphopeptides). However, no quantitative 
conclusion can be drawn from these experiments regarding the efficiency of both methods. It should 
also be kept in mind that the loading, washing, and elution conditions used here for both enrichment 
methods were the optimal conditions for Ti4+-IMAC. The conditions for this novel system still need 
further optimization; therefore an improvement of the results here reported is expected. 
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Figure 4.9 – MALDI-TOF mass spectra of a semi-complex mixture of α-casein, β-casein, and BSA: (A) before 
enrichment; (B) after enrichment with Ti4+-IMAC; (C) after enrichment with MNP-Si-Si-Dex-A8A3; (D) after 
enrichment with MNP-Si-Si-Dex-A8C2. Samples were dissolved in 10 µL 25mg/mL 2,5-DHB in 70 % (v/v) 
ACN/1% (w/v) H3PO4 and 0.5 µL was spotted on the MALDI plate for analysis. Peaks correspondent to 
phosphopeptides are marked with letter P and the respective sequence is described in Table 4.2 and Table 4.3. 
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Table 4.2 – Phosphopeptides detected by MALDI-TOF MS analysis from a semi-complex mixture of α-casein, 
β-casein, and BSA, after enrichment with Ti
4+
-IMAC.  
Peptide 
ID 
Peptide sequence 
No. of 
missed 
cleavages 
No. of 
phosphorylation 
sites 
[M+H]+ 
(Da) 
Protein 
P1 TVDMESTEVFTK 0 1 1466.61 α-s2 casein 
P2 VPQLEIVPNSAEER 0 1 1660.77 α-s1 casein 
P3 YLGEYLIVPNSAEER 0 1 1832.84 α-s1 casein 
P4 DIGSESTEDQAMEDIK 0 2 1927.68 α-s1 casein 
P5 YKVPQLEIVPNSAEER 1 1 1951.94 α-s1 casein 
P6 FQSEEQQQTEDELQDK 0 1 2061.82 β-casein 
P7 FQSEEQQQTEDELQDKIHPF(a) 1 1 2556.10 β-casein 
P8 Q*MEAESISSSEEIVPNSVEQK 0 5 2703.88 α-s1 casein 
P9 RELEELNVPGEIVESLSSSEESITR 1 4 3122.24 β-casein 
(a) Chymotrypsin cleavage.  
Q* - pyroglutamination on Gln;  S - phosphoserine. 
 
 
Table 4.3 - Phosphopeptides detected by MALDI-TOF MS analysis from a semi-complex mixture of α-casein, 
β-casein, and BSA, after enrichment with MNP-Si-Si-Dex-A8A3.  
Peptide 
ID 
Peptide sequence 
No. of 
missed 
cleavages 
No. of 
phosphorylation 
sites (b) 
[M+H]+ 
(Da) 
Protein 
P1 TVDMESTEVFTK 0 1 1466.59 α-s2 casein 
P2 TVDMESTEVFTKK 1 1 1594.76 α-s2 casein 
P3 VPQLEIVPNSAEER 0 1 1660.79 α-s1 casein 
P4 TVD[Mo]ES*TEVFTKKTK 2 0 (1) 1759.93 α-s2 casein 
P5 YLGEYLIVPNSAEER 0 1 1832.86 α-s1 casein 
P6 YKVPQLEIVPNSAEER 1 1 1951.94 α-s1 casein 
P7 FQSEEQQQTEDELQDK 0 1 2061.81 β-casein 
P8 KNTMEHVS*S*S*EES*IISQETY(a) 1 3 (4) 2555.00 α-s2 casein 
P8 NTMEHVS*S*S*EES*IISQETYK 0 3 (4) 2555.00 α-s2 casein 
P9 RELEELNVPGEIVESLSSSEESITR 1 4 3122.19 β-casein 
(a)
 Chymotrypsin cleavage.
 
(b) Number of phosphorylation sites if there is no hydrolysis of the phosphate group during strong alkaline elution is given in 
parenthesis. 
[Mo] – oxidized Met; S – phosphoserine; S* - Potential phosphorylation site. 
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4.4. Conclusions  
 
A novel magnetic adsorbent for the selective capture of phosphorylated peptides has been 
developed. Iron oxide MNPs have been coated with silica and dextran and functionalized with a 
triazine and an Ugi-based ligand. To our knowledge, this is the first time that small synthetic 
biomimetic ligands have been used for phospho-fishing. Ligand A8A3 was able to selectively capture 
phosphopeptides from 6 pmol of a semi-complex sample of α-casein, β-casein, and BSA. The MS 
spectrum presented nine peaks correspondent to phosphorylated peptides with increased signal 
intensities, when compared to non-enriched samples.  
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CHAPTER 5 
Development of β-hairpin peptidomimetics as phosphate-binding ligands 
 
 
Summary 
 
Cyclic β-hairpin structures have been developed by structural-based design as peptidomimetics of 
the Brca1 C-terminal (BRCT) domain. The amino acid residues and spatial constraints involved in the 
molecular recognition of a phosphorylated peptide by the BRCT domain were identified in silico and 
crafted onto a 14-mer β-hairpin template. The cyclic β-hairpins were synthesized using standard 
Fmoc solid-phase chemistry, purified by high-performance liquid chromatography (HPLC), and 
immobilized onto a chromatographic support (agarose). One of the β-hairpin structures (Cyclic-M2: 
Cyclo(Glu-Gly-Phe-Gly-Dap-Gly-Dap-DPro-Pro-Gly-Val-Arg-Thr-Gly), where Dap is diaminopropionic 
acid) presented selectivity for binding to the phosphorylated target, allowing for a recovery yield of 
65% upon elution. 
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5.1. Introduction 
 
The term “peptidomimetics” dates from the 1980´s and its concept has been evolving in the last 
decades.  It refers to the design and preparation of analogues of natural peptides, protein fragments, 
or even entire proteins [1]. Peptidomimetics are valuable tools for understanding the interplay 
between protein structure and function, besides their potential commercial use as therapeutic 
agents [2, 3]. A peptidomimetic can be a fully synthetic molecule, a peptoid (i.e. oligomer of N-
substituted glycines), a β-peptide, a modified natural peptide (for example by the incorporation of 
non-natural amino acids), among others [4].  
Research was initially focused on the discovery of small drug-like compounds, but has shifted to 
more complex molecules with secondary structure and conformational restrictions [2]. For in vivo 
applications, peptides are valuable alternatives to small synthetic molecules, as they present lower 
toxicity and higher target selectivity [5]. In particular, cyclic peptides have the advantage of being 
more resistant to proteolytic digestion, because they do not present terminal carboxyl and amine 
groups. Their conformational and structural rigidity confers them superior receptor selectivity, 
improved biological activity, and biochemical stability [5, 6]. Cyclic peptides usually present 10 to 
1000-fold higher target-affinity when compared to their linear counterparts [7]. Cyclic peptides may 
be synthesized by either biological or synthetic methods. Biological methods include phage display, 
mRNA display, and split-intein mediated circular ligation. Synthetic methods comprise sequential 
synthesis, parallel synthesis, and split-and-pool synthesis [5].  
Phage display allows the generation of large libraries of peptides (≈ 109), which are displayed at the 
surface of phages. These phages are screened against the target of interest, and the ones that 
selectively bind the target are then amplified in bacterial cells. This process is called biopanning and 
is usually repeated 3 to 5 times [8]. The incorporation of Cys residues in peptide sequence allows 
their cyclization through the formation of disulfide bonds, which will naturally occur inside the 
bacterial cell. However, disulfide bonds are not stable and may be reduced to form thiol groups again 
[5, 7]. In spite of allowing great complexity, phage display is limited to the use of the 20 natural 
amino acids [5]. 
In mRNA display, encoded peptide and protein libraries are covalently linked to the 3’ end of their 
own mRNA through a DNA-puromycin linker. Peptides are then screened against their targets and 
positive hits may be amplified by reverse transcription polymerase chain reaction (RT-PCR), followed 
by more rounds of selection [9, 10]. This method allows constructing libraries of 1013 molecules, 
increasing sequence complexity when compared to phage display, besides allowing the incorporation 
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of unnatural amino acids [10]. On the other hand, it has the disadvantage of producing only one 
peptide per mRNA molecule, which means that if the peptide fails to couple to the mRNA template, a 
good binder may be lost during the selection [5]. Millward and co-workers have prepared cyclic 
peptides using mRNA display technology by post-translational crosslinking with disuccinimidyl 
glutarate of the terminal amine group of the peptide to a Lys side chain in the C-terminal region [7]. 
However, cyclization may not be selective if the peptide presents more amino acid residues with 
amine side chains besides the fixed Lys [5].  
Inteins are protein sequences which catalyse their excision from precursor proteins and ligate their 
flanking protein sequences (called N- and C-exteins) [11, 12]. Split-intein mediated circular ligation is 
a technique based on the manipulation of protein splicing, which uses the Synechocystis sp PCC6803 
DnaE split intein to produce libraries of cyclic peptides (≈108) [11, 13, 14]. This technique is again 
limited by the use of the natural ribosomal amino acids [5]. 
Synthetic peptide libraries may be constructed using sequential synthesis, i.e. the synthesis of each 
peptide individually from the beginning to the end. However, this process does not permit great 
variability and it is much time-consuming [5]. Parallel synthesis allows the simultaneous preparation 
of hundreds or thousands of peptides, which remains well below the values obtained with biological 
methods [5, 15, 16].  
Millions of peptides may be synthesized using the “split-and-pool” protocol, which consists of 
distributing resin beads between reaction vessels containing different amino acids. After the first 
amino acid coupling, the beads are pooled together and then split again for another cycle [17]. The 
main disadvantage of this method is the difficulty to determine peptide sequences after the 
screening for target-binding.  Edman degradation is not applicable to cyclic peptides, because they 
do not possess an N-terminal group. On the other hand, cyclic peptide sequencing using mass 
spectrometry is often difficult because ring opening occurs at multiple positions, which complicates 
spectral interpretation [5, 6]. A few strategies have been developed to overcome these issues. Joo 
and co-workers reported a spatial segregation approach consisting of segregating a resin bead into 
two layers: an outer layer displaying the cyclic peptide and an inner layer carrying the correspondent 
linear peptide. The linear peptide is used for sequencing, whereas the cyclic peptide may be 
screened against the target molecule [6]. Kwon and co-workers developed a different “one bead two 
compounds” approach relying on differential deprotection to create two very similar peptoids 
(although the method is also feasible for peptides). The only difference between the peptoids is that 
only one of them contains a Cys to promote the binding to a maleimide-activated support and a Glu 
residue to facilitate cyclization. In this way, only the cyclic peptide will bind to the target [18].  
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In summary, biological methods for peptide synthesis provide great diversity, but are usually more 
limited in terms of building blocks. Peptide sequence is also facilitated because of the 
phenotype/genotype association.  Synthetic methods are more limited in quantitative terms, but still 
provide high complexity as they allow chemical versatility.    
The most common secondary structures of proteins are α-helices and β-sheets [19, 20]. These 
constitute great scaffolds for biomimetic design, and libraries of peptides with both of these 
conformations have already been reported. Mimicking spatial orientations is fundamental when 
developing a peptide library as the conformational flexibility of peptides in solution has been linked 
to decreased binding to their targets [21]. This work will focus on the development of β-hairpin 
peptides, which are the simplest form of antiparallel β-sheets.   
A β-hairpin is composed of two antiparallel β-strands connected by a turn/ loop [21, 22] (Figure 5.1).  
 
 
Figure 5.1 – Schematic representation of a 14-mer β-hairpin. Interchain hydrogen bonds are represented by 
dashed lines. 
 
The mechanism for β-hairpin folding is not yet fully understood due to their inherent tendency to 
aggregate in solution, and because β-hairpins have limited ability to fold in the absence of their 
tertiary protein context [21, 23]. Different mechanisms have been proposed. In 2010, Lewandowska 
and co-workers reviewed the results of experimental studies of the structure of β-hairpin of the B1 
domain of protein G, and concluded that the “broken-zipper” was the most plausible mechanism. 
According to this mechanism, the turn region bends due to favourable local interactions and 
facilitates the formation of hydrophobic interactions between nonpolar amino acids near the turn, 
followed by the formation of nonpolar contacts farther from the turn. Hydrogen-bonding between 
residues in the backbone of the peptide seem to have a role in later stages of β-hairpin folding, 
assisting to fix the structure. In addition, electrostatic interactions and salt-bridges across β-strands 
most likely contribute for β-hairpin stability. However, the prevailing structure-determining factors 
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according to this model are the local interactions at the turn regions and hydrophobic interactions 
[23]. In 2013, Makwana and co-workers studied the effect of Tyr-His and Cys-His interacting pairs in 
β-hairpin stability. They concluded that the electrostatic interactions between sulphur and imidazole 
from the Cys-His pair lead to higher structure stabilization than the aromatic interactions of the Tyr-
His pair [24]. In the same year, Danelius and co-workers reported that interstrand hydrogen-bonding 
does have a stabilizing effect on β-hairpin peptides [25].  
Cyclization is known to stabilize the folded conformation of β-hairpins [25]. Cyclic peptides have less 
flexible conformations and higher extent of solvation, presenting larger diffusion coefficients [26]. 
Cyclization may occur in different manners: (i) head-to-tail (C-terminus to N-terminus); (ii) head-to-
side chain; (iii) side chain-to-tail; and (iv) side chain-to-side chain [27]. Ring closing can be attained 
through a variety of covalent bonds, such as amide, disulfide, lactone, ether, thioether, etc. [5]. 
Recently, Park and co-workers developed a “click” cyclization methodology where they have cyclized 
β-hairpins in different positions through azide-alkyne chemistry [28].  
β-Hairpin formation is also promoted by the incorporation of centrally positioned turn-inducing 
structural elements, such as DPro-LAmino acid [29]. In particular, the heterochiral diproline unit - 
DPro-LPro - has been extensively studied, and is known to adopt a type II’ β-turn which induces β-
hairpin formation and promotes stability [29, 30].  
Two faces can be defined on this type of cyclic β-hairpin structures: a binding face containing key 
amino acids for target recognition, and a property-tuning face comprising amino acids which are 
incorporated to enhance solubility and avoid aggregation (Figure 5.2) [31].  
 
 
Figure 5.2 – Illustration of a 
D
Pro-
L
Pro β-hairpin. Amino acids comprising the binding face for target recognition 
are represented in red; amino acids comprising the property-tuning face to control solubility and aggregation 
are represented in blue; and amino acids used for attachment to the solid-support are depicted in green.  
 
Binding Face
Property-tuning face
Amino acids used 
for immobilization 
onto the solid 
support
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Here, it is reported the chemical synthesis of cyclized β-hairpin peptides which were designed to 
mimic the phosphate-binding region of the Brca1 C-terminal (BRCT) phosphoprotein-binding domain. 
The peptides were synthesized using Fmoc solid-phase chemistry, which allowed the introduction of 
chemical diversity by the use of unnatural amino acids. DPro-LPro unit was introduced to facilitate β-
hairpin formation, and peptides were cyclized through amide bonds in a head-to-tail manner. The 
ability of these β-hairpin peptidomimetics to bind to their phosphorylated target was also 
investigated.     
 
5.2. Materials and Methods 
 
5.2.1. Chemicals 
 
All reagents were of the highest purity available and the solvents were HPLC-gradient. 
 
2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), benzotriazole-1-
yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP), H-Gly-2-ClTrt resin, and H-
Glu(OtBu)-2-ClTrt resin were acquired from Novabiochem. 2-(N-Morpholino)ethanesulfonic acid 
(MES), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), 5,5’-dithiobis(2-nitrobenzoic 
acid) (Ellman’s reagent), acetic anhydride, ammonium hydroxide  solution, anisole, bicinchoninic acid 
kit for protein determination  (BCA), diethyl ether, epichlorohydrin, ethanothiol, 
ethylenediaminetetraacetic acid (EDTA), ethylenediaminetetraacetic acid tetrasodium salt hydrate 
(EDTA-Na), iodoacetic anhydride, N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDC), N,N-
diisopropylethylamine (DIEA), N-Hydroxysuccinimide (NHS), ninhydrin, phenol, piperidine, potassium 
cyanide, pyridine, sodium phosphate dibasic heptahydrate, sodium phosphate monobasic 
monohydrate thioanisole, trifluoroacetic acid (TFA), triisopropylsilane (TIS), 
tris(hydroxymethyl)aminomethane (Tris), and β-mercaptoethanol were obtained from Sigma-Aldrich. 
Acetonitrile (ACN), bond-Breaker tris(2-carboxyethyl)phosphine (TCEP) solution, chloroform, 
dichloromethane (DCM), methanol (MeOH), N,N-dimethylformamide (DMF), and N-methyl-2-
pyrrolidone (NMP) were obtained from Fisher Scientific. Ethanol, sodium chloride (NaCl), and sodium 
hydroxide (NaOH) were purchased from Panreac. 2-Propanol, L-cysteine, and O-(7-azabenzotriazole-
1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HATU) were purchased from Roth, Acros 
Organics, and GenScript Corporation, respectively. Nitrogen gas was supplied by Air Liquide. N-
fluorenylmethoxycarbonyl (Fmoc)-protected amino acids (Fmoc-Arg(Pbf)-OH, Fmoc-Cys(Trt)-OH, 
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Fmoc-Dpr(Boc)-OH (Dap), Fmoc-D-Pro-OH, Fmoc-Gly-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Pro-OH, 
Fmoc-Thr(tBu)-OH, Fmoc-Val-OH) were purchased either from CEM or Novabiochem. Gly-Ala-Ala-Tyr-
Asp-Ile-Ser-Gln-Val-Phe-Pro-Phe-Ala-Lys (GK14) and Gly-Ala-Ala-Tyr-Asp-Ile-pSer-Gln-Val-Phe-Pro-
Phe-Ala-Lys (GK14-P) peptides (pSer is phosphoserine) were > 98% pure and were obtained from 
Genecust. Unless otherwise noticed peptides contain free N- and C-terminals.  
 
5.2.2. Chromatographic materials 
 
SepharoseTM CL-6B was acquired from GE Healthcare. Captiva 96-well 20u filter plate with the 
respective duo seal 96-well Pl seal and Captiva 96-well plate cover were purchased from Agilent 
Technologies. Half-area UV-Star® 96-well microplates and 96-well transparent microplates were 
obtained from Greiner Bio-One and Sarstedt, respectively. 
 
5.2.3. Software 
 
Peptides were sketched on PyMOL Molecular Graphics System v.1.3 (Schrödinger), and their 
properties were determined using isoelectric point, logD, and pKa plugins from MarvinSketch 4.1.13 
software (ChemAxon). Automated docking was performed in Autodock 4.0 software package6. 
 
5.2.4. Methods 
 
5.2.4.1. Solid-phase synthesis of protected peptidomimetic scaffolds 
 
Three fully protected linear peptides were prepared on a Liberty automated peptide synthesizer 
(CEM) using standard Fmoc solid-phase chemistry [32]. The sequence of the peptides was the 
following: Cys-Gly-Gly-Gly-Gly-Gly-Gly-DPro-Pro-Gly-Val-Gly-Thr-Gly (M0); Cys-Gly-Phe-Gly-Ile-Gly-Ile-
DPro-Pro-Arg-Val-Gly-Thr-Gly (M1); Glu-Gly-Phe-Gly-Dap-Gly-Dap-DPro-Pro-Gly-Val-Arg-Thr-Gly (M2). 
The resins used were H-Gly-2-ClTrt for peptides M0 and M1, and H-Glu(OtBu)-2-ClTrt for peptide M2. 
Resin substitutions were 0.46 meq/g and 0.57 meq/g, respectively. These resins were used to obtain 
fully protected peptides with carboxylate end terminals after cleavage from the resin using mild 
acidic conditions. The activating agent was HBTU and the activator base was DIEA in NMP. 20% 
Piperidine in DMF was used for deprotection of the Fmoc group. After each amino acid coupling, the 
                                                        
6 Automated docking was performed in our group by Dr. Ricardo Branco. 
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resin was end-capped with 20% acetic anhydride in DMF to block unreacted active sites. In the end, 
resins were thoroughly washed in a sinter funnel under vacuum pressure with DMF and DCM, and 
dried under vacuum.  
A small aliquot of each resin was treated as indicated below to cleave and fully deprotect the 
peptides for electrospray ionization mass spectrometry (ESI-MS) analysis. This step was carried out to 
confirm if the synthesized peptides have the expected molecular weight before proceeding with 
cyclization. Peptides M0 and M1, containing Cys residues, were dissolved in 2 mL of 90% (v/v) TFA/ 
5% (v/v) thioanisole/ 3% (v/v) ethanothiol/ 2% (v/v) anisol and peptide M2 in 2 mL of 95% TFA/ 2.5% 
MilliQ water/ 2.5% TIS (v/v), and stirred for 2 h under nitrogen gas. Each resin was filtered in a sinter 
funnel under vacuum pressure and washed with TFA. Nitrogen gas was bubbled into the filtrate in 
order to remove TFA. Cold diethyl ether was added to precipitate the peptide, but peptide 
precipitation was unsuccessful. Diethyl ether was evaporated with nitrogen gas, and an oil/ gel was 
obtained. This step was repeated in order to wash the crude peptide. The oily sample was then 
dissolved in (i) 50% MeOH (v/v) + 0.1% acetic acid for M0 and M1, or (ii) ACN for M2; and then 
analysed by ESI-MS using an API-linear ion trap in positive ion mode7.  
After confirming the molecular weight, the remaining resin-coupled peptides were cleaved from the 
resin using mild acidic conditions to obtain fully protected derivatives. The following protocol was 
employed: (i) 1 g of dry resin was pre-swelled in DCM in a sealable glass funnel, and then excess DCM 
was removed; (ii) a 10 mL solution of 1% TFA in DCM (v/v) was added to the resin, the funnel was 
sealed and the mixture was stirred for 2 min; and (iii) the solution was then filtered under vacuum 
pressure into a vial containing 800 µL of DIEA to neutralize the solution and stop the reaction. Steps 
(ii) and (iii) were repeated 4 times; the resin was washed with 10 mL of DCM; and steps (ii) and (iii) 
were repeated four additional times. Finally, the resin was washed 3 times with 10 mL of DCM. A 
small aliquot of each of the filtrate samples was analysed by thin layer chromatography (TLC) using a 
mixture of 10% MeOH in chloroform as the mobile phase. All the filtrates containing peptides were 
pooled together and DCM was evaporated in the rotary evaporator. dd Water was added in order to 
precipitate the protected peptide, but a gel was formed instead of a white precipitate. Water was 
then removed in the rotary evaporator. 
 
 
 
                                                        
7 MS assays were performed in the Mass Spectrometry Laboratory at the Analytical Services Unit of the 
Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa. 
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5.2.4.2. Cyclization of M2 peptide 
 
M2 peptide was solubilized in 5 mL of MeOH. The cyclization reaction consisted in adding aliquots of 
1 mL peptide solution, followed by 30 µL DIEA (12 molar equivalents (eq.) relative to peptide) and 
200 µL HATU in DMF (1.5 molar eq. HATU relative to peptide), to 25 mL DCM every 30 min under a N2 
atmosphere. During the cyclization reaction small aliquots were dried in a Schlenk line, dissolved in 
50% solvent A/ 50% solvent B (v/v), where solvent A is 99.9% MilliQ water/ 0.1% TFA (v/v) and 
solvent B is 90% ACN/ 9.9% MilliQ water/ 0.1% TFA (v/v/v), and analysed by analytical reverse-phase 
HPLC (Phenomenex Jupiter Proteo column, 250 mm × 4.6 mm, 4 μm, 90 Å). The cyclic peptide 
solution was placed in the rotary evaporator in order to evaporate DCM, DMF, and MeOH. The cyclic 
peptide was then resuspended in DCM and a liquid-liquid extraction was performed with water in 
order to eliminate the presence of the coupling reagents and DIEA, which will be soluble in the 
aqueous phase. The organic phase was collected and DCM was evaporated in the rotary evaporator. 
Cyclic-M2 was then deprotected by solubilizing the peptide in 10 mL 95% TFA/ 2.5% MilliQ water/ 
2.5% TIS (v/v) and using the same strategy used for the linear protected M2 described in §5.2.4.1. 
Unprotected Cyclic-M2 was then purified by preparative reverse phase HPLC (Phenomenex Jupiter 
Proteo column, 250 mm × 21.20 mm, 4 μm, 90 Å) using solvent A and solvent B. The peptide was 
eluted from the column with a linear gradient from 20% to 40% B in 30 min at a flow rate of 10 
mL/min (Retention time (Rt) = 12 min). A sample of Cyclic-M2 was then analysed by Matrix-assisted 
laser desorption/ionization mass spectrometry (MALDI-MS). The sample was dissolved in 50% (v/v) 
ACN and spotted onto the MALDI plate using 5 mg/mL α-CHCA in 50% (v/v) ACN/ 5% (v/v) formic 
acid. Mass spectrum has been acquired in the positive reflectron mode using a 4800 Plus MALDI-
TOF/TOF MS analyser. Cyclic-M2 was liophilized and stored at -20°C.   
 
5.2.4.3. Cyclization of M0 and M1 peptides 
 
The linear protected peptide (M0 or M1) was dissolved in 20 mL MeOH, and added to a round-
bottom flask containing 500 mL DCM, 3 molar eq. of PyBOP, and 4 molar eq. of DIEA. Cyclization 
reaction was followed by analytical reverse-phase HPLC (Phenomenex Jupiter Proteo column, 250 
mm × 4.6 mm, 4 μm, 90 Å) using the same solvent system as described before. DCM and MeOH were 
evaporated in the rotary evaporator; the peptide was resuspended in DCM and a liquid-liquid 
extraction was performed with dd water. The organic phase was collected and DCM was evaporated 
in the rotary evaporator.  Full deprotection of Cyclic-M0 and Cyclic-M1 was performed by solubilizing 
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the peptides in 10 mL 90% (v/v) TFA/ 5% (v/v) thioanisole/ 3% (v/v) ethanothiol/ 2% (v/v) anisol and 
following the procedure described in  §5.2.4.1. Unprotected cyclic peptides were purified by 
preparative reverse phase HPLC (Phenomenex Jupiter Proteo column, 250 mm × 21.20 mm, 4 μm, 90 
Å) using solvent A and solvent B. Cyclic-M0 was eluted from the column with a linear gradient from 
10% to 30% B in 30 min at a flow rate of 10 mL/min (Rt = 24 min); and Cyclic-M1 was eluted from the 
column with a linear gradient from 20% to 35% B in 20 min at a flow rate of 10 mL/min (Rt = 11 min). 
Cyclic peptides were then analysed by MS. Cyclic-M0 and Cyclic-M1 were dissolved in MeOH and 
analysed by ESI-MS in an API-linear ion trap in positive ion mode. Both peptides were liophilized and 
stored at -20°C. 
 
5.2.4.4. Ellman’s test to determine free sulfhydryl groups on Cyclic-M0 and Cyclic-M1 
 
Cyclic peptides were dissolved in reaction buffer (0.1 M sodium phosphate buffer, 1 M EDTA, pH 8) to 
a final concentration of 1 mM. A solution of 4 mg/mL of Ellman’s reagent in reaction buffer was 
freshly prepared.  250 µL of the 1 mM peptide solution was added to 50 µL Ellman’s reagent solution 
and 2.5 mL reaction buffer; the mixture was incubated at room temperature for 15 min, and the 
absorbance was measured at 412 nm in an EnVision Multilabel plate reader from PerkinElmer. A 
calibration curve was represented by standard solutions of Cys (0-1.5 mM). 
 
5.2.4.5. Modification of agarose with iodoacetyl groups 
 
Aminated agarose was prepared according to §2.2.4.4, and then resuspended in a solution of 
iodoacetic anhydride (3 molar eq. relative to epoxy groups in epoxy-activated agarose) in DMF to a 
final concentration of 1 g aminated agarose/ mL. DIEA was added and the mixture was incubated 2 h 
at room temperature with agitation (250 rpm). Finally, iodoacetylated agarose was washed with 2x 
DMF, 2x 50% (v/v) DMF/ dd water, and 5x dd water. The success of reaction was confirmed by the 
Kaiser test described in §2.2.4.4. 
 
5.2.4.6. Immobilization of Cyclic-M0 and Cyclic-M1 onto iodoacetylated agarose 
 
Iodoacetylated agarose was thoroughly washed with coupling buffer (50 mM Tris, 5 mM EDTA-Na, 
pH 8.5) in a sinter funnel under vacuum pressure. Cyclic-M0 and Cyclic-M1 (1 molar eq. relative to 
epoxy groups on epoxy-activated agarose) were solubilized in 1 mL of coupling buffer and 50 µL of 
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TCEP. The mixture was incubated at room temperature for 30 min with agitation, and an aliquot of 
50 µL was taken to determine coupling efficiency. Peptide solution (1 mL) was added to 1 g of 
iodoacetylated agarose and incubated 15 min with agitation at room temperature, followed by 
additional 30 min incubation without agitation. Flow-through was collected and the resin was 
washed with 1 M NaCl (3x 1 mL) and coupling buffer (2x 1 mL). 1 mL of 50 mM of a blocking agent 
(cysteine, ethanethiol, or β-mercaptoethanol) was added to the resin, followed by 15 min incubation 
with agitation and 30 min incubation without agitation at room temperature. Finally, the resin was 
washed with coupling buffer (3x 1 mL). Absorbance of loading, flow-through and washes was 
measured in a microplate reader (Tecan F200) using a 280 (5) nm filter (Tecan). Calibration curves 
were obtained for each peptide using a 0-1 mg/mL concentration range.  
 
5.2.4.7. Immobilization of Cyclic-M2 onto aminated agarose 
 
Cyclic-M2 (1.5 molar eq. relative to epoxy groups in epoxy-activated agarose) was dissolved in 1 mL 
of activation buffer (0.1 M MES, 0.5 M NaCl, pH 6), followed by the addition of EDC (10 molar eq. 
relative to peptide) and NHS (to a final concentration of 5 mM) and incubation for 15 min at room 
temperature with mild agitation. The peptide solution was added to aminated agarose (prepared 
according to §2.2.4.4) and 1 M HEPES pH 8 was added until the pH of the mixture rose to 7. The 
mixture was incubated 2 h at room temperature with mild agitation. The resin was thoroughly 
washed with activation buffer. Loading, flow-through and washes were quantified using the BCA 
assay described in §2.2.4.13. 
 
5.2.4.8. Screening of cyclic peptides against GK14 and GK14-P 
 
Cyclic-M0 and Cyclic-M1 peptides were distributed between the wells of a 96-well filter plate (0.25 g 
of cyclic peptide-functionalized resin/well). The plates were washed with regeneration buffer (0.1 M 
NaOH in 30% isopropanol) followed by dd water (3 cycles of washes, 0.75 mL/well), followed by 
binding buffer (8x 0.75 mL/well on average). GK14 and GK14-P peptides were solubilized in binding 
buffer (0.5 mg/mL) and 0.25 mL of each peptide was loaded per well. The cyclic peptide-
functionalized resins were incubated with GK14 and GK14-P peptides for 1h at room temperature 
with manual shaking. After filtration, the resins were washed with binding buffer (8x 0.25 mL). Both 
the flow-through and washes were collected in 96-well microplates by centrifugation at 600 rpm for 
20 s, and quantified using the BCA assay described in §2.2.4.13. The same procedure was used to 
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Cyclic-M2, but 0.125 g of cyclic peptide-functionalized resin/well and solutions of 1 mg/mL of GK14 
and GK14-P were used instead. This experiment was also performed for blank agarose, which was 
used as control. Binding buffers were: (i) 50 mM Gly pH 3 and 50 mM HEPES pH 8. GK14 and GK14-P 
were further eluted from the Cyclic-M2-functionalized resin using 50 mM HEPES, 250 mM NaCl, pH 8. 
Elution fractions were also quantified using BCA assay. 
 
5.3. Results and Discussion 
 
5.3.1. Rational design of β-hairpin cyclic peptides 8 
 
As previously referred in Chapter 1, the BRCT domain is a human phosphoprotein-binding domain 
linked with the occurrence of breast and ovarian cancers. These domains recognize the consensus 
sequence pSer-X-X-Phe, where X is any amino acid. The superimposition of nine crystallographic 
structures of the BRCA1-BRCT domain in complex with different phosphopeptide sequences 
confirmed the existence of a highly conserved binding mode (Figure 5.3). pSer is recognized by three 
highly conserved residues: Ser1655, Gly1656, and Lys1702; while Phe is stabilized by hydrogen-
bonding and salt-bridging to Arg1699 and non-polar interactions with Met1775. The determinants 
for phosphopeptide recognition are described in detail in §1.2.1.2. 
 
 
 
Figure 5.3 - Superposition of 9 crystallographic structures of the BRCA1-BRCT domain (PDB codes: 1T15, 
1T29, 1T2V, 1Y98, 3COJ, 3K0H, 3K0K, 3K15 and 3K16). 
 
                                                        
8 Molecular modelling studies were conducted in our laboratory by Dr. Ricardo Branco. 
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A solution NMR structure of a 14-mer β-hairpin cyclic peptide (PDB code: 2NS4) was used as 
template to design a small library of peptidomimetics. The idea was to build a smaller functional 
mimic of the BRCT domain. The template had the following amino acid sequence: cyclo(Lys(1)-Gly(2)-
Arg(3)-Arg(4)-Ile(5)-Arg(6)-Ile(7)-
DPro(8)-Pro(9)-Arg(10)-Val(11)-Arg(12)-Thr(13)-Arg(14)). Nine in silico point 
mutations were introduced in order to provide structural and functional diversity at specific positions 
of interest. Specifically, four Arg residues at positions 4, 6, 10 or 12, and 14 were knocked out by a 
Gly mutation. Arg at position 10 or 12 was conserved to prompt electrostatic interactions and 
hydrogen-bonding at the hydrophilic pocket, which are mainly established in the crystallographic 
structure of BRCA1-BRCT domain between the backbone atoms of Ser1655 and Gly1656, as well as 
the side chain of Lys 1702, and pSer moiety. Lys at position 1 was considered the preferential site for 
peptide immobilization on the solid support, as it is positioned at the opposite site of the DPro-Pro 
unit which induces a β-turn on the peptide. Lys was mutated to a Gln or a Met residue which account 
for the anchoring point9. Arg at position 3 was mutated to a Phe which mimics the Phe1704 of the 
hydrophobic-binding pocked that accommodates the Phe of the phosphorylated peptide. Two Ile 
residues at positions 5 and 7 were mutated to the non-natural amino acid diaminopropionic acid 
(Dap), in order to mimic the side chain interactions between Lys1702 and the phosphate group of the 
target peptide at different interatomic distances. A control peptide (Cyclic-M0) in which all the 
previously mutated positions were converted to Gly residues (with the exception of the anchoring 
point) was also designed. Cyclic peptides were sketched in PyMOL Molecular Graphics System v.1.3 
(Schrödinger) and docked with GK14-P and its non-phosphorylated version GK14 using the Autodock 
v.4.2 software package. GK14-P is the phosphorylated peptide which is in complex with the BRCA-
BRCT domain in the crystallographic structure 1T2V (PDB code) presented in Figure 5.3.  
Two β-hairpin peptides (Cyclic-M1 and Cyclic-M2) were selected as the best candidates based on the 
estimated docking free energy of binding. Sequences of cyclic β-hairpin peptides and their targets are 
presented in Table 5.1. Their affinity constants (Ka, M
-1) relative to the phosphorylated target GK14-P 
are presented in Table 5.2.  
  
                                                        
9
 Peptides were chemically synthesized using either a Glu or Cys residue for anchoring, which after 
immobilization to the solid-support become Gln and Met, respectively.   
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Table 5.1 – Amino acid sequences of cyclic β-hairpin peptides and their targets. Residues used for the 
immobilization to the solid-support are represented in green. Residues involved in molecular recognition are 
represented in red. pSer is depicted in bold. 
Peptide ID Amino acid sequence 
Cyclic-M0 Cyclo(Cys-Gly-Gly-Gly-Gly-Gly-Gly-DPro-Pro-Gly-Val-Gly-Thr-Gly) 
Cyclic-M1 Cyclo(Cys-Gly-Phe-Gly-Ile-Gly-Ile-DPro-Pro-Arg-Val-Gly-Thr-Gly) 
Cyclic-M2 Cyclo(Glu-Gly-Phe-Gly-Dap-Gly-Dap-DPro-Pro-Gly-Val-Arg-Thr-Gly) 
GK14 Gly-Ala-Ala-Tyr-Asp-Ile-Ser-Gln-Val-Phe-Pro-Phe-Ala-Lys 
GK14-P Gly-Ala-Ala-Tyr-Asp-Ile-pSer-Gln-Val-Phe-Pro-Phe-Ala-Lys 
 
 
Table 5.2 – Affinity constants (Ka, M-1) of selected cyclic peptides towards the phosphorylated target GK14-P 
and its non-phosphorylated version. 
Ka (M
-1) 
Target peptide 
Non-Phosphorylated (GK14) Phosphorylated (GK14-P) 
β
-H
ai
rp
in
 
p
e
p
ti
d
o
m
im
e
ti
cs
 
Cyclic-M0 3.05 x 102 4.85 x 101 
Cyclic-M1 5.93 x 10-1 2.39 x 103 
Cyclic-M2 1.62 x 10-2 3.78 x 103 
 
 
The highest scored docking solutions of Cyclic-M1 and Cyclic-M2 in complex with the phosphorylated 
peptide GK14-P are depicted in Figure 5.4. The phosphate group coordinates to Arg at position 10 or 
12, both positioned at the same face of the β-hairpin structure, together with a Phe at position 3. 
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Figure 5.4 – Highest scored docking solution of A) Cyclic-M1 and B) Cyclic-M2 in complex with 
phosphorylated peptide GK14-P. 
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5.3.2. Synthesis of β-hairpin cyclic peptides 
 
Standard microwave-assisted solid-phase Fmoc chemistry was used to prepare protected linear 
peptides M0, M1 and M2. 2-Chlorotrityl resins (pre-loaded with Gly or Glu) were used to obtain free 
carboxylic C-terminal groups. Peptides can be cyclized on the solid support, which has the advantage 
of facilitating the purification process. However, functional groups on solid-supported peptides are 
less prone to react together when compared to functional groups of peptides that freely diffuse in 
solution [27]. Therefore, in this work protected linear peptides were cleaved from the solid support 
before cyclization. Short treatments with 1% TFA (v/v) in DCM were used to cleave from the resin the 
fully protected peptides with free C- and N- terminal groups. 
Small aliquots were fully deprotected with 90% (v/v) TFA/ 5% (v/v) thioanisole/ 3% (v/v) ethanothiol/ 
2% (v/v) anisol (for M0 and M1) and 95% TFA/ 2.5% MilliQ water/ 2.5% TIS (v/v) (for M2) and 
analysed by ESI-MS. The mass spectrum of M0 in positive ion mode presented two high intensity 
peaks: m/z 1030 Da (z=+1) and m/z 1068 Da (z=+1). The first peak corresponds to the molecular mass 
of linear M0, and the second peak to a potassium adduct of m/z 1030 Da. The mass spectrum of M1 
in positive ion mode presented a set of three most abundant peaks in different forms of ionization: 
m/z 1331 Da (z=+1), m/z 666 Da (z=+2), and m/z 685 Da (z=+2). The first and second peaks 
correspond to the molecular mass of linear M1, and the third peak to a potassium adduct of m/z 666 
Da. The mass spectrum of M2 in positive ion mode presents a set of two most abundant peaks in 
different forms of ionization: m/z 1302 Da (z=+1) and m/z 652 Da (z=+2), which correspond to the 
molecular mass of linear M2. 
Cyclization reaction of the protected peptide was performed manually in solution. The M2 peptide 
was cyclized using HATU as coupling reagent. HATU has been reported to give better reaction yields 
than other coupling reagents, such as HBTU and PyBOP [33]. A stepwise addition protocol was 
followed in order to avoid the use of high amounts of solvents, because cyclization reactions require 
the use of submillimolar peptide concentrations to avoid peptide oligo- and polymerization [27, 34]. 
However, in this work poor results were obtained using this approach. The cyclization reaction was 
followed by analytical reverse-phase HPLC and the chromatograms of Cyclic-M2 presented numerous 
peaks. This might be due to: (i) formation of oligomers; or (ii) presence of contaminants, due either 
to the fact that the linear peptide could not be precipitated in previous experimental steps and 
therefore could not be properly washed or to the fact that HATU reacted also with the N-terminal 
amine in addition to activate the C-terminal carboxylic group. Therefore, a less reactive coupling 
reagent that is unable to form the N-terminal adduct was used cyclize M0 and M1 peptides. HATU 
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was replaced by PyBOP and a larger amount of solvent was employed (to keep high dilution 
conditions). Indeed, the chromatograms obtained when using the latter strategy were cleaner, 
presenting sharp peaks correspondent to the cyclic peptides. 
After cyclization, peptides were fully deprotected using the methodology described above, purified in 
a preparative reverse-phase HPLC, and analysed by ESI-MS in positive ion mode to confirm their 
molecular weight. The mass spectrum of Cyclic-M0 presented three high intensity peaks: m/z 1011 
Da (z=+1), m/z 1033 Da (z=+1), and m/z 1049 Da (z=+1). The first peak corresponds to the molecular 
mass of Cyclic-M0, the second and third peaks to sodium and potassium adducts of m/z 1011 Da, 
respectively. The mass spectrum of Cyclic-M1 presented one high intensity peak at m/z 1312 Da 
(z=+1), correspondent to the molecular mass of Cyclic-M1. Cyclic-M2 was analysed by MALDI-TOF-MS 
and its mass spectrum presented a high intensity peak at m/z 1284 Da correspondent to the 
molecular weight of the peptide. 
Cyclic peptides were then analysed by analytical reverse-phase HPLC to determine their purity. All 
peptides were > 95% pure. 
 
5.3.3. Immobilization of β-hairpin cyclic peptides 
 
Two different approaches were used to immobilize β-hairpin cyclic peptides on a chromatographic 
support (agarose). Cyclic-M0 and Cyclic-M1 were immobilized on iodoacetylated agarose through the 
sulfhydryl group of their Cys residues, while Cyclic-M2 was immobilized on aminated agarose through 
the side chain carboxyl group of its Glu residue using carbodiimide chemistry. 
The functionalization of solid supports with iodoacetyl groups has already been extensively reported 
[35, 36]. In this work, aminated agarose was reacted with iodoacetic anhydride to yield iodoacetyl-
functionalized agarose beads. The success of the reaction was confirmed by the Kaiser test (Figure 
5.5A). 
Ellman’s test was perfomed to determine the percentage of free sulfhydryl groups available in the 
peptides to react with the iodoacetylated agarose. Ellman’s test is a colorimetric test based on the 
reaction between 5,5'-dithio-bis-(2-nitrobenzoic acid) and sulfhydryl groups, which yields a mixed 
disulfide and 2-nitro-5-thiobenzoate ion (TNB2-). TNB2- presents an intense yellow colour and 
absorbance at 412 nm (Figure 5.5B). Cyclic-M0 and Cyclic-M1 presented 79% and 60% of free 
sulfhydryl groups, respectively. 
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Figure 5.5 – A) Kaiser test of iodoacetyl-functionalized agarose (on the left) and aminated agarose (on the 
right). Aminated agarose presented a purple/blue colour characteristic of the presence of primary amines, in 
contrast with iodoacetylated agarose which presented a whitish colour. B) Ellman’s test of 0 mM Cys 
(control) and 15 mM Cys in 0.1 M sodium phosphate buffer, 1 M EDTA, pH 8. Free sulfhydryl groups of Cys 
react with Ellman’s reagent to yield a mixed disulfide and TNB
2-
 ion, which has a characteristic yellow colour. 
 
The reaction between iodoacetyl-functionalized agarose and free sulfhydryl groups of peptides Cys 
residues is illustrated in Figure 5.6. The reaction was carried out in 50 mM Tris, 5 mM EDTA-Na, pH 
8.5. The pH of the solution should be kept between 7.5 and 9, in order to avoid unwanted side 
reactions with amine functional groups at higher pH values. EDTA-Na was added to the coupling 
buffer to prevent disulfide bond formation [37]. As the Ellman’s test revealed that 30-40% of the 
thiol groups were oxidized, a reducing agent (TCEP) was added to the peptide solution prior to resin 
coupling. TCEP was selected because it does not interfere with the immobilization reaction, since it 
does not have sulfhydryl groups in its structure [38]. Unreacted sites on iodoacetylated agarose were 
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blocked using a blocking agent (cysteine, ethanethiol, or β-mercaptoethanol) in order to prevent side 
reactions, as iodine ion is an excellent leaving group. 
 
 
Figure 5.6 – Strategy for the immobilization of peptides through Cys residue. Aminated agarose reacts with 
iodoacetic anhydride to yield iodoacetylated agarose, which in turn reacts with peptides through their Cys 
sulfydryl groups. 
 
As TCEP interferes with the BCA quantification method, unbound Cyclic-M0 and Cyclic-M1 were 
quantified by absorbance at 280 nm in order to determine the yield of immobilization, which was 
60% for both peptides.  
Quantification of these peptides at 280 nm was possible due to the presence of Pro residues 
embedded along the peptide. Although Pro residue itself presents a low molar extinction coefficient, 
it displays increased absorbance when it is part of a peptide chain (except at the N-terminus), 
probably due to the cyclic nature of the three-carbon side chain to the nitrogen of the peptide 
backbone. In addition, the presence of two Pro residues together seems to further enhance this 
effect [39]. Peptides could not be quantified at 205 nm due to the interference of EDTA-Na. At 280 
nm neither EDTA-Na (< 30 mM) nor TCEP interfere with peptide quantification [40-42].  
A different strategy was followed for the immobilization of Cyclic-M2. The carboxylic group of the 
unique Glu side chain of Cyclic-M2 was activated by reaction with EDC and NHS, yielding an amine-
reactive ester, which will promptly react with aminated agarose (Figure 5.7). This reaction should be 
carried out in amine- and carboxyl-free buffers. Unbound Cyclic-M2 was quantified using the BCA 
assay to determine the yield of the immobilization reaction, which was 33%.  
 
+
DIEA
DMF
2h, RT
SH-Peptide 
50 mM Tris, 5 mM EDTA-Na, pH 8.5
TCEP
45 min, RT
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Figure 5.7 – Immobilization of peptides through their carboxylic groups onto aminated agarose. Activation of 
carboxylic groups of peptides with EDC and NHS yields an amine-reactive ester, which reacts with aminated 
agarose at pH 7. 
 
5.3.4. Screening  β-hairpin cyclic peptides for binding to GK14 and GK14-P peptides 
 
Cyclic-M0 and Cyclic-M1 were screened against their phosphorylated target GK14-P and its non-
phosphorylated version at acid and basic pH. Control experiments were also carried out using the 
blocked agarose solid support (iodoacetylated agarose reacted with cysteine, ethanethiol or β-
mercaptoethanol).  
Figure 5.8 shows that both Cyclic-M0 and Cyclic-M1 peptides bind the phosphorylated target GK14-P 
at pH 3. Cyclic-M0 was not expected to bind, as it is a negative control. However, all blocked solid 
support controls bind exactly the same amount of target peptide than Cyclic-M0 and Cyclic-M1. This 
means that the problem may not be arising from the lack of specificity of the cyclic β-hairpin towards 
the target, but from the non-specific binding of the target to the blocked resin. 
  
(EDC)
(NHS)
0.1 M MES, 0.5 M NaCl, pH 7
2h, RT
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Figure 5.8 – Screening of cyclic peptide-immobilized agarose against GK14 and GK14-P after blocking 
unreacted sites with: A) ethanethiol; B) β-mercaptoethanol; and C) Cys. Screenings were performed by adding 
0.25 mL of peptide in binding buffer (0.5 mg/ mL) to each well of a 96-well filter plate containing 0.25 g of resin. 
The unbound peptides from flow-through and washes were collected in 96-well microplates and quantified 
using the BCA assay. Binding buffers were: 50 mM Gly pH 3 and 50 mM HEPES pH 8. Controls correspond to 
iodoactelyated agarose reacted with A) ethanethiol (Control 1); B) β-mercaptoethanol (Control 2); and C) Cys 
(Control 3). Blank agarose was also used as control in each case. 
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Cyclic-M2, which was immobilized through carbodiimide chemistry, was also screened against GK14 
and G14-P. The screening was performed at pH 8, because of the non-specific binding observed for 
agarose (control) at acidic pH. At pH 3 agarose binds approximately 38% to GK14-P, while no binding 
is observed at pH 8. The non-phosphorylated peptide does not bind to agarose at any of the pH 
values tested (Figure 5.8). 
Cyclic-M2 bound approximately 0.54±0.04 mg GK14-P/g Cyclic-M2-functionalized resin. It was highly 
selective toward GK14-P, presenting a phosphopeptide mole fraction (defined in §Equation 2.2) of 
97%. GK14-P was successfully eluted from the resin using 50 mM HEPES, 250 mM NaCl pH 8, with up 
to 61±25% recovery.  
Immobilization yields and binding capacity for GK14-P of Cyclic-M0, Cyclic-M1, and Cyclic-M2 are 
presented in Table 5.3. 
 
Table 5.3 – Comparison between Cyclic-M0, Cyclic-M1, and Cyclic-M2 in terms of immobilizations yields and 
binding capacity for GK14-P (N=2). 
Peptide 
ID 
Yield of 
immobilization 
(%)a 
µmol Immobilized 
cyclic peptide/ g 
moist resin 
Binding at pH 8 
(mg GK14-P/g 
moist resin) 
GK14-P 
mole fraction 
(%) 
Elution 
(%) 
Cyclic-M0 60 48.51±0.48 0 0 - 
Cyclic-M1 60 47.26±0.76 0 0 - 
Cyclic-M2 33 32.38±0.08 0.54±0.04 97±5 61±25 
a
 Yield of immobilization relative to the amount of functional groups in the solid support. 
 
The yield of immobilization is lower for Cyclic-M2, probably due to peptide cross-linking, since it is 
plausible that some of the activated carboxyl groups of the peptide might react with amine groups of 
Dap and Arg amino acids, while others will react with aminated agarose. In terms of binding capacity 
at pH 8, Cyclic-M0 and Cyclic-M1 do not bind to the target, while Cyclic-M2 is highly selective for 
GK14-P. Cyclic-M2 is illustrated in Figure 5.9. 
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Figure 5.9 – Illustration of Cyclic-M2 sketched in PyMOL Molecular Graphics System v.1.3 (Schrödinger). The 
diproline unit and the amino acids involved in molecular recognition are highlighted in 3 letter codes. 
 
To better understand the interactions between Cyclic-M2 and GK14-P, both peptides were sketched 
in PyMOL Molecular Graphics System v.1.3 (Schrödinger) and their properties determined in 
MarvinSketch 4.1.13 software (ChemAxon) (Table 5.4).  
 
 
Table 5.4 – Properties of Cyclic-M2 and GK14-P determined using pI and logD plugins of MarvinSketch 4.1.13 
software (ChemAxon). pI – Isoelectric point. 
 pI Net Charge at pH 8 logD at pH 8 
Cyclic-M2 12.55 2.09 -15.04 
GK14-P 3.77 -2.90 -14.30 
pI: isoelectric point. 
 
At pH 8 the peptides have opposite net charges, which means they most likely establish electrostatic 
interactions. Only three residues are ionisable in Cyclic-M2: Dap at position 5 (pKa=7.79), Dap at 
position 7 (pKa=8.39), and Arg at position 12 (pKa=11.85). GK14-P has five charged functional groups 
at pH 8: one negative charge on Asp side chain; two negative charges on the phosphate group of 
pSer; one positive charge on Lys side chain; and one negative charge on the carboxyl terminal group 
(Figure 5.10). The fact that Cyclic-M2 selectively binds GK14-P but not GK14 indicates that the 
presence of the phosphate group is vital for the molecular recognition of the peptide. 
Phe
Dap
Dap
DPro
Pro
Arg
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Figure 5.10 – pKa values of the functional groups of GK14-P. The charged amino acids at pH 8 are highlighted 
with dashed lines. Values were determined using the pKa Plugin from MarvinSketch (ChemAxon).  
   
Negative logD values indicate that both peptides are hydrophilic at pH 8 (Table 5.4). However, this 
does not exclude the establishment of hydrophobic interactions between the non-polar functional 
groups of the peptides, as it was observed in the molecular docking studies. 
 
5.4. Conclusions 
 
Three cyclic β-hairpin structures mimicking the BRCA1-BRCT domain were successfully synthesized by 
chemical methods. Linear precursors were cyclized by two different methodologies, one based on 
the stepwise addition of the peptide and HATU, and another on the use of PyBOP as coupling reagent 
and higher amounts of solvents. The latter revealed to be more efficient in this work. Either a Cys or 
a Glu residue was introduced into the β-hairpins structure in order to facilitate their immobilization 
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onto an agarose resin after cyclization. Peptides containing Cys (Cyclic-M0 and Cyclic-M1) were 
attached to iodoacetylated agarose with immobilization yields of 60%, but the need to block the 
unreacted iodoacetyl groups renders this methodology less effective, because the target peptides 
(GK14 and GK14-P) bind non-specifically to the solid support. Therefore, the ability of Cyclic-M0 and 
Cyclic-M1 to specifically recognize GK14-P remains unknown. Cyclic-M2 contained a Glu residue and 
was therefore immobilized using carbodiimide chemistry, presenting an immobilization yield of 33%. 
Cyclic-M2 was highly selective at pH 8 towards the phosphorylated peptide GK14-P, which 
subsequently was successfully eluted from the resin under mild conditions.  
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CHAPTER 6 
Concluding remarks 
 
Two types of synthetic affinity reagents were developed for the specific binding of phosphorylated 
peptides: small organic ligands and cyclic β-hairpin peptides.  
The small synthetic ligands were designed to mimic the interactions occurring in the phosphate-
binding pockets of the human phosphoprotein-binding domains. Very recently, Marx and co-workers 
built 96 combinatorial libraries comprising more than 100,000 phosphorylated and non-
phosphorylated synthetic peptides. The idea was to acquire a large number of mass spectrometric 
data to evaluate the performance of several computational tools (e.g. Mascot) currently employed 
for peptide identification and phosphorylation-site localization. They have also compared different 
fragmentation methods (beam-type collision-induced dissociation (HCD) and electron transfer 
dissociation (ETD)) and characterized the chromatographic profile of the synthesized peptides [1]. 
While they have focused on the combinatorial synthesis of phosphorylated peptides, we developed 
combinatorial libraries of phosphopeptide-binders. Both strategies represent complementary tools 
to facilitate the identification and profiling of clinically relevant phosphorylated proteins and 
peptides. 
The combinatorial libraries were based on three chemical reactions: (i) nucleophilic substitutions on 
a triazine ring; (ii) Ugi multicomponent reaction; and (iii) tandem Petasis-Ugi multicomponent 
reaction. The feasibility of these reactions on agarose was confirmed by Inductively Coupled Plasma - 
Atomic Emission Spectroscopy (ICP-AES) and fluorescence microscopy (Table 6.1). Petasis-Ugi 
scaffold presented the lowest reaction yield; therefore, synthesis conditions should be further 
optimized, by testing different solvents, temperatures, and reaction times. To our knowledge, this is 
the first time that a Petasis-Ugi scaffold has been reported for affinity chromatography.   
 
Table 6.1 – Reaction yields of triazine, Ugi, and Petasis-Ugi reactions on agarose determined from ICP-AES 
analysis. 
 
Scaffolds 
Triazine 
(Ligand A10A10) 
Ugi 
(Ligand A10C2) 
Petasis-Ugi 
(D3bA10B2) 
Reaction Yields (%) 100 94 44 
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A variety of amines, aldehydes, and carboxylic acids were used as building blocks for the introduction 
of chemical diversity in the scaffold molecules, mimicking key amino acid residues involved in 
phosphate recognition. After several steps of selection, two lead ligands were identified – A8A3 and 
A8C2, based on triazine and Ugi reactions, respectively. Interestingly, both of these ligands present a 
chemical group mimicking a Histidine amino acid residue, confirming a role for the imidazole group 
on phosphate coordination, most likely trough the establishment of both hydrophobic and 
electrostatic interactions.  
A8A3 and A8C2 were screened against both mono- and multi-phosphorylated peptides in a wide pH 
range (3-11) and NaCl concentrations (0-1M), and both ligands presented higher binding capacities 
and higher selectivity at pH 3. The presence of low concentrations of NaCl enhanced the selectivity 
for multi-phosphorylated peptides, but not for mono-phosphorylated species. Both acidic and basic 
conditions can be used to elute phosphopeptides from these ligands. In particular, the addition of 
H3PO4 to the elution solution allows for the recovery of both mono- and multi-phosphorylated 
peptides from both ligands.  
Partition equilibrium experiments indicated that weak affinity interactions govern ligand-peptide 
binding, providing improved kinetics, high-resolution and rapid throughput.  
Ligands A8A3 and A8C2 were further immobilized onto iron oxide magnetic nanoparticles coated 
with silica and dextran (MNP-Si-Si-Dex). Ligands immobilized on MNP-Si-Si-Dex presented enhanced 
binding capacities (10-fold higher) and lower selectivity (especially for the mono-phosphorylated 
species) towards the phosphopeptide targets than the same ligands immobilized on agarose.  
MNP-Si-Si-Dex-A8A3 and MNP-Si-Si-Dex-A8C2 were further screened against a tryptic semi-complex 
mixture of two phosphorylated proteins - α-casein and β-casein - and one non-phosphorylated 
protein - bovine serum albumin. The mass spectrum of MNP-Si-Si-Dex-A8C2 presented a low signal-
to-noise ratio and no peptides could be identified (neither phosphorylated nor non-phosphorylated).  
The mass spectrum of MNP-Si-Si-Dex-A8A3 was dominated by the presence of peaks correspondent 
to phosphorylated peptides. Nine phosphorylated peptides were identified from a 6 pmol semi-
complex sample, comprising both mono- and multi-phosphorylated peptides. A Ti4+-IMAC approach 
was tested in parallel and yielded equivalent results. Future work includes determining the sensitivity 
of our method, by testing samples with lower concentrations and decreasing the ratio between 
phosphopeptides and non-phosphopeptides in the original tryptic sample.  
A different line of study was followed for the synthesis of cyclic β-hairpin peptidomimetics. Instead of 
performing broad structural studies of the ten human PDBs and synthesizing ligands in a 
combinatorial manner, we have focused on a specific domain known to be involved in breast and 
ovarian cancers: the Brca1 C-terminal (BRCT) domain. Based on the crystallographic structure of the 
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BRCA1-BRCT domain in complex with its phosphorylated target Gly-Ala-Ala-Tyr-Asp-Ile-pSer-Gln-Val-
Phe-Pro-Phe-Ala-Lys (GK14-P), a structure-based design approach has been employed for the 
development of cyclic β-hairpin peptides. These peptides act as miniaturized versions of the BRCT 
domain, mimicking specific regions of phosphate recognition. A lead candidate with the sequence 
cyclo(Glu-Gly-Phe-Gly-Dap-Gly-Dap-DPro-Pro-Gly-Val-Arg-Thr-Gly) – Cyclic-M2 - has been identified, 
presenting high binding capacity and selectivity towards GK14-P. 
This concept can be applied to other PDBs and drive the development of highly specific diagnostic 
tools. For example, SH2 domains have been used in large-scale far-western analysis and reverse-
phase protein arrays to profile phosphoprotein and phosphopeptide binding [2]. The employment of 
miniaturized versions of PBDs would avoid the laborious synthesis of whole domains, while helping 
to elucidate the molecular mechanisms behind a variety of cellular processes. Conversely, small non-
peptide SH2 ligands have been developed as tools for the discovery of novel drugs by blocking SH2-
phosphoprotein interactions [3]. 
It should be noted that both A8A3 and A8C2 present their highest selectivity towards a 
phosphopeptide with the sequence pSer-Gln-Val-Phe-Pro-Trp (SW6-P), which comprises a consensus 
sequence known to specifically bind to BRCT domain. The three peptidomimetic scaffolds 
immobilized on agarose were compared in terms of binding capacity and selectivity towards their 
target peptides (Table 6.2). Cyclic-M2 presents a lower binding capacity, but it employs mild binding 
and elution conditions, which might be a competitive advantage, especially for the enrichment of 
phosphoproteins in non-denaturating conditions. The commercially available Phos-tagTM Agarose 
reagent for phosphopeptide separation is reported to have 3-5 µmol Phos-tag/ mL-gel [4]. However, 
to our knowledge, there is no data available referring to the amount of phosphopeptides that 
actually bind to the support. Results are usually evaluated by SDS-PAGE and Western blotting [5, 6]. 
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Table 6.2 – Binding capacity (µmol target peptide/ g moist agarose) and phosphopeptide mole fraction (%) of 
ligands A8A3, A8C2, and Cyclic-M2 immobilized on agarose towards their respective target peptides.  
Screenings were performed at optimal binding conditions in each case. A8A3 and A8C2 were screened against 
SW6-P at pH 4, and Cyclic-M2 was screened against GK14-P at pH 8. Peptides were quantified by fluorescence 
microscopy in case of A8A3 and A8C2, and by BCA assay in case of Cyclic-M2.  
 Peptidomimetics 
 A8A3 A8C2 Cyclic-M2 
Phosporylated peptide bound 
(µmol target peptide/ g moist agarose) 
0.9 1 0.3 
Phosphopeptide mole fraction (%) 100 97 97 
Target peptide 
Peptide ID: SW6-P 
pS-Q-V-F-P-W 
Peptide ID: GK14-P 
G-A-A-Y-D-I-pS-Q-V-F-P-F-A-K 
  
Both strategies described in this work, either based on the combinatorial synthesis of small 
peptidomimetics or on the rational design of miniaturized versions of PBDs, present novel 
alternatives to conventional antibody-based and metal-chelating methodologies. All these 
methodologies do not necessary mutually exclude each other. On the contrary, in our view, the high 
complexity of phosphorylation events and the difficulties to isolate clinically-relevant phosphorylated 
species creates a need to build more comprehensive, integrative, and complementary approaches 
for phosphopeptide enrichment. 
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